IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF ALABAMA SOUTHERN DIVISION

CHRISTINE BENNETT,

Plaintiff,

* CIVIL ACTION NO. 1:06cv723-MHT v.

ARMY FLEET SUPPORT, LLC,

Defendant.

DEFENDANT ARMY FLEET SUPPORT, LLC'S NOTICE OF FILING EVIDENCE

Defendant Army Fleet Support, LLC, hereby gives notice of filing of the following evidentiary submissions in support of its contemporaneously filed Motion for Partial Summary Judgment as to Plaintiff Christine Bennett's claims:

Exhibit	Description
A	Affidavit of John L. Hamlin;
В	Excepts from the Deposition of Christine Bennett and selected Exhibits thereto;
C	Affidavit of Ed Brown;
D	Affidavit of Tammie Brunson Maddox;
E	Affidavit of Thomas A. Green;
F	Affidavit of Jerry Fowler;
G	Affidavit of Tom Thomasino;
Н	Affidavit of Thomas Ford;
I	PDR Electronic Library - Kadian Capsules; and
J	PDR Electronic Library - Lortab 10.

ARMBRECHT JACKSON LLP Post Office Box 290

Mobile, Alabama 36601

Telephone: (251) 405-1300 Facsimile: (251) 432-6843

/s/ Kirk C. Shaw (SHAWK0466)

Attorneys for Army Fleet Support LLC

CERTIFICATE OF SERVICE

I hereby certify that on June 15, 2007, I electronically filed the foregoing with the Clerk of the Court using the CM/ECF system which will send notification of such filings to the following:

> Jon C. Goldfarb (jgoldfarb@wcqp.com) WIGGINS, CHILDS, QUINN & PANTAZIS P.C. The Kress Building 301 19th Street North Birmingham, Alabama 35203

> Ethan R. Dettling (edettling@wcqp.com) WIGGINS, CHILDS, QUINN & PANTAZIS P.C. The Kress Building 301 19th Street North Birmingham, Alabama 35203

> > /s/ Kirk C. Shaw (SHAWK0466)

EXHIBIT B

```
IN THE UNITED STATES DISTRICT COURT
 1
             FOR THE MIDDLE DISTRICT OF ALABAMA
                      SOUTHERN DIVISION
 3
                                            GOPY
 4
    CHRISTINE BENNETT,
 5
          Plaintiff,
 6
    VS.
                              ) CASE NO. 1:06cv723-MHT
 7
    ARMY FLEET SUPPORT,
    LLC,
          Defendant.
10
11
12
13
14
1.5
16
             The deposition of CHRISTINE BENNETT,
    taken pursuant to Federal Rules of Civil
17
    Procedure before Lisa M. Bryan, Court Reporter
18
    and Notary Public, State at Large, at the Holiday
19
     Inn Express, U.S. 84 & Boll Weevil Circle,
20
    Enterprise, Alabama, on the 21st day of March,
21
    2007, at approximately 9:00 a.m., pursuant to
22
    notice.
23
```

I think you applied for employment with ·Q. DynCorp in 1999? Yes, sir. I looked for jobs in other places and put in applications in between that time. ...8

2

3

4

5

6

7

. . 8

9

10

11 12

13

14

15

16

17 18

19

20

21

22

- Let me ask you -- I am going to ask you Q. about this in a minute. But just in your own words, can you tell me what the job of an AAE&I tech, that's armament, avionics, electrical, and instrument technician, what the job duties entailed when you began work there at DynCorp?
 - During which month? Α.
 - Well, when you --Q.
- Because when I first started, I went to Α. I was taken to several different projects, and they each entailed a different thing.

Q. Okay.

15.

A. It wasn't just I was thrown out here and that was my job from the day I started until the day I went out for my knee surgery. I worked in several different areas that they have there.

- Q. Well, just kind of walk me through, as you recall, what jobs you got assigned to.
- A. Okay. I worked for a time in the bore sighting stall, which is where we work with armament, and the avionics technicians work together, to maintain the systems on the aircraft for the gunnery and sight systems. I also worked unscheduled maintenance, which means anything that just pops up out of the blue that the flight line crew doesn't have time to fix and it's not set for scheduled maintenance. Then that was something that we would fix at the time.

I also worked out on the flight line for a time. On the flight line, we dealt with the aircraft itself also, again, but at this point, we were dealing with the pilots and the students in there a lot of the times. Sometimes they weren't out there. Sometimes it was something

that we fixed when they returned.

I worked in the hangar for a short time during a phase to see what they did in the phase barn. I also worked in the EETF. And I also worked on 58-Ds for a while.

... 8

```
1
 2
 3
 4
 5
 6
 7
... 8
 9
10
11
              On March 20th?
12
         Α.
              The day that you were injured.
13
         Q.
              No, it was the next morning.
         Α.
14
              Okay. And then the following day, you
15
         Q.
     went to see Dr. Granger?
16
              Yes.
         Α.
17
              And Dr. Granger allowed you to return to
         Q.
18
     work doing light-duty work; did he not?
19
               (Nods head.)
         Α.
20
              Did you come back --
21
         Q.
              Yes, he did.
22
         Α.
23
              -- the same day you went to see Dr.
         Q.
```

Granger? 1 Yes, sir. I came back to work, and I Α. 2 worked up until the first day of surgery. 3 What did you do during that interim? 4. Q. I worked doing different things in and 5 around and for the EETF. 6 7. Q. Light-duty work? Yes. Paperwork. 8 Α. Sitting at a desk? Q. Paperwork, pulling cards out of 10 Α. different boxes. 11 Q. And he did the first surgery on you, I 12 believe, on April 12th of 2002? 13 14 Α. Yes. It was an arthroscopic procedure? 15 Q. 16 Α. Yes. 17 18 19 20 21 22 23

-16

Q. -- employee? Now, you had your first knee replacement on January 17th of 2003?

A. Yes.

- Q. And you did not return to work for DynCorp after that date, did you?
- A. No. Actually I started to. I kept bugging Dr. Granger about letting me go back, and he was going to return me -- we were -- he was in the process of getting the paperwork together to return me to work when I started having some problems. And I wound up not going back because, at that point, we were trying to figure out what the problem with my leg was.
 - Q. And eventually you had some surgery, and it was determined you had infection there in the knee?
 - A. Well, when I went in, he originally told me that he was going to go in to see if the bottom portion of the original total knee that he had put in was maybe causing a problem. And originally it was going to be a revision of the bottom portion of the knee. He wasn't sure

Case 1:06-cv-00723-MHT-CSC Document 36-3 Filed 06/15/2007 Page 12 of 85 i... 8 Yeah. Now, one week later -- this was

```
done on April 6th of 2004. And I think on April
1
    13th, Dr. Granger stated that you had reached
2
    maximum medical improvement?
3
        Α.
             Yes.
4
             Does that sound right?
5
        Q.
             I think that's the date. Either the
6
    13th or the 14th. I don't remember.
7
8
                  (Whereupon, Defendant's Exhibit 19
9
                 was marked for identification
10
                 and is attached hereto.)
11
12
             I'm going to hand you Defendant's
13
        Ο.
    Exhibit 19. I don't know that you have seen
1.4
    this. Let me ask you if you did see that? This
15
    is Dr. Granger's letter to the case manager on
16
    your worker's comp claim, informing them that you
17
    had reached maximum medical improvement on April
18
    13th of 2004.
19
             I have not seen it, but --
20
        Α.
             That date, though, is consistent with
21
        Q.
    your memory?
22
             Yes.
```

Α.

```
1
  2
  3
  5
 6
9.- 8
 10
 11
 12
 13
 14
 15
               Well, let's drop back on another
 16
          Q.
      subject. You made a worker's comp claim against
. 17
      DynCorp?
 18
               Yes.
          Α.
 19
               You filed suit?
 20
          Q.
               Yes.
          Α.
 21
               And in that regard, you had a functional
 22
          Q.
      capacity evaluation in April of 2004?
 23
```

Yes. 1 Α. 2 (Whereupon, Defendant's Exhibit 16 3 was marked for identification 4 and is attached hereto.) 5 6 I'm going to hand you what's been marked 7 Q., as Defendant's Exhibit 16. Do you recognize this 8 as a summary of the results of that evaluation? 9 Yes. 10 Α. 11 (Whereupon, Defendant's Exhibit 17 12 was marked for identification 13 and is attached hereto.) 14 15 And do you recognize Defendant's Exhibit 16 Q. 17 as the Measurements & Assessment for Physician 17 Determined Impairment that was done along with 18 this evaluation? 19 Yes. Α. 20 21 (Whereupon, Defendant's Exhibit 18 22 was marked for identification 23

and is attached hereto.) And then do you recognize this Exhibit 18 as more details about the evaluation? Yes. Α. 7 :

the cartilage was torn. Also, that he had to 1 remove torn cartilage. And there were also 2 several tears in the ligaments and what not. 3 think the phrase he used when he told my mother, 4 that when he got in there, it was a mess. 5 This is not the first problem you've had 6 with that right knee, is it? 7 No. Α. 8. And you had two surgeries before? 9 Q. Yes. 10 Α. Ο. And it goes all the way back to junior 11 high school? 12 Eighth grade year. 13 Α. And you injured yourself, was it 14 Q. cheerleading? 15 No. 16 Α. How did you --17 Ο. At P.E. 18 Α. All right. And so you had the two 19 Q. surgeries before you went to work for DynCorp? 20 À. Yes. 21 Now, after your surgery on April 12th of 22 Q.

2002, you didn't return to work for DynCorp until

```
August or September of that year; is that
 1
     correct?
 2
         Α.
              Right.
 3
              Now, do you recall precisely when you
         Q.
 4
     returned to work for DynCorp?
 5
              I believe it was August 26th. I'm not a
        Α.
 6
     hundred percent positive on that.
 7:
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
```

Now, you actually visited Dr. Granger on Ο. 1 the 14th of April. 2 3 (Whereupon, Defendant's Exhibit 20 4 was marked for identification 5 and is attached hereto.) 6 7. And I am going to show you Exhibit 20, ** 8 which is notes from Dr. Granger's medical file on 9 Do you see there at the top the notes of 10 visit on April 13th, 2004? 11 Yes. 12 Α. Do you recall that visit? 13 Q. Yes. 14 Α. 15 16 17 18 19 20 21 22 23

Page 20 of 85 203 Case 1:06-cv-00723-MHT-CSC Document 36-3 Filed 06/15/2007 ... 8 And you rated your pain at about a 6 on Q. a scale of 0 to 10? Yes. 21. Α. Now, he also wrote you a Return to Work Q. Slip on that date.

(Whereupon, Defendant's Exhibit 21 was marked for identification and is attached hereto.)

7:

... 8

- Q. I'm going to show you Exhibit 21. Do you recognize this?
- A. Yes.
 - Q. And on it he said you may return to work that day, subject to the work restrictions based on the functional capacity evaluation?
 - A. Yes.
 - Q. And did you take that out to AFS?
 - A. The next morning, because I believe -it was either that afternoon or the next morning.
 I believe that afternoon, by the time we got out
 of his office, the HR department was already
 closed for the day. They close at 3:30. So I
 believe it was the next morning. I'm not
 positive.

and is attached hereto.)

7:

· 8

Q. Let me show you what's been marked as Defendant's Exhibit 22. Now, this is an e-mail from Chad Falcon to Mr. Brownell responding to his inquiry. And apparently Mr. Brownell passed this message on to you, because it came out of your -- this particular copy came out of your file.

A. Yes. This was something that I got a copy of at arbitration.

- Q. Oh, I'm sorry. Never mind. Strike that. Who did you turn it into at AFS?
- A. I believe Darlene is the one that I handed this to.
 - Q. The first person you handed it to?
 - A. Yes.

2

3

4

5

6

7

9

10

11

12

13

14

15

16

17

18

19

20

21

2.2

- Q. Do you know Tammy Maddox?
- A. Yes.
- Q. Was it Tammy Maddox perhaps that you gave it to?
- A. It may have been. I get -- they both have dark hair, and I haven't seen them enough to know sometimes --
 - Q. Did you --
 - A. -- which one it was I gave what to.
 - Q. Did you talk with Arlene first?
- A. When I went in, signed in to turn this in -- and it may have been Tammy, because I think she's the one that had the desk over off to the left when you come into the Department of Human Resources at the time. She was the one that had taken Chad Falcon's position, so that's probably who I talked to first. That's who this was given

1 to.

3

4

5

6

7

- 8

9

10

11

12

13

14

15

16

17

18

19

20

21


22

23

- Q. Okay. And what do you recall of the conversation between you and her?
- A. I gave this -- I opened the envelope and gave her this letter here that says To Whom It May Concern, the medical pass, and told her that my doctor's office had just returned these to me, and that I was returning them -- or I was turning them into them to try to return to work.

(Whereupon, Defendant's Exhibit 37 was marked for identification and is attached hereto.)

- Q. Is Defendant's Exhibit 37 a copy of the medical pass that you gave to Tammy with those other documents?
 - A. I am not a hundred percent sure.
- Q. Well, do you recognize Dr. Granger's signature down at the bottom of that page?
 - A. Yes.
 - Q. And the date, January 13th, 2005?
 - A. Yes.



1 2 3 4 5 6 (Whereupon, Defendant's Exhibit 29 7 was marked for identification 8 and is attached hereto.) 9 10 Let me show you Defendant's Exhibit 29. 11 Q. Do you recognize this as the charge of 12 discrimination --13 Yes. 14 Α. -- that you filed with the EEOC? 15 Q. Yes. Α. 16 17 18 19 20 21 22 23

5. (Whereupon, Defendant's Exhibit 41 was marked for identification and is attached hereto.) I'm going to hand you what's been marked as Defendant's Exhibit 41. Is this the Dismissal and Notice of Rights letter that you received from the EEOC regarding your charge of discrimination against AFS?

Case 1:06-cv-00723-MHT-CSC Document 36-3 Filed 06/15/2007 Page 28 of 85 87

1 2

A. That's not exactly an easy question to answer. Like I said, it has been a while since I've been out there. And I know that we have had people out there who have been on crutches before, who have worked the flight line and have been able to do it every day during the short time that they were, whether it was six weeks,

eight weeks, whatever. They worked the flight

Their partners worked with them. line. 1 The other crews out there worked with them. 2 No one had a problem with it. And they were able to do 3 it. 4 They did the ground work. They did the 5 paperwork, anything that needed to be done that 6 didn't deal with a lot of heavy lifting or 7. something like that. That's what that particular 8 person did. I know it's been done before. 9 Who do you say has done this before that 10 0. 11 used crutches? Steve Milstead. Α. 12 . Q. And he was an AAE&I tech? 13 Yes, sir. 14 Α. And what was his problem that required 15 0. him to use a crutch? 16 He broke his foot and he used two 17 crutches. 18 Do you know how long he had to use 19 0. crutches? 20

A. That, I'm not sure. I know it was several weeks.

21

22

23

Q. And what did he do during the time he

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

was working, using crutches?

- He was a leadman, but he had to go get parts and put them in his truck for those that worked out on the flight line. He was a flight line lead. He had to get parts. He had to walk and put them in his truck, take them out to the flight line. But, again, people worked with him. They made sure that he was able to do his job.
- Now, leadman -- like you said, he has a truck. His duties wouldn't be the same as somebody in your situation, would they?
- Actually, according to the job descriptions, the leadman has to be able to do the essential functions and duty of the classification that he is leading.
- But does he ordinarily get out there and Q. work with the tools like --
 - Α. Yes.
 - -- the AAE&I techs? Q.
- There are many, many times that -- more Α. often than not, your lead is over there helping you do something.
 - How was he accommodated by others that Q.

- he's working with during the time he was on crutches?
- A. They helped him with carrying parts,

 putting them in the truck for him, carrying

 books, manuals for the aircraft. I don't

 remember all of the things. I know they carried

 his tool box out, put it in his truck for him, in

 the back of his truck for him so that he could

 get to it in case he needed his tools.
 - Q. Did he? I mean, did he work doing the tasks that he would have done before he broke his foot?
 - A. My understanding was that he did, but I was not allowed on the flight line or on the airfield itself at that point, and so I don't know. I can't tell you. I didn't see him myself.
 - Q. You did not see --
 - A. Right.

11

12

13

14

15

16

17

18

19

20

- Q. -- him do it? Why were you not allowed on the flight line?
- 22 A. Because I had not been accommodated to 23 go to any sort of work out there at this point.

No, I'm talking about at the time that Q. 1 he was injured. Were you --2 I wasn't at work. . A. 3 -- working when he was injured? 4 Q. No, sir. 5 Α. Oh, okay. So this is what others have 6 Q. told you; is that right? 7. Yes. Α. s.• 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

```
1
2
3
4
5
6
10
11
12
13
14
15
16
17
              Now, let me go back to -- you mentioned
         Q.
18
     somebody at DynCorp that was being allowed to
19
     take a morphine pump. Who was that?
20
              Jerry Fowler.
21
         Α.
              And what did he do?
22
         Q.
```

He is an AAE&I technician.

Α.

- Q. And what specifically was he doing?
 - A. He was in the EETF.

- Q. And is that something he was doing permanently or something that he did for a short while?
 - A. The morphine pump?
 - Q. The morphine pump?
- A. My understanding is he is not using it right now.
- Q. I mean, while you were at DynCorp, did he use it all of the time there; do you know?
- A. Yes, he used it -- it was on all of the time. He had his little bag. As a matter of fact, it was in -- I don't remember if it was injected into his neck up here where it directly went in, but he had a little bag that he had to wear that it was constantly giving him doses of morphine all day long.
- Q. What was the problem that necessitated the morphine pump?
- A. He had a sinus surgery that went bad years ago, and they tore the sack of his brain when they went in to do the sinus surgery, and so

he has a lot of problems with dizziness and pain and balance and what not. And he's taken a variety of pain medications over the years. He gets severe migraines. And there have been many times that he's had to lay his head down on his desk, take a pain pill and lay his head down on his desk and take a nap for a little while, to try see if he can get rid of his headache.

- Q. Is he working for AFS?
- A. Yes.

- Q. Still in the EETF shop?
- A. Yes.
- Q. But you don't know if he is still -- well, you said he is not using the morphine pump now?
- A. I don't know if he is using anything else right now at home or not. I am sure he probably is, because I know that the severity of the headaches that he was having, he's taking some sort of narcotic he's got to be taking some sort of narcotic, because he has just been his headaches are almost debilitating. Well, they are debilitating.

When was the last time you talked to Q. 1 him? 2 Right before my arbitration case. Α. 3 That would have been in May of --Q. 4 '06. Α. 5 **--** 2006? Q. 6 Uh-huh. 7: Α. Did he testify in that case? Q. a. 8 No, he didn't. Α. 9 10 11 12 13 14 15 16 17 18 19 20 Q. Now, were there any other employees at 21 DynCorp that were taking morphine or narcotics --22 There are --Α. 23

- Q. -- that you were aware of?
- A. There have been a number of them that
 have come through. Some of them have been on a
 short-term basis. I know we had an armament guy
 that had to take -- he took Lortab, 10s, all day,
 every day just about, because of the severe
 rheumatoid arthritis that he had in all of his
 joints.
 - o. Who was that?
 - A. Bullet.
 - Q. Bullet?
- 12 A. Bullet.

1

10

- 13 Q. Do you know his real name?
- 14 A. I believe it's Perry Phelps.
- 15 Q. F-e-l-t?
- 16 A. No. P-h-e-l-p-s.
- 17 Q. Oh, Phillips. I'm sorry.
- A. No. Phelps.
- 19 Q. P-h-e-l-p-s?
- 20 A. P-h-e-l-p-s. Some of them, we go by 21 nicknames, and it's hard --
- 22 Q. Sure.
- A. -- to remember what their real name is.

- Q. I understand. Now, was that for a limited duration, or did you understand he was taking Lortab --
 - A. No. My understanding was he had to take it all day, every day. His -- you had to understand, his hands were just -- I mean, his hands are severely --
 - Q. Deformed?

-⊊a- 8

- A. -- deformed because of the arthritis.

 He's had to have several surgeries done on his

 feet because of the deformation of the arthritis.
- Q. Anybody else that you knew of at DynCorp that was --
- A. There were quite a few folks that came through on a six to eight-week basis that I know for a fact that they were taking different forms of narcotic pain medication on the job, that they were told that, you know, if you have to take something, you just let your supervisor know.

We had one girl that was taking Lortab, 10s, every four hours. She was a QC. And her supervisor told her that when she took one of her pills, if she started feeling sleepy or whatever,

just lay her head down on her desk and take a 1 2 nap. Who was that? 3 * Q. Stacie -- I don't remember her last 4 Α. 5 name. Stacie? 0. I believe it was Stacie. I know Tammy 7 has had -- I can't remember Tammy's last name either. 9 Let me ask you. What was Stacie's job? 10 0. Quality inspector. 11 Α. Would she have been an inspector on what 12 0. the AAE&I techs do? 13 She went around, I think, and inspected 14 parts and stuff like that. She wasn't assigned 15 to the flight line, to my knowledge. My 16 understanding was she did parts and --17 All right. Do you know if -- is she 18 0. working for AFS? 19 20 Α. Yes. 21 Q. In quality? I believe so. She may not be there now. 22 Α. She's changed a couple of times to different

positions.

1

2

3

4

5

6

7 ^

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

- Q. What about Bullet?
- A. He just recently retired.
- Q. And then Tammy -- what --
- A. I can't remember her last name. I don't remember what she did out there. I just know off, every once in a while, you would see her. She was she would break her foot. She'd finally get it healed, and about five or six months later, she'd come back and hurt her knee or something. I mean, she was accident prone, I guess.
 - Q. And you say she was taking what?
- A. I don't remember exactly. I know it was a narcotic, but I can't remember if it was Lortab or Lorcet or -- it was in the family.
- Q. Anybody else you know of that were taking narcotics while working at DynCorp?
- A. There were several. Off the top of my head, I can't remember names right now. I mean -- (stops talking).
 - Q. Was Tammy -- is she employed by AFS?
 - A. I believe she's still employed by them.

I understand. Now, was that for a Q. 1 limited duration, or did you understand he was Ż taking Lortab --3 No. My understanding was he had to take 4 it all day, every day. His -- you had to 5 understand, his hands were just -- I mean, his 6 hands are severely --7: Deformed? Ο. *** 8 -- deformed because of the arthritis. 9 He's had to have several surgeries done on his 10 feet because of the deformation of the arthritis. 11 12 13 14 15 16 17 18 19 20 21 22 23

1
2
3 Q. I
4 knowledge
5 light-dut
6 A. 5

7:

8

9

10

11

12

13

14

15

16

17

18

19

20

21

- Q. Let me back up a second. To your knowledge, did DynCorp have any permanent light-duty jobs for AAE&I techs?
- A. That are actually listed as permanent, no.
- Q. Did they have any permanent light-duty jobs, whether it's listed or not?
 - A. Yes.
 - Q. DynCorp did?
 - A. Yes.
 - Q. Who filled these positions?
 - A. Jerry Fowler fills one of them.
 - Q. All right. Anybody else?
- A. There is -- Bullet worked in a light-duty position for years because of his arthritis. I mean, they -- they've got numerous people out there who have handicaps that have been allowed to stay in their classification, and have been afforded accommodation as they need it to be able to do their job.

1 2 3 4 5 6 7 8 9 10 Tony Ford is another one who has -- I 11 think it's Tony Ford, or maybe it's Tom Ford. 12 don't remember. I know he's got back problems, 13 and he is in a clerk's position, but I believe he 14 was a mechanic when he hurt his back. I don't 15 remember. 16 But his permanent job is clerk? 17 Q. It is now. 18 Α. 19 He's not working as a mechanic --Q. No, not anymore 20 Α. 21 22

```
1
 2
 3
 5
 6
 7
w 8
 9
10
11
12
13
                   (Whereupon, Defendant's Exhibit 15
14
                   was marked for identification
15
                   and is attached hereto.)
16
17
              I'm going to hand you what has been
         0.
18
     marked as Defendant's Exhibit 15. These are the
19
     records of Dr. Flanagan.
20
              Uh-huh.
21
         Α.
              You started getting -- Dr. Flanagan is
22
     the physician responsible for your pain
23
```

management; is he not? 1 Yes. 2 Α. And you started with him in, I think, · Q. 3 March or February of 2003, after your first total 4 knee replacement; is that right? 5 Yes. 6 Α. And do you recognize this exhibit as a 7. Q. list of the medications you took beginning in ... 8 April of 2003, and through October of 2006? 9 Α. It looks fairly accurate, yes. 10 I mean, do you see any errors in it? 11 0. No, I don't see any errors. Α. 12 13 14 15 16 17 18 19 20 21 22 23

```
1
2
3
4
5
10
11
             Well, I noticed he switched you over to
12
        Q.
    Kadian in December of '03.
13
             Yes.
        Α.
14
             And you've been taking Kadian ever
15
        Q.
    since?
16
             Yes.
17
        Α.
             And in April of '04, you would have been
        Q.
18
    taking it at that point daily, Lortab, 10
19
    milligrams, twice a day, Flexeril, 10 milligrams,
20
    twice a day, and then Bextra and Prevacid.
21
                                                    Is
    that right?
22
             No, the only two for 4/15 --
23
        À.
```

```
Oh, I'm sorry. I'm looking at the wrong
1
        Q.
2
             -- was Lortab and Kadian.
3
        Α.
4
```

- Well, before that, on March 22nd, Q. Okav. you had been prescribed Bextra and Prevacid?
 - Α. Yes.

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

- And Flexeril? 0.
- Α. (Nods head.)
- At that point -- all right. I noticed 0. on the March 22nd, on the Kadian -- do you see that line?
 - Α. Yes.
- You were prescribed 62 tablets at 60 0. milligrams each, and you were back for a refill on that on April 15th. And he gave you at that time a prescription for then and a prescription for May and a prescription for June. Again, 62 tablets. So it appears at that point that you were taking two a day.
 - That's what he had prescribed it for. Α.
 - And that's what you were taking, right? Q.
 - Yes, at that time. Α.
 - And do you continue taking two a day? Q.

I take two a day right now. 1 Α. Okay. And are you still taking Lortab? 2 Q. For a breakthrough when needed, yes. Α. Well, it looks like the last Ο. 4 prescription on that one was two a day, and then 5 additional as needed. This is back in October of 6 '06. Is that the way you take it, two a day, and 7: then if you need another one, you take a third ... 8 one? 9 10 MR. DETTLING: Object to the form. 11 12 I take it when I need it. No. 13 may be days that I don't take it at all. 14 There may be days that I may have to have two. There 15 may be days that I have to have three. 16 17 18 19 20 21 22

-- employee? Now, you had your first knee replacement on January 17th of 2003? Yes. Α. And you did not return to work for Q. DynCorp after that date, did you? No Α. × 8

1 2 3 4 5 6 7 9 10 11 Had you talked to anybody out there 12 Ο. about returning to work before that day? 13 After the last surgery? Α. 14 Well, any time when AFS was the 15 0. contractor at Ft. Rucker. 16 That was the first --17 Α. No. The first occasion to talk to anybody? 18 Q. 19 Yes. Α. Okay. And what do you recall of your 20 Q. conversation with Mr. Falcon? 21 Well, when I went in to see him, I gave 22 23 him this particular sheet of paper right here,

| which shows the --

· « 8

- Q. You're pointing to the document marked Granger 159?
 - A. Yeah, and it's Exhibit 16.
 - Q. Okay.
- A. I went in and gave him this page,
 because this is what Dr. Granger said, Just go in
 and hand them this. That will show them what
 your weight limits are. I went in and turned
 that into him at work. Told him that I wanted to
 return to work, that it was going to be
 restricted, as he could see on the paper. And he
 told me that he didn't have a file on me. He
 would make some phone calls and would get back
 with me as to when I could return to work.
 - Q. Was that all of the conversation that y'all had on that occasion?
 - A. On that day, yes.
 - Q. And what happened next?
 - A. I went back in probably a day or two later. I didn't waste much time in continuing to go back up there to see if they had gotten answers for me. And was told at the time that --

the second time that I went in to see him, I was told that they could not accommodate my restrictions at that time, and that if I wanted to, that I could call DynCorp and request that they give me a job working with them somewhere in this area or somewhere where they had a position available. 7 ~

DynCorp - Fort Rucker Division

Job Description

ARMAMENT, AVIONICS, ELECTRICAL, AND INSTRUMENT TECHNICIAN

SUMMARY: Performs inspections, checks, troubleshooting, repair, overhaul, maintenance and preservation of avionics and similar equipment. Performs calibration of tools and equipment. Performs boresighting operations.

ESSENTIAL DUTIES AND RESPONSIBILITIES:

- 1. Must be able to work with and maintain standard and non-standard test equipment, instruments, meters, and gauges used in troubleshooting, repair, and overhaul of aircraft armament, avionics, electrical, and instrument systems.
- Performs inspection, functional check, troubleshooting, modification, repair, overhaul, and maintenance and preservation of avionics, radio, electromechanical, radar, navigation, autopilot, automatic stabilization, instrument, ASE equipment, photo and armament systems, components, and parts.
- Works with design, test, and development personnel in adapting new armament, avionics, electrical, and instrumentation designs to aircraft installations; and fabricates/assembles the needed wires, panels, and test and recording devices to accomplish the assigned job.
- 4. Performs in-house calibration requirements of tools and equipment used by employees in this and lower classifications.
- 5. May be required to participate in aerial flights.
- 6. Performs boresighting operations that require both mechanical and electrical adjustments. This classification will work with the classification of Aircraft Armament Technician in accomplishing the boresighting operation. When boresighting operations require only mechanical adjustments, i.e., when there are no electrical testing or adjustments in the boresighting operation, the Aircraft Armament Technician will be assigned to perform the boresighting operation.

OTHER DUTIES AND RESPONSIBILITIES:

- Must be able to write, read, and understand and work with blueprints, schematic and engineering drawings, sketches, wiring diagrams, printed circuits and cards, manufacturer's specifications, maintenance manuals, and other reference sources used in avionics, radio, instrument, radar, navigation systems, autopilot, automatic stabilization, photography, armament, and electromechanical fabrication, maintenance, repair, and overhaul.
- May be required to obtain aircraft run-up authorization.
- 3. Completes and maintains records and reports as functional assignments require.
- 4. Operates aircraft towing equipment in aircraft towing operations.

EDUCATION AND EXPERIENCE:

- 1. High school diploma or equivalent-General Educational Development (GED) certificate.
- 2. Must be a graduate of a recognized school (civilian or military) or show equivalent qualifications for armament electronics/avionics maintenance, repair, and overhaul; or must demonstrate an ability to perform inspection, troubleshooting, major repair, modification, and overhaul of components in aircraft avionics, radio, NAVAID, radar, autopilot, electromechanical, instmment, ASE equipment, and armament systems.

OTHER REQUIREMENTS:

- Must have a broad knowledge of AC/DC electricity, electromechanical components, radio and electronics (state-of-the-art) including radar and navigation, autopilot/automatic stabilization, and armament systems as used in aircraft.
- .2. Must have a knowledge of, and ability to apply, shop mathematics in the performance of the job.



SOUTHERN BONE & JOINT REHAB OCCUPATIONAL MEDICINE DIVISION 1480 ROSS CLARK CIRCLE, S.E. DOTHAN, AL 36301

April 06, 2004

D.Keith Granger, M.D. Southern Bone & Joint Specialist, P.C. 1500 Ross Clark Circle, S.E. Dothan, AL 36301

Patient: Bennett, Christine R.

Filed 06/15/2007

SSN: 423-21-1807

DOI: 03/20/02 Test Date: 04/06/2004

Dear Dr. Granger:

Thank you for referring Ms. Bennett for an FCE. It was performed on 04/06/2004 and she was very pleasant and cooperative.

MEDICAL RECORD NUMBER: 4099978

DIAGNOSIS: s/p Right TKA revision

OUTCOME SUMMARY

- 1. Regular Duty Job Title: Avionics technician
- 2. Regular Duty Physical Demands: MEDIUM-HEAVY by best estimate and from patient's verbal job description.
- 3. Valid FCE? Fully Valid with material handling, ROM, musculoskeletal exertion, etc...
- 4. Patient Physical Demand Level: LIGHT
- 5. Job Match? NO. The patient does not demonstrate the ROM, Strength, endurance, or balance to carry out the essential functions of an avionics technician with AFS. Several tests were stopped due to elevated HR.
- 6. Inappropriate Illness Behavior/Symptom Exaggeration? Minimal patterns identified.



7. Recommendations:

- a. Work release to the LIGHT physical demand classification within the FCE summary sheet guidelines due to poor CV fitness and limited muscular endurance, per judgment of Dr. Granger.
- b. The patient should be fine for constant sitting and upper extremity activity to include assembling, supply, etc., as well as occasional standing and walking activities as outlined on the FCE form.
- c. Continue PT with special emphasis on quad strengthening, gait, cardiovascular fitness, and balance activities.
- d. Perform impairment rating after 4-6 wks of intense CV/muscular endurance exercise if Dr.Granger feels that the patient is at MMI. This exercise may be performed in the pool to decrease joint forces as well as by focusing on UE aerobic exercise. The patient should be able to perform more standing activities if her CV/muscular endurance increases.

FCE RESULTS

The results indicate that Ms. Bennett is able to work at the LIGHT Physical Demand Level for an 8 hour day according to the <u>Dictionary of Occupational Titles</u>, U.S. Department of Labor, 1991. Her specific acceptable Leg Lift capability was 0.0 lb and Torso Lift capability was 30.0 lb. The patient is unable to squat, but can kneel occasionally as shown below. The detailed results are on the enclosed FCE form.

BLANKENSHIP SYSTEM RELIABILITY PROFILE

Ms. Bennett exhibited minimal symptom/disability exaggeration behavior by our criteria. She passed 22/26 validity criteria during the FCE, 85%, which suggests good effort and valid results which can be used for medical and vocational planning. Therefore, the minimal symptom/disability exaggeration classification did not affect the FCE results and may have been due to normal personality traits, anxiety regarding re-injury, a misunderstanding of the self report pain scales and other similar factors.

Again, thank you for referring Ms. Bennett for this evaluation. A more detailed narrative report is available upon request.

Sincerely,

Director Occupational Medicine

Southern Bone & Joint Rehal


Joseph T. McDaniel, MSPT

I agree with the above work release guidelines and certify them as medically correct.

Keith Granger, M.D.

cc: Chad Falcon

Enclosures:



Case 1:06-cv-00723-MHT-CSCFUNCTION RG3 CF/96/15/2007

Name: Christine R. Bennett

Age: 35 Dx:

Sex: F

Ht: 65.5

Wt: 120

FCE Date: 04/06/2004 SSN: 423-21-1807

MATERIAL HANDLING ABILITY

WORK ACTIVITY	POSTURE	INFREQUENT	0001010111		
BARRIER LIFT			OCCASIONAL	FREQUENT	CONSTANT
BACK LIFT		0 lb	0 lb	_ 0 lb	0 lb
		35 lb	30 lb	0 lb	0 fb
LEG LIFT	4	0 16	0 lb	0 lb	
POWER LIFT	80 S	0 lb	0 lb	di 0	0 lb
SHOULDER LIFT		25 lb	20 lb		<u>0 lb</u>
OVERHEAD LIFT		25 lb	20 lb	0 lb	0 lb
TWO HAND CARRY	K _P V	15 lb		0 lb	0 lb
ONE HAND CARRY	ላ ለ	15 lb	51b	0 lb	0 lb
WALKING PUSH/PULL	& W		5 lb	0 lb	dl 0
STANDING PUSH/PULI	$h\Box$	24/24 lb	20/20 lb	0 lb	0 lb
STATE OF THE STATE	$\sim \kappa \times$	24/24 lb	<u>0 lb</u>	0 lb	0 lb

NON MATERIAL HANDLING ABILITY

WORK ACTIVITY	000000		
WORK ACTIVITY	POSTURE QUALIFICATION	WORK ACTIVITY	POSTURE OUR ISLOATION
BENDING	OCCASIONAL		POSTURE QUALIFICATION
	W OCCASIONAL	STAIR CLIMBING	INFREQUENT
SQUATTING	Ø NO ·	LADDER CLIMBING	(A)
KNEELING	OCCASIONAL		NO NO
14 TELENIO	OCCASIONAL	CRAWLING	ASSE BH NO
	•		

REPETITIVE & STATIC WORK ABILITY

WORK ACTIVITY POSTURE QUALIFICATION	WORK ACTIVITY POSTURE QUALIFICATION
STANDING CONSTANT STANDING CONSTANT OCCASIONAL	ARM CONTROLS: RIGHT
WALKING CCASIONAL	LEFT V⊗ LIGHT LEG CONTROLS: RIGHT R LIGHT
FORWARD REACHING INFREQUENT OVERHEAD REACHING OCCASIONAL	LEFT LIGHT
CRITICAL BALANCING NO	FINE HAND: RIGHT YES LEFT YES
WORK CLASSIFICATION	LIGHT

ADDITIONAL COMMENTS

AUTHORIZATION certify that these FCE results represent the patient's current work ability within the limitations of the testing process. EVALUATOR 04/06/2004

Date I agree with these work restrictions with any changes I have made, they can be used for the return to work process.

414104

F U N C STRENGTH CLASSIFICATION SEDENTARY MATERIAL HANDLING 1-10 B STTING CONSTAINT STANDINGWALKING OCCASIONAL EREQUENCY DEFINITIONS PERCENT OF DAY MATERIAL HANDLING REPETITIONS NON-MATERIAL HANDLING REPETITIONS	11-15 ID CONSTANT	LIGHT 16-20 B CONSTANT CONSTANT OCCASIONAL 3-33% 5-32	VALUATIO UGHT-MEDIUM 21-35 B CONSTANT CONSTANT FREQUENT 34-00% 33-280	N WORK D	EFINITONS MEDIUM-HEAVY 51-75 Ib CONSTANT CONSTANT	HEAVY 78-100 b CONSTANT CONSTANT	VERY HEAVY Own 100 Ib CONSTANT CONSTANT
REPETITIVE WORK REPETITIONS	1-50	5-32 51-250	33-250 250-1,000	261-2,000 1,000-20,000	NOTE. Extrapol	lations May Have	Been Included Med for All Workers

The Blankenship System Functional Capacity Evaluation



SOUTHERN BONE & JOINT REHAB OCCUPATIONAL MEDICINE DIVISION 1480 ROSS CLARK CIRCLE, S.E. DOTHAN, AL 36301

MEASUREMENTS & ASSESSMENT FOR PHYSICIAN DETERMINED IMPAIRMENT

PATIENT:

SSN:

CHRISTINE BENNETT (99978

04/06/04

DIAGNOSIS CODE:

423-21-1807

RIGHT TOTAL KNEE REVISION

REFERRING PHYSICIAN: PHYSICAL THERAPIST:

KEITH GRANGER, M.D.
JOSEPH MCDANIEL, MSPT

Dear Dr. Granger:

Ms. Bennett was evaluated for impairment consideration regarding her S/P right total knee arthroplasty revision. This evaluation is conducted to the <u>AMA Guides to the Evaluation of Permanent Impairment</u>, 4th Edition, hereafter referred to as <u>The Guides</u>.

LOSS OF MOTION: Right knee 5° to 90°.

STRENGTH: Grossly 4+/5 throughout the right knee.

EDEMA: Girth measurements revealed 36cm at the right knee joint, 35cm at the left knee joint.

<u>OUAD ATROPHY</u>: Girth measurements revealed 37cm on the right at 10cm above the superior patella, and 41cm at the left knee at 10cm above the superior patella.

STATIC POSTURE: The knee is held in approximately 8° of valgus.

PAIN: The patient is reporting constant pain in a 7-8/10 range.

RECOMMENDED IMPAIRMENT: The diagnosis based impairment method was used, which is tables 64 and 66 in <u>The Guides</u>. Consideration is given to pain, in which the patient scored 10 points; range of motion, in which the patient scored 19 points; stability, in which the patient scored 25 points; then deductions are made based on alignment of the knee flexion contracture and extension lag. The patient has a 5° extension lag, which scored her five points. No flexion contracture, and the knee is held in 8 to 9° of valgus, which scored the patient six points. This results in 54 minus 11, for a total of 43 points. This converts to an impairment of 75% of the lower extremity and 30% of the whole person, per table 64 in <u>The Guides</u> and is the recommended impairment at this time.

Thank you very much for this referral. Please let me know if there are any questions or considerations you would like to see included with this impairment evaluation.

Sincerely

JOSEPH MCDANIEL, MSPT

DIRECTOR, OCCUPATIONAL MEDICINE DIVISION

JM/mt

DD: 04/08/04 DT: 04/12/04



Granger 154

PATIENT: SSN:

04/06/04 PAGE 2

I agree with the above Impairment Rating and certify as medically correct.

KELHI GRANGER, M.D.

DATE

The Blankenship System

FCE

DETAILED NARRATIVE REPORT

Patient: Bennett, Christine R. SSN: 423-21-1807
DOI: 03/20/02
Test Date: 04/06/2004

INFORMED CONSENT

Prior to the evaluation, informed consent was obtained. Ms. Bennett was informed that she would not be asked to perform any activity she did not feel she could perform and she could stop any test secondary to pain, if she desired. She was instructed to exert her best effort on each test with no pain increase.

PERSONAL DATA

Height: 65.5 inches Weight: 120 lb Age: 35

Body Build: Average Race: Caucasian

Smoking History: less than 1 pack/day

WC or PI Attorney:

PROBLEM

Ms. Bennett reports an injury on 03/20/02 and she reports the following information about her injury:

Primary Injury: Knee

Side: Right

History: 35 YOWM who tripped over a box while working on 3/20/02 resulting in injury. Subsequently she has had 4 knee surgeries with the most recent being a TKA revision due to staph. infection on 12/9/03.

Diagnosis: Right TKA

Procedures: same

Symptoms: pain, swelling, trouble walking, very weak muscles

Cardiac History: No

Hypertension: No

Medications: No



Sinus Rhythm: Regular

Job Specific: Yes

DOT Category: Professional, Technical and Managerial

Occupation: Avionics technician

Critical Demands: climbing of aircraft squatting, bending, lifting, kneeling frequent lifting of 30 pounds

Estimated PDC: MEDIUM

DAILY 24-HOUR PROFILE

Prior to the evaluation, the patient is asked how a typical day is spent between sleeping, walking, and sitting. The total must equal 24 hours. The patient's results are below.

Sleeping or Lying 8 hrs.
Standing or Walking 6 hrs.
Sitting 10 hrs.
TOTAL 24 hrs.

Ms. Bennett reports that she has a driver's license and can drive or ride in a car for 1 hours before needing a rest.

POSTURE

The patient's joint posture(s) are characterized by the following:

KNEE

Genu Valgus

Standing with Knee Flexion

Quad Atrophy Right

ANKLE & FOOT

Right Foot Supination (Varus)

Right Calf Atrophy

Neurological - Back & Lower Extremities

_	<u>LEFT</u>	<u>RIGHT</u>
L2	N/T	Normal
L3	N/T	Decreased
L4	N/T	Normal
L5	N/T	Decreased
Regional Loss]	No

TENDERNESS

Palpation was performed for deep tenderness and the following areas were found to be tender:

KNEE	LEFT	RIGHT
Joint Swelling	N/T	Moderate
Patella	N/T	Slight
Medial Joint Line	N/T	Moderate
Pes Anserinus	N/T	Moderate
Lateral Joint Line	N/T	Moderate

MANUAL MUSCLE TESTING

The results of the Manual Muscle Test(s) are listed below.

Muscle Tested KNEE	LEFT	RIGHT	DEFICIT	COGWHEEL
Semitendinosus/Membranosus	\mathbf{N}	N	0%	None
Biceps Femoris	N	N	0%	None
Quadriceps	N	N	0%	None

GONIOMETRY

Goniometry measurements were taken according to protocol described in Guides to the Evaluation of Permanent Impairment, AMA, 4th Edition, 1993. The patient is asked to move their joint as far as they are able to move and their maximum bending angle is documented. Repeat trial consistency is one of the primary validity criteria to determine if the results are valid and can be used as a measure of the patient's medical impairment and flexibility. Test validity is also determined by observing the patient's joint range of motion while they are distracted by another task. The data should not be used if the range of motion improves by distraction compared to the measured motion. Right to left deficits can be calculated to determine the amount of loss of motion due to the injury or disease. Goniometry may be used to determine improvement in a treatment or rehabilitation program. Ms. Bennett's results are listed below.

<u>KNEE</u>	,	<u>LEFT</u>	RIGHT
Flexion		135.0	85.0
Extension		0.0	5.0

GAIT PATTERN

Ms. Bennett does not use a cane during ambulation. Her speed is slow, there is no splinting, no holding, the movement patterns are asymmetrical, and there is poor correlation with the pain rating. She exhibits a knee pain limp and her behavior is appropriate.

REPETITIVE MOVEMENT TESTS

The Repetitive Movement Tests (RMT) evaluate the patient's ability to perform four common work activities, Repetitive Bending, Squatting, Kneeling, and Overhead Reaching. They are asked to perform one repetition and 10 repetitions at a controlled speed for all three movements and 10 fast repetitions for Bending and Overhead Reaching. The test results are analyzed for each test sequence before proceeding to the next test sequence. Any test is stopped if pain increases significantly or at the patient's request. Consistency of the movement patterns, willingness to move, pain, spasm, symmetry of motion, velocity of motion, and end range stretch are critically evaluated and an estimation is made regarding the patient's ability to move during an 8 hour work shift. Additional RMT tests are performed on the Hands, Wrists, Forearms or Neck for injuries to those areas. The results of Ms. Bennett's evaluation are list below.

		PAIN K	ATINGS
		Joints Stressed	Primary Injury
m	PRE TEST:		7/10+
Forward Bending Classification:	Frequent	7/10+	7/10+
Squatting Classification:	No	7/10+	8/10+
Overhead Reaching Classification:	Frequent	7/10+	7/10+
Hand Open - Close Classification:	Frequent	7/10+	7/10+
	POST TEST:		6/10+

FORWARD BENDING - 1 TIME CONTROLLED

The range of motion was normal, the speed was average, there was no end range stretch, the movement pattern was symmetrical, the behavior was normal, and the movement pattern had equivocal correlation with the pain rating which was 7/10+.

FORWARD BENDING - 10 TIMES CONTROLLED

The range of motion was normal, the speed was slow, there was end range stretch, the movement pattern

was symmetrical, the behavior was normal, and the movement pattern had equivocal correlation with the pain rating which was 7/10+.

FORWARD BENDING - 10 TIMES FAST (Normal < 14.0 seconds)

Ms. Bennett completed 10 repetitions in 15 seconds. The range of motion was normal, the speed was slow, there was end range stretch, the movement pattern was symmetrical, the behavior was normal, and the movement pattern had equivocal correlation with the pain rating which was 7/10+.

SQUATTING - 1 TIME CONTROLLED

Case 1:06-cv-00723-MHT-CSC

The range of motion was markedly decreased, the speed was very slow, the behavior was one of overreaction, and the movement pattern did not correlate with the pain rating which was 8/10+.

OVERHEAD REACHING - 1 TIME CONTROLLED

The range of motion was normal, the speed was average, there was end range stretch, the behavior was normal, and the movement pattern correlated with the pain rating which was 7/10+.

OVERHEAD REACHING - 10 TIMES CONTROLLED

The range of motion was normal, the speed was average, there was end range stretch, the behavior was normal, and the movement pattern correlated with the pain rating which was 7/10+.

OVERHEAD REACHING - 10 TIMES FAST (Normal < 7.0 seconds)

Ms. Bennett completed 10 repetitions in 6 seconds. The range of motion was normal, the speed was average, there was end range stretch, the behavior was normal, and the movement pattern correlated with the pain rating which was 7/10+,

HAND OPEN - CLOSING - 1 TIME CONTROLLED

The range of motion was normal, the speed was average, there was end range stretch, the behavior was normal, and the movement pattern correlated with the pain rating which was 7/10+.

HAND OPEN - CLOSING - 10 TIMES CONTROLLED

The range of motion was normal, the speed was average, there was end range stretch, the behavior was normal, and the movement pattern correlated with the pain rating which was 7/10+.

HAND OPEN - CLOSING - 10 TIMES FAST (Normal < 4.0 seconds)

Ms. Bennett completed 10 repetitions in 5 seconds. The range of motion was normal, the speed was average, there was end range stretch, the behavior was normal, and the movement pattern correlated with the pain rating which was 7/10+.

DISTRACTED MOVEMENT PATTERNS

The patient's movement patterns are observed directly during any Pre-PCE activities, which may include a Musculoskeletal Evaluation, a Gait Analysis, and the Repetitive Movement Tests. They are then observed by distraction throughout the FCE. If there are any improvements in the movement patterns by distraction, including increased range of motion, increased velocity, improved quality, decreased holding, decreased splinting, decreased limping, or any other change which signifies an improvement in the patient's movement ability, or if the patient's pain behavior decreases or their affect improves compared to the Pre-FCE activities, the Musculoskeletal Evaluation, the Gait Analysis or the Repetitive Movement Tests, it indicates that the patient's movement ability is better than what was demonstrated by direct observation when they were given ample opportunity to demonstrate their best performance. This represents a failed validity criteria, a non-organic sign, and suggests that the patient is attempting to control the test results to demonstrate more pain and disability than are actually present, the motivation of which is not known.

SUMMARY OF OBSERVED DISTRACTED MOVEMENT PATTERNS

Ms. Bennett's movement patterns did not change by distraction during the remainder of the FCE; therefore, the results of the Repetitive Movement Tests are considered valid.

STATIC STRENGTH TESTS

Static Whole Body Strength Tests are performed according to the protocol documented in Ergonomics Guide for the Assessment of Human Static Strength, D.B. Chaffin, Ph.D., AIHA J., 1975; Functional Capacity Evaluation: The Procedure Manual, K. L. Blankenship, Macon, GA, 1994; and The Protocol Manual, K. L. Blankenship, Macon, GA, 1998. Six whole body test postures are documented in the Work Practices Guide for Manual Lifting, NIOSH, Cincinnati, OH, 1981, and two postures, Pushing and Pulling, were designed by Keith L. Blankenship, P.T.. Only selected postures are tested depending upon the patient's condition and the necessity for the data. Test validity is determined by the following criteria:

- 1. Coefficient of Variation of the Mean Forces for each test
- 2. Coefficient of Variation of the Last Two Mean Forces for each test
- 3. The Curve Coefficient of Variation of each exertion of each test
- 4. Visual Analysis of the Force Curves for each test
- 5. A Fatigue Response over 5 seconds for each curve for each test
- 6. Percentiles of Strength for each posture
- 7. The Presence of a Functional Strength Deficit
- 8. Results of the Pain Replication Test
- 9. The Relationship between the postures
- 10. The percent between a repeated series of a test posture
- 11. The patient's test behavior

A summary of Ms. Bennett's results is listed on the table below.

		•	PKI	STEST PAIN:	8/10+	
			P	RE TEST HR:	101	
STATIC TEST	PEAK FORCE	MEAN FORCE	<u>CV</u>	FATIGUE	PERCENTILE	<u>PAIN</u>
Arm Lift	41.0 lb	41.0 lb	-		36%	8/10+
Hi Near Lift	49.0 lb	47.0 lb			22%	9/10+
Hi Far Lift	24.0 lb	20.0 lb			10%	9/10+
Back Lift	30.0 lb	25.0 lb			5%	9/10+
Push	43.0 lb	42.0 lb			7%	8/10+
			PO	ST TEST HR:	121	
				TEST PAIN:		

OCCASIONAL AND INFREQUENT MATERIAL HANDLING TESTS (OMH AND IMH)

The tests for Infrequent and Occasional Material Handling are documented in The Design of Manual Handling Tasks: Revised Tables of Maximum Acceptable Weights and Forces, S.H. Snook and V.M. Ciriello, Ergonomics, 1991. IMH is defined as 1-4 lifts per day and OMH is defined as 5-32 lifts per day, spread out over the course of the day. The evaluator makes the decision regarding how many tests are requested from the patient, but a routine protocol involves all postures tested for OMH and only selected postures tested for IMH. Up to four decision making paradigms may be used for the IMH and OMH weights, Psychophysical, Kinesiophysical, Statistical and Computerized. Psychophysical is a form of testing where the patient chooses the acceptable weights based on their pain, their anxiety regarding reinjury, their level of strength and fitness and their inherent motivation to perform material handling following their injury. Kinesiophysical is a form of testing where the evaluator makes the decision about the acceptable weight considering items such as, the medical impairment, confirmed pain levels, range of motion, velocity of movement, body mechanics and forced body mechanic changes, the appearance of muscle strain, muscle recruitment patterns, counterbalancing strategies, patient stability and the general appearance of overload. The Statistical approach considers databases and known statistical patterns which can show whether or not a person is working within acceptable patterns for their sex, strength levels and fitness levels. The fourth decision making method is Computerized Isoinertial Lifting (CIL). CIL objectively documents the acceleration and deceleration forces and patterns which provides the most accurate measures of pain inhibition and biomechanical overload.

The IMH and OMH tests are started at submaximal weights and the weight is progressively increased at safe levels until the proper weight is identified for each frequency. The patient is not asked to complete any test they feel is too difficult or which would place them at risk of injury, but they are asked to exert their best effort to achieve their maximum safe lifting ability.

Page 65 of 85

The Maximum Weight Lifted (MWL) is the heaviest weight the patient completes or attempts for each posture. The OMH Result Weight is the weight that all of the data identifies as the safe and acceptable weight for each posture for handling 5-32 times per day and the IMH weight is the safe and acceptable weight for selected postures for 1-4 times per day. The Percentile Rank is how the patient compares to Snook and Ciriello's Database of Healthy, Industrial Norms. The OMH-HR is the heart rate documented for the OMH weight and the IMH/OMH Pain is the amount of pain reported by the patient for the IMH and OMH weights. Lifting and Carrying are recorded by weight and Pushing and Pulling are recorded by force exerted, not the weight or mass of the object moved. The worker's OMH weights are compared to the Dictionary of Occupational Titles, U.S. Department of Labor, 1991, Vol. I and II, called the DOT Physical Demand Levels, which are shown below.

DOT CLASSIFICATION	OMH WEIGHTS
Sedentary	1-10 lb
Light	11-20 lb
Medium	21-50 lb
Heavy	51-100 lb
Very Heavy	over 100 lb

Extrapolations are also made between the five DOT categories to offer a more specific description of the worker's ability. These new categories are shown below with the DOT Categories.

STRENGTH CLASSIFICATION	OMH WEIGHTS
Sedentary	1-10 lb
Sedentary-Light	11-15 lb
Light	16-20 lb
Light-Medium	21-35 lb
Medium	36-50 lb
Medium-Heavy	51-75 lb
Heavy	76-100 lb
Very Heavy	over 100 lb

A summary of Ms. Bennett results is listed on the table below.

PRE TEST PAIN: 7/10+

POST TEST PAIN: 9/10+

OMI				PRE TEST HR:	120	
<u>OMH</u>	<u>MWL</u>	IMH RESULT	OMH RESULT	PERCENTILE		IMH/OMH
<u>TEST</u>	<u>WEIGHT</u>	WEIGHT	WEIGHT	RANK	HR	PAIN
Back Lift	35.0 lb	35.0 lb	30.0 lb	23%	156	
Shoulder Lift	25.0 lb	25.0 lb	20.0 lb	3%		7/10+
Overhead Lift	25.0 lb	25.0 lb	20.0 lb		108	8/10+
Carry	10.0 lb			6%	96	8/10+
•		15.0 lb	10.0 lb	1%	121	8/10+
One Hand Carry	10.0 lb	15.0 lb	10.0 ІЬ	1%	121	9/10+
D. Push/Pull	24.0 lb	24.0 lb	20.0 lb	10%	144	8/10+
			P	OST TEST HR:		0/107

PSYCHOPHYSICAL LIMITATIONS

Back Lift: Maximum Preferred

KINESIOPHYSICAL LIMITATIONS

Back Lift: Slowed Velocity/Muscular Strain

Back Lift: Aerobic End Point

PSYCHOPHYSICAL LIMITATIONS

Shoulder Lift: Maximum Preferred

KINESIOPHYSICAL LIMITATIONS

Shoulder Lift: Slowed Velocity/Muscular Strain

Shoulder Lift: Facial/Neck/Arm Strain

PSYCHOPHYSICAL LIMITATIONS

Overhead Lift: Maximum Preferred

KINESIOPHYSICAL LIMITATIONS

Overhead Lift: Slowed Velocity/Muscular Strain

Overhead Lift: Facial/Neck/Arm Strain

Overhead Lift: Loss of Stability

PSYCHOPHYSICAL LIMITATIONS

Carry: Maximum Preferred Carry: Breathing Difficulties

KINESIOPHYSICAL LIMITATIONS

Carry: Slowed Velocity/Muscular Strain

PSYCHOPHYSICAL LIMITATIONS

Dynamic Push/Pull: Maximum Preferred Dynamic Push/Pull: Breathing Difficulties

KINESIOPHYSICAL LIMITATIONS

Dynamic Push/Pull: Slowed Velocity/Muscular Strain

Dynamic Push/Pull: Excessive Struggle Dynamic Push/Pull: Aerobic End Point

EXTRAPOLATIONS FROM THE STATIC TESTS TO THE OMH ACTIVITIES

The results of the Static Strength Tests are used to extrapolate the patient's Occasional Material Handling (OMH) ability. There are several research papers which support these extrapolations with a potential error of approximately 25%. The extrapolations here are based on unpublished research described in Functional Capacity Evaluation: The Procedure Manual, K. L. Blankenship, Macon, GA, 1994. Three extrapolations are made. The "OMH Expected Extrapolation" is the approximate weight or force the patient should be able to manage dynamically. The "OMH High Extrapolation" is the maximum weight or force the patient should be able to manage dynamically. The "OMH Low Extrapolation" is the minimum Occasional Material Handling weight or force the patient should achieve. The "OMH Maximum Weight Lifted (MWL) Result" is the maximum weight the patient lifted during the Occasional Material Handling Tests. The "Validity Rating" is based on whether the patient's "OMH Maximum Weight Lifted (MWL) Result" is within the High and Low Extrapolation range. If the "OMH Maximum Weight Lifted (MWL) Result" is less than the Low Extrapolation, this suggests that the patient performed submaximally on the Occasional Material Handling Tests, unless otherwise justified. If the patient lifts a weight dynamically which is greater than the OMH High Extrapolation, this suggests submaximal effort on the Static Strength Tests. Either of these findings represents a failed validity criteria. There are two reasons why persons who are passing more than 70% of their FCE Validity Criteria may fail one or more of the validity criteria for these extrapolations.

- 1. They may have allowed a greater pain increase during the Static Strength Tests than they allowed during the Occasional Material Handling Tests.
- 2. They may have experienced pain in a part of the range of motion during the Occasional Material Handling Tests which was not experienced during the Static Strength Tests.

Ms. Bennett's results are listed on the table below.

OMH DYNAMIC ACTIVITY Back Lift Shoulder Lift Overhead Lift Carry	OMH HIGH EXTRAP 18.3 lb 44.7 lb 29.1 lb 47.6 lb	OMH EXPECTED EXTRAP 12.5 lb 30.8 lb 20.1 lb 32.8 lb	OMH LOW EXTRAP 9.5 lb 23.0 lb 15.1 lb 24.6 lb	OMH MWL RESULT 35.0 lb 25.0 lb 25.0 lb 10.0 lb	VALIDITY CRITERIA Invalid Valid Valid
			47.0 10	10.0 10	Invalid

Document 36-3

HAND TESTS

A series of tests are performed for Maximum Grip And Pinch Strength described in Grip and Pinch Strength Normative Data for Adults, V. Mathiowetz, et.al., Arch PM&R, 1985, and tests for Gross and Fine Motor Control using the Purdue Pegboard. There are a number of validity criteria indicating the degree of effort documented in The Seriously Uninjured Hand: Weakness of Grip, H. M. Stokes, JOM, 1983, Detecting Sincerity of Effort When Measuring Grip Strength, B. Niebuhr and R. Marion, Am. J. PM, 1987, Detection of Submaximal Effort by Use of the Rapid Exchange Grip, D. Hildreth, et.al., J. Hand Surg., 1989, and Functional Capacity Evaluation: The Procedure Manual, Keith L. Blankenship, Macon, GA, 1994. The Hand Grip and Pinch Grip tests may also be repeated a second or third time in order to verify the validity of the patient's effort and to evaluate for pain and fatigue responses.

Ms. Bennett's results are listed on the table below.

DOMINANT HAND - Right

PRE TEST PAIN: 7/10+

<u>TEST</u> <u>NAME</u> Hand Grip	Rt Lt	STRENC 87.0 1 75.0 1	<u>ЭТН</u> Ь	PERCENTILE RANK 88% 77%	STRENGTH DEFICIT 14% - Lt 0%	
Key Pinch	Rt	17.0 l	Ь	57%	6% - Lt	
Palmar Pinch	Lt Rt	16.0 ll 23.0 ll	_	50% 90%	0% 0%	
	Lt	23.0 H	Ь	95%	0%	
TEST NAME			<u>AL 1</u>	TRL		TRIAL 3
MAX Grip - 1 MAX Grip - 2		Lt 67.0 lb 75.0 lb	Rt 80.0 I 87.0 I	b 72.0 lb	Rt 79.0 lb 80.0 lb	Lt Rt
MAX Grip - 3		75.0 lb	86.0 1	b		
Key Pinch - I		16.0 lb	17.0 1	Ь		
Key Pinch - 2		15.0 lb	17.0 1	b		
Palmar Pinch - 1		19.0 lb	23.0 1	b		
Palmar Pinch - 2		23.0 lb	23.0 ii	Ď		
Palmar Pinch - 3		22.0 lb	23.0 !!	,		

POST TEST PAIN: /10+

HAND FUNCTION CLASSIFICATION

The patient's ability to use their Upper Extremities and Hands for work is calculated by an algorithm including their demonstrated strength on the Static Strength Tests and the Occasional Material Handling Tests, their Fine Motor Skills scored by the Purdue Pegboard and their observed skill throughout the FCE. The patient's Hand Function is classified on the table below.

HAND FUNCTION CLASSIFICATION	LEFT	RIGHT
Simple Grasp	XX	XX
Fine Motor Skills	XX	XX
Low Speed Assembly	XX	YY

PURDUE PEGBOARD ASSEMBLY TEST

TRIALI	TDIALO	Mark Talan		
TRIAL I	TRIAL 2	TRIAL 3	41/RD 4CB	DED OTHER -
			<u>AVE</u> RAGE	PERCENTILE

32 36 40 36.0 20%

The results of the Purdue Pegboard Assembly Test indicate that Ms. Bennett has excellent fine motor skills and is qualified for Assembly Tasks of pieces in the 1-4 mm. range or larger at a Non Production Rate, but she should be capable of a Production Rate with a short period of training or job acclimation; therefore, she is classified as High Speed Trainable.

NON-MATERIAL HANDLING TESTS (NMH)

The patient is tested on the selected work stations for the Non-Material Handling and Repetitive Activities. In many cases, the data can be extrapolated from the Material Handling Tests and other tests such as the Repetitive Movement tests. The amount of time spent Standing, Walking, and Sitting is obtained from the Activity Profile and the amount of time the patient actually performs these activities throughout the FCE. Stair Climbing, Balancing, and Crawling are directly tested. The ability to use Arm or Leg controls is tested directly or the data is extrapolated from the Static Strength Tests and/or the Material Handling Tests according to the criteria in the Dictionary of Occupational Titles. U.S. Department of Labor, 1991. Professional judgment is required for the NMH decisions since time does not permit exhaustive testing for each activity and there is no published research or database to assist with these decisions. There are also an extremely limited number of validity criteria for the NMH activities. This is a more subjective part of the FCE process; therefore, patient cooperation is required for reliable results. Ms. Bennett's results are listed on the table below.

	PRE	TEST	PAIN:	4/10+
--	-----	------	-------	-------

ACTIVITY TESTED	
SITTING	OUALIFICATION Constant
Pre FCE Sitting	Constant
FCE Sitting	:
Post FCE Sitting	:
STANDING	Occasional
FCE Standing	·
WALKING	Occasional
FCE Walking	·
BENDING	Frequent
Other Test	0 Reps
SQUATTING	No
Other Test	0 Reps
KNEELING	Occasional
Other Test	0 Reps
CRAWLING	No
30 sec. Test	Poor
Constant Test	N/T
ARM CONTROLS - RIGHT	Light
ARM CONTROLS - LEFT	Light
Arm Pull	0.0 tb
Other Test	0 Reps
LEG CONTROLS - RIGHT	Light
LEG CONTROLS - LEFT	Light
Leg Push - Right	0.0 lb
Leg Push - Left	0.0 lb
Other Test	0 Reps
STAIR CLIMBING	Occasional
Pre Test H.R.	96
Test H.R. 1 - 30 steps	121
Test H.R. 2 - 70 steps	168
Test H.R. 3 - 105 steps	0
3 min. Stand H.R.	108
Post RPE	19

Cardiac Rhythm	Regular
Steps Climbed	70
LADDER CLIMBING	No
Pre Test H.R.	96
Distance Climbed	7.0 ft
Post Test H.R.	101
3 min. Stand H.R.	96
Post RPE	17

PSYCHOPHYSICAL LIMITATIONS

Maximum Preferred Breathing Difficulties

KINESIOPHYSICAL LIMITATIONS

Obvious Fatigue Present Aerobic End Point

BODY MECHANICS

The patient's utilization of body mechanics is observed throughout the evaluation. The body mechanics they use intuitively when distracted usually represents what they use naturally during work and leisure activities, even though they may report using a different style. Based on their injury and the amount of weight they are capable of lifting, recommendations may be made in order to decrease the risk for future injury relative to improper body mechanics. Ms. Bennett's body mechanics are classified on the table below.

TEST SEQUENCE	PREFERRED POSTURE	BODY MECHANICS
OMH	Back	Fair

PERCENTILE OF STRENGTH PROFILE

The percentiles of strength for all of the activities tested are analyzed for specific variations. Most individuals will have a percentile ranking which is reasonably consistent across all tests. Specific variations may indicate weakness secondary to pain, neurological deficits, disuse atrophy, poor cardiovascular fitness, or specific lifestyle trends. The patient's strength may be characterized by the word descriptors on the table below.

PERCENTILE PROFILE	PERCENTILE CLASSIFICATION
Exceptional	90-99%
Excellent	80-89%
Well Above Average	70-79%
Above Average	60-69%
Average	41-59%
Below Average	31-40%
Well Below Average	21-30%
Poor	11-20%
Very Poor	1-10%

Ms. Bennett's results are listed on the table below.

FCE TEST	PERCENTILE RANK
OMH - Back Lift	23%
OMH - Shoulder Lift	3%
OMH - Overhead Lift	6%
OMH - Carry	1%
OMH - One Hand Carry	1%
OMH - Dynamic Push/Pull	10%
Hand Grip - Rt	88%

Hand Grip - Lt	77%
Key Pinch - Rt	57%
Key Pinch - Lt	50%
Palmar Pinch - Rt	90%
Palmar Pinch - Lt	95%
Purdue Pegboard	20%

TEST MODULE Occasional Material Handling Hand Grip Pinch Grip	AVERAGE PERCENTILE 7% 83% 73%	Very Poor Excellent
Overall Average	73% 42%	Well Above Average Average

HEART RATE PROFILE

The patient's heart rate is documented at periodic intervals throughout testing. The data is used to determine the patient's suitability for work relative to their level of cardiovascular fitness, which is measured while the patient is actually working. This profile is felt to be more appropriate than a low level fitness evaluation performed on steps, treadmill, or bicycle ergometer because this profile is specific to work activities. If the patient's heart rates exceed their acceptable levels, a cardiovascular fitness program may be necessary prior to return to work. All Continuous Work categories assume that normal breaks are permitted. The acceptable heart rate limits for continuous work are shown below.

CONTINUOUS WORKING TIME	PERCENT MAX H.R	
Continuous Sitting	30-45%	
Continuous Standing	35-50%	
Continuous Walking	45-55%	
Material Handling 10 min.	75-85%	
Material Handling 30 min.	67-75%	
Material Handling 60 min.	60-66%	
Material Handling 4 hrs.	57-63%	
Material Handling 8 hrs.	55-60%	

Ms. Bennett's actual heart rates documented during testing are listed below.

TEST ACTIVITY	<u>H.R.</u>	% MAX H.R.	B .P.
Pre-Test Sitting	84	45%	88/50
Static Strength Testing	121	65%	00,00
Occasional Material Handling	96	52%	
Stair Climbing	168	91%	
3 min. Post Test Standing	108	58%	
Post FCE Sitting	96	52%	
Post FCE Standing	108	58%	

Summary of the Heart Rate Profile

The above Heart Rate Profile indicates a Poor level of cardiovascular fitness for Ms. Bennett. Her overall Validity Profile was classified as valid; therefore, the above heart rate data is considered valid and represents Ms. Bennett's actual level of cardiovascular fitness. If Ms. Bennett wishes to qualify for a higher Physical Demand Classification than she achieved today, it will be necessary to implement a cardiovascular rehabilitation program to improve her level of fitness.

THE BLANKENSHIP RELIABILITY PROFILE

The Blankenship Reliability Profile includes profiles for Symptom/Disability Exaggeration, Non Organic Signs and Validity. The Symptom/Disability Exaggeration Profile is subjective but the Non Organic Signs and Validity Profiles are objective. Patients scoring invalid on all three profiles are felt to be attempting to control the test results to demonstrate a greater level of disability than what is actually present, the motivation of which is not known. Any one of the three profiles may not be reported if insufficient data

exists.

SYMPTOM/DISABILITY EXAGGERATION PROFILE

Symptom/Disability Exaggeration is a clinical behavior in which the patient's symptoms, pain behavior and disability are out of proportion to their medical impairment and movement patterns observed mainly by distraction. This assessment begins with the patient completing questionnaires which help the evaluator understand the patient's perspective of their symptoms and disability. Next, an intake interview is conducted and the patient's description of their symptoms and disability are correlated with their actual medical impairment. Then, the FCE is conducted and the following observations of the patient are made.

- True Pain Behavior
- 2. Overreaction Behavior
- 3. The Movement Patterns of the Injured Body Part
- 4. The Patient's Symptomatic Reports
- 5. Non Organic Test Results
- 6. True Strength and Strength Deficits
- 7. Movement Patterns that Improve by Distraction
- 8. General Attitude
- 9. Motivation to Cooperate
- 10. Deliberate Use of Poor Body Mechanics that Increase Stress on the Injured Body Part

Any significant lack of correlation between the patient's perception of their symptoms and disability and the actual test results, including the observation of normal to near normal movement patterns observed either by direct observation or by distraction, represents Symptom/Disability Exaggeration Behavior. Observing the movement patterns of the injured body part is the best way to determine if any significant level of pain and disability exists due to the neurophysiological relationship that exists between pain and the ability to move. When significant pain is present, the patient is unable to move normally, and when there is no pain, normal movement patterns are possible. Therefore, if a patient reports a high level of pain and disability, but the movement patterns of their injured body part are normal, this is neurophysiologically impossible and the patient is demonstrates Symptom/Disability Exaggerator behavior. The motivation for this behavior is unknown and cannot be discovered by the FCE alone, but one of the most blatant acts of Symptom/Disability Exaggeration behavior is abnormal movement patterns and pain affect demonstrated by direct observation which improve significantly by distraction. The patient must offer a suitable explanation for this finding, or conscious malingering may be assumed.

Since professional judgment is involved, Symptom/Disability Exaggeration behavior is not documented unless there is a significant disparity between the patient's subjective reports and behavior and the evaluator's observations of the patient's actual movement patterns, general behavior and test results. Symptom/Disability Exaggeration behavior generally represents an obstacle to effective rehabilitation and return to work, and an effort should be placed on determining why this inappropriate clinical behavior exists. The scores of Ms. Bennett's questionnaires are classified as follows:

PAIN QUESTIONNAIRE SUMMARY - CRITERIA SCORED: 10

		ALD. IV
1/10 in the LOW Category	10.0%	
0/10 in the MODERATE Category	0.0%	PAIN O. PROFILE
9/10 in the HIGH Category	90.0%	High

NUMERIC PAIN RATING PROFILE (0-10+)	PAIN RATING
Pre-Test Pain	7/10+
Repetitive Movement Tests	6/10+
Static Strength Tests	0/10+
Occasional Material Handling	9/10+
Continuous Stair Climbing	9/10+
Post-Test Pain	10/10+
NUMERIC PAIN RATING PROFILE - High	6.8/10+

Page 72 of 85

MOVEMENT PATTERN CLASSIFICATION

X The Movement Patterns and Behavior Are Consistent with the Symptoms and Disability The Movement Patterns and Behavior Are Not Consistent with the Symptoms and Disability

SYMPTOM/DISABILITY EXAGGERATION CLASSIFICATION

Symptom/Disability Exaggeration is Not Present (NSE)

Minimal Symptom/Disability Exaggeration Exists (MSE) True Symptom/Disability Exaggeration Exists (TSE) Overt Symptom/Disability Exaggeration Exists (OSE)

VALIDITY PROFILE

The Validity Profile is comprised of a cohort of individual tests that collectively help determine whether or not the patient is exerting their best effort during all of the FCE tests. Effort is defined as the physical ability and motivation to complete a task within the individual's pain tolerance. A significant increase in pain is not required. If the patient exerts effort up to the point of a barely perceptible pain increase, or slightly below that level so there is no pain increase at all, then they will pass the overall Validity Profile. If the patient does not pass the overall Validity Profile, then they have not exerted their best effort. The patient cannot assert that they were not able to exert their best effort due to pain since they are not asked to tolerate any pain increase at all, or at least no more than a barely perceptible increase, which everyone can perceive. And since the patient is not asked to perform tasks for which they do not have the physical ability, or if they do not have the physical ability, the test data should reveal that, then the only reason for not passing the overall Validity Profile is that the patient was not motivated to cooperate with the evaluation process and exert their best effort. The patient must then explain why they were not motivated to cooperate with the testing process to demonstrate their current ability to work, and their reason may not be secondary to pain. Therefore, failing the Overall Validity Profile is viewed as a voluntary act of noncompliance with the testing process and with the professionals who requested the test. Current research, submitted to Spine, shows that a strong indicator of whether or not an evaluee is cooperating with and exerting their best effort on a functional test is the Evaluator's professional judgment; however, most of the Validity Criteria of The Blankenship System FCE are based on published research. A few are based on K. Blankenship's unpublished research. The Blankenship System FCE Bibliography sites the published and unpublished works.

It is believed that a reliable overall Validity Profile should contain at least 20 validity criteria. A Validity Profile of less than 20 may also be reliable, but the evaluator must add their professional judgment regarding the reliability of the test results.

There is also an empirical relationship between the number of validity criteria passed and the degree of effort exerted during testing and the reliability of the test results for predicting work performance. This algorithm was developed by K. Blankenship published in the revised edition of, The Blankenship System Functional Capacity Evaluation: The Protocoi Manual, revision began in 1996, Macon, GA. That revised algorithm is shown below.

Validity Criteria Passed	Degree of Effort Word Descriptor	
90-100%	Excellent Effort	Valid Results
80-89%	Good Effort	Valid Results
70-79%	Fair Effort	Valid Results
70-75%	Borderline Valid, Results are Cons	servative
60-69%	Poor Effort	Borderline Invalid
***	•	Results
<60%	Very Poor Effort	Invalid Results
< 20 Criteria	May Be Unreliable, Professional J	udgment Required

The Validity Criteria for Ms. Bennett are listed below and the Validity of Effort Classification is summarized at the end.

Validity Category

Validity

Bennett, Christine R.

Lower Partners to A Company	
Lower Extremity MMT: Cogwheel Release	Valid
All Lill #1: Coefficient of Variation CV	
Arm Lift #1: Force Curve Analysis and the Course Civ	Invalid
Tibu Float Lift #1; Coefficient of Variation CV	Valid
right Near Lift #1: Force Curve Analysis and the Common Curve	Valid
High Far Lift #1: Coefficient of Variation, CV	Valid
High Far Lift #1: Force Curve Analysis and the Curve CV	Valid
Back Lift #1: Coefficient of Variation, CV	Valid
Back Lift #1: Force Come And I	Invalid
Back Lift #1: Force Curve Analysis and the Curve CV Push #1: Coefficient of Variation, CV	Valid
Push #1: Force Cump As 1	Valid
Push #1: Force Curve Analysis and the Curve CV	Valid
OMH Extrapolation: Static to Dynamic Back Lift	Invalid
OMH Extrapolation: Static to Dynamic Shoulder Lift	Valid
OMH Extrapolation: Static to Dynamic Overhead Lift	Valid
Own Extrapolation: Static to Dynamic Carey	Invalid
Series #1 Hand Grip Consistency: Left	Valid
Series #1 Hand Grip Consistency: Right	Valid
Key Pinch Series#1 Consistency: Left	
Key Pinch Series#1 Consistency: Right	Valid
Palmar Pinch Series#1 Consistency Left	Valid
Palmar Pinch Series#1 Consistency: Right	Valid
Series #2 Hand Grip Consistency: Left	Valid
Series #2 Hand Grip Consistency: Right	Valid
Consistency: Series 1-2: Max Hand Grip Left	Valid
Consistency: Series 1-2: Max Hand Grip Right	Valid
NMH Stair Climb (RPE - HR) Result	Valid
Positive Distraction, Symptom Exaggeration and Overresction	Valid
- State Condition Symptom Exaggeration and Overregation	

nptom Exaggeration and Overreaction are scored 1 time each in overall score using the worst-case validity score.

VALIDITY PROFILE SUMMARY
TOTAL VALIDITY CRITERIA SCORED 26

TOTAL VALIDITY CRITERIA PASSED

22 (85%)

Validity of Results: Valid - Good Effort

04/06/2004

12/22/2005

Test Date

Report Date

Joseph T. McDaniel, MSPT

SOUTHERN BONE & JOINT SPECIALISTS, P.C.

To:	Whom it may concern	Date: 4//3/0	4
Name	:Christine Bennett.	/ /	ŧ
This	s to certify that this patient		
4	Was treated in my office today.		
()	Will be unable to work for the period		
y	May return to work on 4/3/04		
()	Should not participate in physical education for the period		
a /\	and Whok nexternion should on Ed	Σ	





B.R. Brownell

Falcon, Chad [falconc@frmaint.com] From:

Sent: Tuesday, May 11, 2004 2:14 PM

To: Brownell, B.R.

Leingang, Shirley; Whitney, Robert A.; Harris, Arlean Cc:

Subject: Bennett, Christine

B.R.:

Based on Christine Bennett's Functional Capacity Evaluation (FCE), which lists her permanent restrictions, the Company cannot accommodate her work restrictions as an Avionics Technician per Field Management. Plus; the FCE specifically states within the OUTCOME SUMMARY: #5 Job Match? NO. The patient does not demonstrate the Range of motion, strength, endurance, or balance to carry out the essential functions of an Avionics Technician with Army Fleet Support. Employee may seek advice from Bob Whitney on which other classifications she may be deemed qualified to perform. In accordance with Article 35, employee may reclassify. Employee may qualify for Temporary Partial Disability and if the reclassification pays a lower base rate. Employee may also qualify for vocational rehabilitation per Alabama State Workers' Compensation. Any questions concerning Christine Bennett's Workers' Compensation Benefits will need to be directed to the DynCorp point of contact since she is a DynCorp work-related injury. Please respond at your convenience if you have any additional questions concerning this issue.

Best Regards.

R. Chad Falcon ARMY FLEET SUPPORT

Administrator, Workers' Compensation

Email: falconc@frmaint.com Phone: 334-503-3428

Fax: 334-598-0476 E-fax: 334-598-5694





TO BE COMPLETED BY SUPERVISOR PURPOSE: ON THE 10B INJURY ON THE 10B ILLNESS PHYSICAL EXAM SICKNESSANJURY NOT WORK RELATED AF ON THE 10B INJURY/ILLNESS GIVE DATE: NATURE OF INJURY/ILLNESS: THIS IS: INITIAL FOLLOW UP DATE DEPARTED FROM WORK.
PURPOSE: ON THE JOB INJURY ON THE JOB ILLNESS PHYSICAL EXAM SICKNESSANJURY NOT WORK RELATED JF ON THE JOB INJURY/ILLNESS GIVE DATE: NATURE OF INJURY/ILLNESS:
ON THE JOB INJURY/ILLNESS CIVE DATE: NATURE OF INJURY/ILLNESS:
IF ON THE 10B INJURY/ILLNESS CIVE DATE: NATURE OF INJURY/ILLNESS:
THE IS. DEPART FOLLOWITH PLANTS IN THE PROPERTY OF THE PROPERT
THIS IS: INITIAL FOLLOW UP DATE DEPARTED FROM WORK: TIME DEPARTED: VISIT VISIT
SUPERVISOR'S SIGNATURE: DATE:
TO BE COMPLETED BY PHYSICIAN/FACILITY VISITED (EMPLOYEE MUST ENSURE ALL BLOCKS ARE COMPLETED)
NAME OF FACILITY VISITED: Southern Bone & Joint PHONE HUMBER 793-263
MAILING ADDRESS KCC DOMAN
DATE TIME IN TIME OUT
TYPE OF TREATMENT Z EXAMINATION X-RAY LAB SPLINT SUTURE THERAPY BYE PATCH
DIACHOSIS: PRESCRIBED MEDICATION(S)
Disposition: (Please "k" thru box to murk disposition)
DATE EMPLOYEE ABLE TO RETURN TO WORK: 4/6/04-FCE completed
Able to work - no restrictions
Able to work - with following restrictions
Must keep dressing clean and dry No lifting No work near hexardous or moving machinary
Limited use of band May lift up to 30-40 lbs No work requiring use of both eyes (driving, climbing, etc.)
No exposure to solvents or chemicals No prolonged standing or welking No use of
May ellimb steins with rading with rading or stooping
Other
Estimate recovery date and return to full duty:
UNABLE TO WORK
RG-BXAM - DATE:TIME:
PHYSICIAN'S COMMENTS:
PHYSICIAN'S NAME Print) D. WITH GOODS SIGNATURE
TO BE COMPLETED BY ADMINISTRATIVE SERVICES
CLEARED PERSONNEL - DATE: TIME: SIGNATURE:
DATE RETURNED TO WORK: RESTRICTIONS NO RESTRICTIONS APPROVED:
A A A A A A A A A A A A A A A A A A A
TO BE COMPLETED BY SUPERVISOR: (EMPLOYEE MUST CLEAR PERSONNEL UNLESS PREVIOUSLY ARRANGED WITH ADMINISTRATIVE SERVICES)
RESIDENCE DATE 9 13 05 TIME:
DISTRIBUTION: ORIGINAL Finance/Accounting
YELLOW - Personnel File PINK - Workers Comp File Form 81-261
- Heritanovanical

CHARGE OF D	SCRIMINATION	,	AGENO	ΣΥ	CHAR	GE NUMBER			
This form is affected by the Privacy Act of 1974; form.	See Privacy Act Statement before completin	g this		FEPA EEOC					
	Please also file with other approp	•••	gencies.			and EEOC			
NAME(Indicate Mr., Ms., Mrs.)	State or local Agency, if an		ME TELEPHON	IE (Includ	In Asso Co. 4x)				
CHRISTINE R.	BENNETT	1101	WE TELEFITOR		34) 894-5481				
STREET ADDRESS CIT	Y, STATE AND ZIP CODE				_ ,,	DATE OF BIRTH			
1036 CO. RD. 154 NEW	V BROCKTON, AL 36351					07/23/1968			
NAMED IS THE EMPLOYER, LABOR ORGAL AGENCY WHO DISCRIMINATED AGAINST	NIZATION, EMPLOYMENT AGENCY, AP ME (If more than one list below.)	PRENT	ICESHIP COM	мгттее,	STATE OR LOCA	AL GOVERNMENT			
NAME	NUMBER OF EMPLOYEES, MEMBERS			1	TELEPHONE (Incl	lude Arca Code)			
Army Fleet Support, LLC			(334)	598-0401					
	Y, STATE AND ZIP CODE					COUNTY			
P.O. Box 620309 Fort R	tucker, AL 36362	· · · · ·			·	Dale			
NAME		TEL	EPHONE NUM	IBER (In	clude Area Code)				
STREET ADDRESS CIT	Y, STATE AND ZIP CODE					COUNTY			
CAUSE OF DISCRIMINATION BASED ON (C	TOOK PLACE EARLIEST								
The Color IX	lary [] privately []		LAY ODICDY						
	·		IAL ORIGIN		12/01/2002				
RETALIATION AGE	X DISABILITY X OTHER (atnest	Г	12/01/2003 X CONTINUI	NG ACTION			
THE PARTICULARS ARE (If additional paper		<u> </u>	**************************************						
I was employed as an Armament, Avio the-job injury occurred on March 20, 2 awarded the contract as of December 1 refused to accommodate my disability	nics, Electrical, and Instrument Tech 2002. At this time Dyncorp was the G , 2003. Since December 1, 2003, an	Govern d cont	ment Contractinuing throug	tor. Ar h this d	my Fleet Suppo ate, Army Fleet	ort, LLC, was t Support, LLC, has			
Alabama (Exhibit 1). I am including a perform the Essential Duties and Response	I have seniority on over 120 Armament, Avionics, Electrical, and Instrument Technicians currently working on the job at Ft. Rucker, Alabama (Exhibit 1). I am including a copy of my restrictions (Exhibit 2) and Medical Pass (Exhibit 3) from Keith Granger, M.D. I can perform the Essential Duties and Responsibilities of my job description with reasonable accommodations as has been provided for male employees by Army Fleet Support, LLC. I am enclosing a copy of my job description (Exhibit 4).								
Please also see the Army Fleet Support Commitment (Exhibit 6).	I, LLC, EEO statement (Exhibit 5) as	nd the a	Army Floot S	upport,	LLC, Affirmati	ve Action			
Exhibit 7 is a copy of a letter mailed to As of this date Army Fleet Support, LI	Army Fleet Support, LLC General l LC, has not responded to this letter.	Manage	er Thomas A.	Green,	by my attorney	s on June 28, 2005.			
			•						
	•								
I want this charge filed with both the EEOC and will advise the agencies if I change my address	o the State of local Agency, it any. I	TARY -	(When necessar	y for State	e and Local Requir	ernents)			
cooperate fully with them in the processing of procedures.	ny charge in accordance with their	vear or at	firm that I have lge, information	read the a	above charge and the	nat it is true to the best of			
I declare under penalty of perjury that the foreg			E OF COMPLA						
* Mustine Bentus Date 07/29/2005 Charging Part	SU (Da		ED AND SWOP and year)	RN TO BI	EFORE ME THIS I	DATE			

EEOC FORM 5 (REV. 3/01)



EEOU Form 161 (3/98)

U.S. EQUAL EMPLOYMENT OPPORTUNITY COMMISSION

	DISMISSAL AND A	10-10-		·				
To:	DISMISSAL AND N		OF RIGHTS					
	1036 County Road 154	From:	Birmingham	District Office				
	New Brockton, Alabama 36351		Ridge Park P	lace				
			1130 22 nd Stre	et South				
	·		Suite 2000 Birmingham	Alabama 35205				
F1			gnam,	Alabama 35205				
<u> </u>	On behalf of person(s) aggrieved whose identity is CONFIDENTIAL (29 CFR § 1601.7(a))		•					
EEOC Char	EEOU Representat	ive		Telephone No.				
130-200		son, in	vestigator	(205) 212-2128				
I HE EEO	S IS CLOSING ITS FILE ON THIS CHARGE FOR THE	FOLLOW!	NG DEACON.					
	The facts alleged in the charge fail to state a claim under any	of the statu	ites enforced by the E	EEOC.				
	Your allegations did not involve a disability as defined by the	Americans	with Disabilities Act.					
4.5	The Respondent employs less than the required number of el	nplovees o	r is not otherwise cov	orod by the sta				
	Your charge was not timely filed with EEOC; in other words, ye charge.	ou waited to	o long after the date(s	ered by the statues. s) of the alleged discrimination to file your				
	Having been given 30 days in which to							
	interviews/conferences, or otherwise failed to cooperate to the extent that it was not possible to resolve your charge. While reasonable efforts were made to locate you, we were not able to do so.							
	You were given 30 days to accept a reasonable settlement of	er that affor	rds full solias sanstanta					
X	The EEOC issues the following determination: Based upon its i establishes violations of the statutes. This does not certify that to any other issues that might be construed as having been ra	nvestigation	n, the EEOC is unable					
	The EEOC has adopted the findings of the state or local fair el							
	Other (briefly state)		practices agency that	investigated this charge.				
	- NOTICE OF S (See the additional information	UIT RIG	HTS - d to this form.)	•				
rederal law of this Not oe differen	ne Americans with Disabilities Act, and/or the Agismissal and of your right to sue that we will send you based on this charge in federal or state court. You lice; or your right to sue based on this charge will be t.)	ur lawsuit lost. (The	must be filed We time limit for filing	against the respondent(s) under ITHIN 90 DAYS of your receipt g suit based on a state claim may				
Equal Pay alleged EP Defore you	Act (EPA): EPA suits must be filed in federal or so a underpayment. This means that backpay due for a file suit may not be collectible.	tate court any viola	within 2 years (3 ations that occur	years for willful violations) of the red more than 2 years (3 years)				
	On behalf of the C	ommission	1					
	1		•					

Enclosure(s)

Wilmer Tharpe

Attorney At Law

P.O. Box 311506

CC:

Elses & Hinton fax Bernice Williams-Kimbrough, District Director Enterprise, Alabama 36331

Darlene Whelan Director, Human Resources Army Fleet Support P.O. Box 620309

Fort Rucker, AL 36362-0309



PATRI MANAGETTES No Pocument 36-3 Page 79 of 85 Filed 06/15/2007 in belle ? Southeast Alabama MEDICAL **Prescription Flow Sheet** CENTER Date Name of Drug Dose Frequency Refills M.D. BID. TID PRN ME Blo bid-tid anselva does to neek BUD-TUD PRN toners bid-tid mr 10-20-90 Flanagan 087

#1981, mi:RX Flow Sheet: 9/01,

PAIN 1 NG-AND 22 MET CENT Document 36-3

Filed 06/15/2007(~P3/4089) of 85

Southeast Alabama:
MEDICAL

Prescription Flow Sheet

Prescription Flow Sheet CENTER										
Date	Name of Drug	Dose	Frequency	#	Refills	Part Colorado				
4-14-01	flucie	10	tid	93		M.D.				
4-14-05	Kadian	50	hid.	62		ME				
4-14-05	loutab	10	bid-tid mn bt	75		MP				
4-14-01	Nexium	20	Cil	31	0					
5-13-05	Herenie	(0)	Fid	93		1V1				
5-13-05	Lorab	10	bid-tid am bt	75		(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)				
5-13-05	Kadian	50	bid	62	0	ME				
6-13-06	Hexeril	10	Fid	93	0	MF				
6130	Lorab	10	bid-tid-pm	170	0	ME				
6-13-05	Kadian	50	bid	(g)	0	ME				
7-15-05	Kadian	50	bid	(0a	0	MP				
7-150/	Lortab	10	bidtid my	75	0	ME				
7-150	Herri	10	tid	93	0	ME				
B-16 V	Kadian	50	bid	62	0	ME				
8-4-5		10	bid-tid pro	75	0	MF				
8-16-07	Alyens	10	tid '	93	0	mP				
8-14-05	Louis Tours		WAO		Θ	M				
01100	x acuan	Soma	TPO BID	62	4	NIF				
2/10/0	ortub	10	TRO BID tal	RUJS	: 6	ME				
1100	therent	LOMO	7107a	93	4	ME				
10.17.65	1 allah	50	bld	62	e '	MF				
10.17.65	Loud	10	bia-tid pro	75	a .	ME				
10-17-05	Kadian	10	tid	931	0	MP				
11-18-05	Loual	50	oid	623		MF				
11-18-05	flexens		2-3×dpm	75	0	ME				
11-18-00	lidodum		600 - C	gs.	0	mP				
12/105	Kadian	5/·	79day TPto neck	3).	<u> 6</u>	ME				
12-16-05	Louah	10 10	<u>Ird</u> 2-3xd mn	102 75 93	<u> </u>					
	Lexens	10	eoxd βνη gdayto 3xd		<u> </u>	ME				
	Gidadum	51.		73		ME I				
1-17-06	Kadian	50	gagisto neck	3						
1-17-06	Wilab	lθ	the first of the f	UA.	The state of the s	ME 880				
26406	Lortalo	10		7 <u>\$</u> 75		W斯勒				
altico	Radian	100	2-3×0 prn PyD			To the state of th				
8 400	Lortal	10	2 3xd DrN	3. Sec. 15. 15. 15. 15.	12 20 May 12 C. 1.	The second secon				
3/400	Kadian	50	Blo			<u>ጥ</u> € MF				
	· · — — — — — — — — — — — — — — — — — —			V		DO 33%				



PASEN : MACHEN Pocument 36-3 Filed 06/15/2007 Page 81 of 85

<u>Southeast Alabama</u>

	Prescription	on Flow Sheet		Character R	. 1	MEDICA CENTER
	Date	Name of Drug	Dose	Frequency	molt	CENTER
	11/18/18	Duralegic	50ma		#	Refills M.D.
	126/03	adame 1	5%) (2	& MF
	12/0/03	AVM29 Voids	1 Ox	no it is	17	Ø MF
	12/2/63	melr 1	157	080 000 12/5/C	3/ 3/	& mf
	12/5/03	Kadian	50 m		15	9 mg
	0/19/03	Radian	30r	BIP	Qd	Q MF
	12/03	Jadian 12/09/13	100n		60	g m
	12/33/03	Hereril	10m	TIP		pm
	1/20/04	Cortab	107	130 min 6/4 PT	93	8 ME
	1/20/04	Herrend	10	TIP	- 12- 012	mi
s Sen.	2-19-04	hadia /23	108	BIP	12	1 mt
	2-19-04	Loyal	100	T po 9 30 min	42	8 MJ
	201.4	may my	 , <i>O</i>	belove PT	-125-1	U MF
	3/2/14	Madian	40	BID	(02	8 MF
	3/2/14	Ditab	10_	BID	62	6 mg
	3/2/14	Gleyenil	10 mg	10	93	EFF
-	3/2/04	Physical Transfer of the Physical Physi	2003	00	61	D mt
ŀ	4/15/04	Thellacide .	20m	100	3/	5 nat
ľ	415/04	Kodio Hirst W		610	(02	2 mF
	10/404	Governo	50 m	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	62	8 ms
		Hexen'l	100	mol-rip	79.00	2 MF
		Bertra		tid	93	* MF
		Prevarid	<u>-00</u>	qa	3/	2 MF
	10/6/04/	Judian 10/15 11/15/14	$\frac{20}{50}$	ga	31	ME
	1-5-051	Ladian 1/15	<u> </u>	hand laid		Om
	-5-05	Larlab	10	pid Fid	UA	D MM
	15-05.	Liverio	10	bid-tid		2 m
	1-5-05	Dextra	2a		93 3	3 MF
L	1-5-05	marrial	20		31 6	MF
1	9/10/00	Kadian	0	TRO BID	131	I M
1	7/10/00	Nevium	30		1001	DMF
Ľ	3-15-05	Kadian	50	1.1	31	O ME
2	3-15-05	Verium	20	1010C	(12)	MP
L	3-15-05	Ortab	70	pid-tid		
Ļ			- ' -		75/2	MF
L		30.0		· · · · · · · · · · · · · · · · · · ·	Flanaga	an 089
					1	ĺ

#1981 mi RX Flow Sheet . 0%

Southeast Alabama

MEDICAL

Prescription Flow Sheet Bluet Christine

	on Flow Sheet popul	th C	nnstine		CENTER
Date	Name of Drug	Dose	Frequency	#	
4-7-18	Perucet	(0)50) I BID PM Break		Refills M.D.
13/20/0	Day Consin	80m	1 080	93	8 M
3/7/8	Percocet	10/500	BIDPM Break	10 2	o m
3713	Miraloso		1 top v 80g liquid	1 booth	
113	Paradere	lob	I + QHS	31	W
317 8	Prevacid	20n	FOD	31	1 MF
3/2/2	V () a	200	TOD	31	1 m
APR 1 8 200	3 Percocot	10	BIP	62	Ø ME
APR 18 200	12		BID	62	8 mF
	PEGCONSIL	80	TID	93	
APR 1 8 200		163 D	of TIP	93	& MF
APR 1 8 200 APR 1 8 200	10-	25,	, Qhs	31	9 mf
APR 1 8 20	102	25%	Thans	62	8 MF
APR 1 8 20	103 franciay	12.5	TISPOD		5 mF
APR 1 8 2	03) namadorie	100	J Ohs	3/	5 M
	Butto	2000	Qp	3(5 mg
APRIA 8-20	13 De maria	7	Q.O	3/	5 mf
6/6/93	Topoma +	100m	Ges total	31	2 1tt
GROS	Oteron tro	14 000	Del 6/18/03	02	Q 01+
12/8/8	7/9× ED10	10m	tell 6203	93/	9 27
7/3/03	Ordicontin	80, Ru	- TIN		LUXT_
7/3/03	Percocet	10/650	SAIR	9.3	Ø M/-
8/7/03	Percocet	10/050	TRIN	62	OMF
8/7/03	Odexortin	80 mg	÷ 71D	62	Ø MF
8 2003	Drycontin	400	TIPYZW	93	2 MF
82803	Oxycontin	80 M	THOPZW	42	& mF
82863	Drycontin 9/4/03	2005 2005	T10 x 200	42	\$ m=
8/28/05	Oxycontin 9/25/03	20m	TTD YZu.	42	\$ mf
728/03	0xyconti 1/9/03	-80~1	BIDEZW	28	8 mt
11)4/63	Ilexerie	100%	TIP	93	8 mg
11/4/03	Jeycontin	40m	TID	42	Ø MF
11/4/03	fercocot	10M	Olo pro	600 6	
11/4/03	freincid	30m	00'	31	5 mf
11/4/03	perta	302	OP	I	5 mx
	Jopanay	100M	ohs	3/ 0	5 mt
1.141020	haradore	1000	Ohs	3/	5 25

Christine Bennett

Prob. No.	Medication/ Amount Dispensed	Init.	Dos∈	No. 01		ОК	Refills/I	Date/Stre	ngth/Initials		
				Refills	Start Star	Nurse Refill			··en-An-inidiz	Reason Discontinued	DEA Contro
	Ultracet		30	\$	9/18/0	Yes No				- a do	2/55
-	Livtobio		30	Ø	-11	Yes No	,				*
	Zanaflageting.	55	30	φ	વીમ્યુટ	Yes No				walnut (X43/
	Zunafauttny		50		idəlo					800 230 9924 W DI	2455
-	Ultracet	1	40	J	•	Yes No					
	Revisab 10	- 11	30	ϕ	a	Yes No					
	Oxycontini tra 20	-	40	Ø	11/6/03	Yes				-ot-to I	Way 53
	Oxylontin	A	D		2/18/02		-			prescripion	705
	Fortal 10	H	30	\$	-,	Yes No			914	prescription en Dorange e topten of	skist Duy
	Ultraced	122	30	6	2	Yes No					155
	30 mosfley tre	3	(V)	Ø	.1	Yes No					
1	-21-03 solds Mudugan Lot	lus +	30	TD8	25	Yes No					
	(rqat 10		3ù ,	T po	Ø	Yes No					rick/
	Stabel Have		11,	in dir	00	Yes No	/				/-
			0č			Yes No		PX			(m)
	2003 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	الد الأ		y		Yes No		化火	Pick (up	ANT .
· _	1-27-5-44 Londol 10	471	*	4		Yes No	Distri	ávlovvy vyliská			
	Morning to	42		V		Yes No		SANDA //		Granger 266	

CONTINUING MEDICATIONS

Christine Bennie

No.	Medication/ Amount Dispensed	Init.	Dose N	lo. of Refills	Date Start Sta	Nurse	Refills/	Date/Stre	ength/Initial		DE
	Actai 5	Ka !	#			Refili Yes	-			Discontinued	Con
	Loctabio			D 6	6-120	Vas	ma	itis	Calle	347-686	S RB
	Intabio	4	50 0 50 0		6/Alo	—				procup	uys:
- 	Zgnafley 4mg		04		1/3/03	Yes			+	उपास्तव	HUSK
- -	Oxegranting Fing		0 4	,		-		-		347-2199	1/53
	Sutat-10		0 0		7/5/07	 					55
	Fortablo	3		1	75/08	V=-				a Do	ļ
- i -	Zavafley you	32	-+ -		1/23/03					5-113161	2/55
:	Oxycenteric	-#- GC		- 1	Paffor	Yes				a Du	S5
i	Petalin 10mg	28	- ^		-,	No Yes				-	·
	Bildin lang		172	V	/	No Yes					
- : 	hanaflexyna	-	12		6/	Yes	2H	1		BXDN	4
- -	Oxygontinal		DP			Yes No		lia	1-M	ast -	
	Lortabio	31 #32	1	0	2012	Yes		- 3	47-	3199-	6
	Retalin 10	F32	1 '			No Yes				pltipick	
	Oxycortingo Oxycortingo Utracet, o	90			<i>a</i>	No Yes				-	
	11thaut 6			8/2	76/	No Yes				(IWA Wax)	<u> </u>
_	Oracorden or	90	A	9/	RI	No Dev les _	A		/-	(101-1100) 800-230-992)	, —
			7			MEDIC	CATION			Granger 267	

No. Amount Dispensed Refills Start Stoo Nurse Refills/Date/Strength/Initials Reason DEA	Nar	me Coop 1:00 ov 0	1070) Door		innte of i	Ottelled OC/A		Daga OF of OF	
11/ Thurs, 10 80 30 1 1/24 80 Jan without 20 30 1 1/24 80 Jan without 20 30 0 1 1/24 80 Jan without 20 4 4 1/2 80 Jan without 20 8 8 100 108 8 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2	Proib,	Medication/	Inf	. Dose	No. 0	f Date	OK	Refills/	Date/Strend	o/2007	Page 85 01 85AC	
123 37	140,			_	Refills		Refill			go y mandia		DEA Control
######################################	12/	Thurs las 800	4	-		12/	Yes	1		1	w-than	
Duad 25M 5 30 xi H2748 No OV DUBS FINTAL 7.5 S #30 & U YOS NO OV DUBS FINTAL 7.5 S #30 & U YOS NO OV DUBS FINTAL 7.5 S #30 & H198 NO OV DUBS FINTAL 7.5 S #30 & H198 NO OV DUBS FINTAL 7.5 S #30 & H198 NO OV DUBS FINTAL 7.5 S #30 & H198 NO OV DUBS Ultram 50 F30 X 9 H198 NO OV DUBS FORTAL 7.5 S #30 & 3990 NO OV DUBS FORTAL 7.5 S #30 & 3990 NO OV DUBS FORTAL 7.5 S #30 & 3990 NO OV DUBS FORTAL 1.5 S #30 & 3990 NO OV DUBS FORTAL 1.5 S #30 & 4190 NO OV DUBS FORTAL 1.5 S #30 & 4190 NO OV DUBS FORTAL 1.0 \$5 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	٠ ,	123 3712	 		<u> </u>	124	<u> </u>	John		an	1	
Buladashy 5 30 xi Harge Ves Birtal 7.5 35 #30 8 " Ves Birtal 7.5 55 #30 9 " Ves Birtal 7.5 55 #30 9 1/18/19 Ves Birtal 7.5 55 #30 9 1/18/19 Ves Birtal 7.5 55 #30 9 1/18/19 Ves Birtal 7.5 55 #30 4 4/18/19 No Bultonolou 50 tor xo 1/24/19 No Bultonolou 50 tor		7 200 Albu	P	# 30	8		1					1
Sixtal 7.5 St 30 & West No O O ANGES No O AN		Nika de 25ha	100		13	 	 	705	1/98	<u> </u>	OU	
Liver 7.5 5 #30 \$ " ves No O Augks Lotal 7.5 5 #30 \$ " ves No O Augks Lotal 7.5 5 #30 \$ 1/13/19 ves Augusta Augks 1/4/10/19/19/19/19/19/19/19/19/19/19/19/19/19/			135	1 30	XT	427/9	<i>(</i> 11			ļ	D	EK.
Notato 7:5 5 50 4 1/3 1/		Lival 7.5	2	4577	~	U					W	
Lotal 7:5 \$ \$30 \$ 41198 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \			2	r 30	190						- W	155
Lotal 7:5 \$ \$30 \$ 41198 \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		Just 7.5	Se	12/2	1	TT: 40	Yes				 	
Shrist 1.5 5 30 0 1 3198 No		J-4100		01	45	3700	No					
Shrtat 1.5 5 430 0 1 3198 405 1010	- 1	0,000001.5	5	30	9	6/11/9	V/					11296
Yelopoten	- 1	· holeline		1	1	 	1		-		DV *	185
Postar 1.5 55 #20 H GINIAN NO ON AND STATE OF TOTAL 10 \$5 1/20 Pros ON		: 0101104-7.5		#30	φ	111319	d Yes No			-	mouth	200/55
Postar 1.5 55 #20 H GINIAN NO ON AND STATE OF TOTAL 10 \$5 1/20 Pros ON		Metopopur	65	/ 0	5	01 11 00	Yes				3476868	
Ultram 50 #30 x2 9/18/98 No No W 255 Lortal 15 5 #30 \$ 3/3/10 No 3476865 \$ 55 Lortal 10 \$ \$ 30 \$ 44/102 No 3476865 \$ 55 Tregungan & #30 \$ 41/402 No 785 Lortal 10 \$ \$ 50 \$ 5/6/0 No 785 Lortal 10 \$ \$ 50 \$ 5/6/0 No 785 Sanglat \$ 50 \$ 7/23 No 0	_	10% top cel	,	non	10	1/34/48	No				T OV PO	155
Ultram 50 #30 x2 9/18/98 No No W 255 Lortal 15 5 #30 \$ 3/3/10 No 3476865 \$ 55 Lortal 10 \$ \$ 30 \$ 44/102 No 3476865 \$ 55 Tregungan & #30 \$ 41/402 No 785 Lortal 10 \$ \$ 50 \$ 5/6/0 No 785 Lortal 10 \$ \$ 50 \$ 5/6/0 No 785 Sanglat \$ 50 \$ 7/23 No 0		Hotalin.5	5	#2	4	rivalad	1 1				N	W-
Lostabris 5 # 30 \$ 31910 Yes 347685 \$ 347685 \$ 5 # 30 \$ 31910 Yes 347685 \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	-			^ 2	<i>/</i> (Diedas					OV	15
Lortable 55 #30 \$ 3/9/10 No 3476865 Plss Lortable 55 #30 \$ 3/9/10 No 3476865 Plss Lortable 55 #30 \$ 3/9/10 No 3476865 Plss Lortable 50 \$ 4/100 No 785 Lortable 50 \$ 4/100 No 785 Lortable 50 \$ 5/100 No 3476865 Plss Lortable 750 \$ 5/100 No 95/100 No 3476865 Plss Lortable 750 \$ 100 Plss Lortable 750 Pl	i	- WENNY 50	4	30	y2	9/18/98	3 I				O	24
Lotablo \$ 30 p 4400 No 347-6865 PS Pregugar & 30 p 4400 No 347-6865 PS Pregugar & 4 p 4 p 5 p 8 p 8 p 8 p 8 p 8 p 8 p 8 p 8 p 8	- 1	lost 125	_	#		/ 1	Vos				01 0	755)
Lostabilo \$ 30 p 4400 No 347-6865 \$ 1000 Pes John John No 347-6865 \$ 1000 Pes John No	_	· · · · · · · · · · · · · · · · · · ·	52	30	Ψ	3/29/0					3471.81	25/50
Tegergan Forty 10 4 2 0 4/15/12 Yes Merengal	Ī	Lortal-10	4	Fa	ζ .		Yes	··				200
Fortablo \$0 \$ 5/6/0 000 360 360 5/6/0 000 360 5/6/0 000 360 000 360 000 360 000 000 000 00	- }	(18 COLGOLD)					No				347-6865	15
Fortablo \$0 \$ 5/6/0 000 360 360 5/6/0 000 360 5/6/0 000 360 000 360 000 360 000 000 000 00		Forte: 104	W	# 2		4/15/	ایدا			·	Willer	
Fortablo \$0 \$ 5/6/0 000 360 360 5/6/0 000 360 5/6/0 000 360 000 360 000 360 000 000 000 00		meser and -						J135			R	
Fortablo \$0 \$ 5/6/0 2/00 300 347-685 45 5/6/02/00 300 5/6/02/00 300 347-685 45 5/6/02/00 300 347-685 45 5/6/02/00 300 347-685 45 5/6/02/00 300 347-685 45 5/6/02/00 300 347-685 45 5/6/02/00 300 5/6/02/02/00 347-685 45 5/6/02/00 300 5/6/02/02/00 347-685 45 5/6/02/00 300 5/6/02/02/00 347-685 5/6/02/02/00 300 5/6/02/02/00 300 5/6/02/02/00 300 5/6/02/02/00 300 5/6/02/02/00 300 5/6/02/02/02/00 300 5/6/02/02/00 300 5/6/02/02/02/00 300 5/6/02/02/00 300 5/6/02/02/02/00 300 5/6/02/02/02/00 300 5/6/02/02/02/02/02/02/02/02/02/02/02/02/02/		Jule	Ì	多(Ø	4119103	No				W DW	ko
Sanafat 30 \$ 5/14/0. No 347-6865 3 4 5/14/0. No 347-68		fortablo			1	-1 (-			
30 \$ 5/4/05/NO \$ 5/4/05/		(()		30	φ	5/6/01	9NO +				310-185	45
30 4 Yes No	.	Letterto	7	30	x	111/	Yes		-		3416003	1/
30,006 750 TOTT pog4-61 320 4 5/23 No 07 MC/19 2007 tab 10 5/20102 No 347-6850 LOTTab 10 5/20 7 No 1944 Yes Mart 0 COULT	+	2 hugla			 	2/16/03	No				a sugar	155
Jostal 10 # 5/23 No 0 Mart 0 (1) 16		30 Hive	ļe	30	Ÿ			•				
Jortal 10 # 123 No 0 Mart 20 1/6		Socker 7.50				1	 -					
Lontabio 5/20 6 5/2002 No 347-6857 Mart 0 CO1/16		7/07/ 200446L	3	2)	f -	1/23		Ø	7		DKA /12	4
wortable of an 1x of yes mart of collections		i)	1	# /	/	51-04			-			
TO TO TO TO TO TO YES TO MOST O COLLE			16	N	P	124102	No			_	347-68 DM	
7 103 (NS) D135 347-1865	1	109 4ab 10 4		handerightarrows	178 16	/4/]		77	r		n Collie	
			\subseteq	40	<u>Y</u> '	102	No	135		34	2-18% E	

EXHIBIT C

STATE OF ALABAMA

COUNTY OF DALE

AFFIDAVIT OF EDWIN B. BROWN

Edwin B. Brown, after being first duly sworn, deposes and says as follows:

- 1. My name is Edwin B. "Ed" Brown. I am over the age of majority and competent to testify to the matters stated herein. This Affidavit is based on my personal knowledge.
- 2. I am the Manager of Human Resource for Army Fleet Support, LLC (AFS) at Fort Rucker, Alabama. I have worked in AFS HR since July 2004 and have held my current position since December, 2005.
- 3. AFS prohibits employees from taking narcotics or mind-altering medications work or within 6 hours before the start of their shift. Attached to my affidavit are the excerpts from the indicated Sections of AFS's Human Resources Procedures Manual that address the subject:
 - a. Section V.C.4. of Chapter 41 (Medical Leave) ("Employees will not be allowed to work while taking narcotics and/or mind-altering medications.") (Attachment "1").
 - b. Section D ("Returning to Work After Medical Treatment") of Chapter 26

 ("Worker's Compensation Program") requires that employees returning to
 work from a work related injury/illness must obtain a written clearance
 from the Worker's Compensation Administrator on a Medical Pass (form
 261) from the employee's treating physician. (Attachment "2"). That Pass

 (Attachment "3") requires the employee to list, on separate lines, all "Non

Narcotics" and all "Narcotics" and states, in bold face print:

** Narcotic Drugs cannot be taken within 6 hours of shift start time nor during shift**

The employee is then required to place his/her initials in a blank below this statement.

- 4. I have checked AFS's records and determined that there are no authorizations for Jerry Fowler or Perry Phelps (who retired on September 30, 2004) to take medications at work and no medical restrictions on them.
- 5. I have checked AFS's records for Thomas Ford and Steven Milstid and determined that Thomas Ford was accommodated for four weeks beginning July 25, 2005, by not requiring him to lift over 25 pounds. Steven Milstid was accommodated for 45 days from November 21, 2005, until January 5, 2006, pursuant to a doctor's instruction that he was not to have any "weight bearing on his right ankle." Neither of these were permanent accommodations.
- 6. An "Ergonomic Analysis" of the Armament, Avionics, Electrical & Instrument
 Technician's job was prepared in October 2006 as part of an analysis of jobs at AFS by Southern
 Bone & Joint Sports Medicine & Rehab/Occupational Medicine Division. Attachment "4" is a
 copy of that Analysis.

Further, Affiant saith not.

Edwin B. Brown

Sworn to and subscribed to before me on this the

14th day of June, 2007.

Case 1:06-cv-00723-MHT-CSC

Satil Bandell

[Affix Notarial Seal]

My Commission Expires:

11-20-2007

Table of Contents **CHAPTER 41**

MEDICAL LEAVE

- PURPOSE: To provide guidelines for administering the policy regarding 1. medical leave of absence.
- 11. OBJECTIVES: To ensure proper administration and monitoring of the Medial Leave programs provided by the Company and to ensure strict adherence to applicable Federal Laws covering medical leave programs including the Family Medical Leave Act (FMLA).
- III. CONTROLS: Supervisors approve disability leave of absence upon established proof of disability and indicate absence code on PAL Card. The Manager, Human Resources and the Benefits Manager both monitor the FMLA program
- IV. **DEFINITIONS:** None.
- V. **PROCEDURES:**
 - A. Disabled employees notify their supervisor of the disability and request leave of absence. The employee submits proof of disability through the Doctor's Certification.
 - B. Extended Medical Leave
 - 1. If disabled longer than 30 days, employees are transferred from their assigned work area to an inactive status under the jurisdiction of the Human Resources Department as follows:

Personal Disability - Direct Labor - Department 40 Personal Disability - Indirect Labor - Department 41 Industrial Accident - Direct Labor - Department 42 Industrial Accident - Indirect Labor - Department 43 Family and Medical Leave - Direct Labor - Department 44 - Indirect Labor - Department 45 Family and Medical leave

- 2. The Personnel Section processes a Personnel Status Change Request (Form 229), transferring the employee to an inactive status and clearing the employee through the department level.
- 3. PAL cards indicating absence code are no longer required when transferred to the Inactive Department.

- C. Employees must present to Manager, Human Resources with a release to return to work signed by their physician. Personnel Section coordinates with the appropriate director to determine location assignment.
 - 1. Personnel Section prepares a Personnel Action report transferring the employee to active status and coordinates with the department head to where he will be assigned.
 - 2. The returning employee may be examined by the company doctor at the discretion of the company. This examination is at the company's expense.
 - 3. The employee is allowed to return to work at light duty or with restrictions if he can be reasonably accommodated for a given period of time. The Manager, Human Resources and the department head maintain coordination during the period of restriction.
 - 4. Employees will not be allowed to work while taking narcotics and/or mind-altering medications.

D. Administrative Terminations

- 1. When an employee is in the inactive department for six months, he is administratively terminated for the maximum time allowed for leave of absence up to five years.
- 2. A Personnel Action report is prepared by the Personnel Section with the following notation on the form "Status change from extended medical leave of absence to terminated."
 - a. This procedure does not apply to employees on leave for industrial accident because their vacation and sick leave accruals continue during such leave.
 - b. The Personnel Action terminates the employee and removes him from the active records of the company.
- 3. The employee's records are annotated "Administrative Termination." A suspense file is established by Personnel to allow the employee leave of absence for a period equal to his length of employment but not to exceed five years.
- 4. Employees are terminated at the expiration of the Administrative Termination period. All personnel records are inactivated and annotated as terminated.

Document 36-4

Filed 06/15/2007

Page 7 of 11

Page Issued: Revised

1 of 260 12/01/03 08/30/05

HUMAN RESOURCES MANUAL Approved by: John Hamlin

Table of Contents CHAPTER 26 WORKERS' COMPENSATION PROGRAM

PURPOSE:

To establish policies and procedures for the administration of the Workers' Compensation Program (WC Program) for work-related injuries and/or illnesses.

OBJECTIVES:

It is the intent of Army Fleet Support (AFS) to provide a safe workplace for all of its employees. However, when an employee does experience a work-related injury or illness, it is the Company's policy, consistent with Alabama State Law, to provide Workers' Compensation Benefits in accordance with the Collective Bargaining Agreement (CBA). These benefits are coordinated with, and may not overlap, any available temporary or permanent disability insurance benefit. Except where inconsistent with Alabama State Law, it is also the Company's policy to require those employees to return to work as soon as medically advisable and to provide limited duty tasks whenever feasible for those employees requiring them.

It is also the intent of AFS to inform all employees of appropriate accident reporting procedures and Workers' Compensation benefits available to them. All new hires will receive the two page "Incident Reporting & Workers' Compensation Benefit Guide" during their in-processing and will be required to review and complete a receipt and acknowledgement for placement in their 201 file.

CONTROLS:

This policy applies to all AFS employees who experience an injury or illness arising out of and in the course of their employment. It also applies to employees whose responsibilities include the administration of the workers compensation program, as well as to ALL Managers and Supervisors. Notification of all accidents and the determination of medical care for employees are the responsibility of the immediate Manager/Supervisor. Program administration and accounting are monitored by Tammie Brunson Maddox, Workers' Compensation Administrative Coordinator; plan implementation and/or changes are approved by the Manager, Human Resources.

The Workers' Compensation Office is located within Army Fleet Support Human Resources Department, 234 Donnell Boulevard, Daleville, Alabama. Normal office hours are Monday through Friday, 6AM ~ 5PM.

Document 36-4

Filed 06/15/2007

Page 8 of 11

Page Issued: Revised

9 of 260 12/01/03 08/30/05

HUMAN RESOURCES MANUAL Approved by: John Hamlin

D.RETURNING TO WORK AFTER MEDICAL TREATMENT

All employees receiving medical treatment and/or examination as the result of a work-related injury/illness will be required to report to the Workers' Compensation Administrator prior to returning to work WITH ONLY ONE EXCEPTION as noted below:

1. The employee must:

- a) Immediately notify the immediate Supervisor and Workers' Compensation Administrator in person or by phone if the authorized physician has indicated the employee's inability to return to work.
- b) Submit all documentation from PrimeCare (or a referral doctor scheduled by PrimeCare) to the Workers' Compensation Administrator the day of the incident or as early as possible the next business day prior to the employee's start of his/her normal workday.
- c) Obtain a signature from the Workers' Compensation Administrator on the Medical Pass (form 261) prior to returning to work.
- 2. Employees are NOT authorized to return to work without receiving written clearance from the Workers' Compensation Administrator WITH ONLY ONE EXCEPTION:

An employee may return to work without the Workers' Compensation Administrator's approval when the results of the medical treatment/examination are received before or after normal business hours (6AM ~ 5PM) of the Workers' Compensation Department and the following guidelines are met;

- a) The employee returns to work on the same workday without the use of any prescribed narcotic medication(s) indicated on the Medical Pass by the treating physician.
- b) All work restrictions (if any) listed on the Medical Pass can be accommodated and approved by the immediate supervisor.
- c) The employee notifies the Workers' Compensation Administrator of the accident (Direct Line 334-503-3247) upon the start of business on the following business day.
- d) The immediate supervisor faxes a copy of the completed Medical Pass to the Workers' Compensation Administrator (598-0476) and sends a follow-up email with the information listed below:
 - ✓ Name of injured/ill employee
 - ✓ Employee's badge number
 - ✓ Date & time of accident
 - ✓ Current date & time
 - ✓ Supervisor's note indicating the accommodation(s) for employee's restrictions, if any.

Page Issued: 10 of 260 12/01/03

Revised

HUMAN RESOURCES MANUAL 08/30/05 Approved by: John Hamlin

AFS - M-0105

3. Employees are required to comply with the prescribed restrictions on a Medical Pass/Work Statement issued by an authorized medical physician. Employees found in violation may be subject to disciplinary action, termination of employment and/or termination of Workers' Compensation benefits.

E. ON THE JOB FATALITY

When an employee dies or is fatally injured/ill on the job, the Workers' Compensation Administrator must be notified immediately (Emergency Number (334-447-4181). The Workers' Compensation Administrator is the initial internal contact and ensures that the deceased or fatally injured employee is taken to a hospital as appropriate for conclusive evidence of death and identity.

- 1. The Workers' Compensation Administrator accomplishes the following:
 - a) Immediately notifies the Director, Human Resources, the General Manager, and Director, EH&S. The General Manager will notify the Contracting Officer and the appropriate corporate officials.
 - b) Ensures the next-of-kin is promptly contacted after conclusive identification is established.
 - c) Coordinates with hospital officials and secures approval of the next of kin when an autopsy is indicated.
 - d) Arranges for the inventory, security and disposition of the personal belongings of the deceased.
- 2. The Director, EH&S accomplishes the following:
 - a. Notifies OSHA of fatality in accordance with 29 CFR Part 1904 Recording and Reporting Occupational Injuries and Illnesses.

F. CLAIMS ADMINISTRATION.

Upon receipt of an Occupational Injury/Illness Report (form 601), the employee's attendance record is reviewed to determine if the employee lost any time from work as a result of the accident. The injury/illness is reported to the Workers' Compensation insurance carrier. The carrier will prepare the Alabama Employer's First Report of Injury and fax it to the Workers' Compensation Administrator for the employee's file.

Work-related accidents involving medical attention are then recorded in the appropriate recording program as they occur. The OSHA 301 report is then generated for placement in the employee accident record. The OSHA 300/300A logs are maintained electronically and then posted as required by OSHA guidelines.



RETURN TO WORK SLIP

DATE:1	TIME:	_ Last Day	Worked:					
OTJ Injury Sh	ort-Term Disab	oility	FMLA	Other				
EMPLOYEE NAME	NUMBER	CLASSIFIC	ATION	LOCATION/SHIFT				
			· · · · · · · · · · · · · · · · · · ·					
Authorized to return to work with	NO RESTRICT	Γ IONS on —						
Presently working and released								
Authorized to return to work on LIGHT DUTY:				owing RESTRICTION/				
Able to Accommodate Medical F	• •		_ Cannot					
 Per Field Representative (r 								
• Date	·							
Comments								
Prescribed Medications								
Non Narcotics:								
Narcotics:								
Narcotic Drugs cannot be				or during shift				
Employee Initials:				- -				
An employee returning with restrictions or assigne the Collective Bargaining Agreement, until Persor duties.	ed to light duty will not anel receives a staten	t be entitled to wo nent from the doc	rk overtime in accor tor stating the emplo	dance with Article 11.1 of yee may return to normal				
Employees on Restricted Duty will be by-passed when scheduling or polling for overtime. If asked, the employee must refuse the overtime. In either case, whether by-passed, or asked and refused, the employee is charged.								
Manager, Personnel Services								
Benefits / Worker's Comp Represe	entative							

Original: Copies: Personnel File

Department Head Employee

Retain 7 Years AT Dispose by Shredding

Form 288 11/09/06

SOUTHERN BONE & JOINT SPORTS MEDICINE & REHAB OCCUPATIONAL MEDICINE DIVISION DOTHAN, ALABAMA

ERGONOMIC ANALYSIS AAENI – ARMY FLEET SUPPORT OCTOBER 31, 2006

JOB DESCRIPTION SUMMARY:

Per the job description manual provided by Army Fleet Support (May 2,2005 through May 4, 2008), an armament, avionics, electrical, and instrument technician performs inspections, checks, troubleshooting, repair, overhaul, maintenance and preservation of avionics and similar equipment. Performs calibration of tools and equipment. Performs boresighting operations.

ERGONOMIC INDICATORS:

To perform the essential physical functions of AAENI the employee must be able to do the following:

- 1. Be able to lift at least 50 pounds on an occasional basis from all levels. Levels include floor-waist, waist-shoulder, and shoulder to overhead.
- 2. Be able to push and /or pull at least 100 pounds on an occasional basis.
- 3. Be able to bend / kneel / squat on a frequent basis.
- 4. Be able to climb a ladder on an occasional basis while holding at least 30 pounds in one hand.
- 5. Be able to frequently reach to shoulder and overhead level.
- 6. Be able to perform simple grasp and fine manipulation tasks on a frequent basis.
- 7. Be able to crawl on an occasional basis.

STRENGTH CLASSIFICATION:

By observation and description, this job would rate in the MEDIUM strength classification.

Jerepry Boswell

Occupational Medicine Case Manager

Southern Bone & Joint Sports Medicine & Rehab / Occupational Medicine Division

EXHIBIT D

ammie Brunson Maddox

STATE OF ALABAMA

COUNTY OF DALE

AFFIDAVIT OF TAMMIE BRUNSON MADDOX

Tammie Brunson Maddox, after being first duly sworn, deposes and says as follows:

- My name is Tammie Brunson Maddox. I am over the age of majority and 1. competent to testify to the matters stated herein. This Affidavit is based on my personal knowledge.
- I am a Program Coordinator, Workers' Compensation/Occupational Health for 2. Army Fleet Support, LLC (AFS) at Fort Rucker, Alabama. I have held this position since 10/25/2004.
- Attached to my Affidavit as Attachment "1" is "Memo of Record" which I 3. prepared regarding Ms. Christine Bennett's visit to my office on or around January 15, 2005 and the events that occurred at that time.

Further, Affiant saith not.

Sworn to and subscribed to

before me on this the

545 day of June 2007.

[Affix Notarial Seal]

My Commission Expires:

MEMO OF RECORD Christine Bennett 2/28/2005

On or around January 13, 2005, Ms. Christine Bennett visited my office and presented documentation requesting a return to work. The documentation she presented included a letter which she presented as a "letter from my physician" and a Medical Pass signed by her physician. The letter was not dated or signed and was typed on plain paper, not letterhead however, it began "This letter is in reference to my patient Christine Bennett." Being unfamiliar with her case, I consulted with both Darlene Whelan, Director of Human Resources and Mark Couch, Labor Relations. Darlene spoke with Ms. Bennett and advised that we would need to review the documentation and speak with her physician's office before a determination regarding return to work could be made. Upon further research I learned that Ms. Bennett was not an AFS employee but rather a former Dyncorp employee that had been out on WC leave since before AFS acquired the Pt. Rucker contract. She had presented AFS with a Functional Capacity Evaluation (FCE) and request to return to work in April, 2004 which was denied based on work restrictions. Upon speaking with her physician's office I was advised that the letter she had presented in January, 2005 had not been authored by her physician but actually had been authored by the patient with the request that her physician review and sign. Her physician's office has since provided me with a letter requesting return to work under the same conditions as the FCE conducted in April, 2004 as well as a statement explaining the patient's request regarding the unsigned letter.

Document 36-5

Tammie Brunson Maddox

Administrative Coordinator/Workers' Compensation

EXHIBIT E

STATE OF ALABAMA

COUNTY OF DALE

AFFIDAVIT OF THOMAS A. GREEN

Thomas A. Green, after being first duly sworn, deposes and says as follows:


- 1. My name is Thomas A. Green. I am over the age of majority and competent to testify to the matters stated herein. This Affidavit is based on my personal knowledge.
 - 2. I am General Manager of Army Fleet Support, LLC at Fort Rucker, Alabama.
- 3. Attached to my Affidavit as Attachment "1" is a copy of my letter of March 1, 2005 to Mr. B. R. Brownell, President and Business Representative of IAM&AW District Lodge No. 74.

Further, Affiant saith not.

Thomas A. Green

Sworn to and subscribed to before me on this the

/4/*5 day of June 2007.



P.O. Box 620309 Fort Rucker, AL 36362-0309

March 1, 2005

Mr. B. R. Brownell
President and Directing Business Representative
IAM&AW District Lodge Number 75
220 Donnell Boulevard
Daleville, AL 36322

Ref: Your letter dated February 28, 2005

Dear Mr. Brownell:

Thank you for your letter reference Ms. Christine R. Bennett. I am aware of our on-going discussion concerning her situation. The letter that you have referenced is this company's first signed letter from a physician specifying Ms. Bennett's physical situation and we are looking at it with care.

In clarification I'd like to state that Ms. Bennett has never been an employee of Army Fleet Support, LLC. She cannot be reinstated.

We previously contacted her doctor on different occasions (every week for the past 6 weeks) and were unable to receive a signed statement from her physician indicating the extent of her restrictions. Upon receiving this notification, our worker's compensation office was informed that Ms. Bennett's restrictions may need to be readdressed due to recent issues. Dr. Granger has indicated he will be providing additional information after his review is complete.

Regardless, Dr. Granger's letter of February 4, 2005 confirms Ms. Bennett has reached her FCE and MMI as indicated in the April 6, 2004 report. As discussed with Ms. Bennett last year, the company is unable to accommodate these restrictions.

In making the company's determination not to accommodate Ms. Bennett's restrictions, rules governing employee moves, reclassifications, realignments, etc., contained in the Collective Bargaining Agreement (CBA) had to be taken into consideration. Since the company cannot guarantee nor restrict her location or type of work on a permanent basis, the IAM would be required to permanently waive seniority rights (as well as associated provisions outlined in Article 35 of the Collective Bargaining Agreement) in Ms. Bennett's situation before the company will consider accommodating her restrictions. To date, I am not aware of the IAM's desire to waive seniority rights in an effort to accommodate an employee's restrictions. Also remember that Ms. Bennett's right to reclassify to other locations and/or classifications would need to be waived, too.

Mr. B. R. Brownell March 1, 2005 Page Two

Additionally, on or about January 13, 2005, Ms. Bennett presented a letter to our Worker's Compensation Administrative Coordinator stating conditions under which she would be able to return to work. The letter was presented by Ms. Bennett as being a "letter from my physician". The opening sentence reads, "This letter is in reference to my patient Christine Bennett." Upon investigation and during contact with her treating physician, it was confirmed that although he had been shown this letter by Ms. Bennett, it had not been written at the direction of his office. As you are aware, this organization takes all misstatements of facts very seriously and has historically terminated for falsification. In addition to the consideration of whether her work restrictions can be reasonably accommodated, this is an issue that must be examined (i.e. do we want to employ an individual that has misrepresented information).

I hope that this information helps clarify this situation, and the Company's right to evaluate each person's ability to work within a classification while respecting the seniority language of the CBA.

Sincerely.

General Manager

TAG/kp

EXHIBIT F

STATE OF ALABAMA

COUNTY OF DALE

AFFIDAVIT OF JERRY FOWLER

Jerry Fowler, after being first duly sworn, deposes and says as follows:

- 1. My name is Jerry Fowler. I am over the age of majority and competent to testify to the matters stated herein. This Affidavit is based on my personal knowledge.
- 2. I am an Armament Avionics Electrical & Instrument Technician (AAAE&I Tech@) for Army Fleet Support, LLC (AAFS@). I have held this position with AFS since December 1, 2003.
- 3. While employed by AFS, I have not used a morphine pump or any other narcotic at work, nor have I taken a narcotic within 6 hours of the start of my shift.
- 4. In 1994, while working for the previous aircraft maintenance contractor,
 DynCorp Technical Services, LLC, I did use a morphine pump for approximately three
 or four days, following a short term disability leave of approximately three weeks. That
 was done with permission from DynCorp=s Human Resources Department.
 - 5. There are no medical restrictions on my working for AFS.

Further, Affiant saith not.

JERRY FOWLER

Sworn to and subscribed to before me on this the day of June, 2007.

NOTARY PURITIE

[Affix Notarial Seal]

My Commission Expires: 11/20/

EXHIBIT G

STATE OF ALABAMA

COUNTY OF DALE

AFFIDAVIT OF TOM THOMASINO

Tom Thomasino, after being first duly sworn, deposes and says as follows:

- 1. My name is Tom Thomasino. I am over the age of majority and competent to testify to the matters stated herein. This Affidavit is based on my personal knowledge.
- 2. I am an Armament Supervisor for Army Fleet Support, LLC ("AFS"). I have held this position with AFS since the beginning of its contract with the government on December 1, 2003. Prior to my employment with AFS, I was employed by DynCorp Technical Services, LLC in that same capacity.
- 3. Perry Phelps, who was nicknamed "Bullet," was an Armament Tech Lead over a crew that was under my supervision off-and-on for approximately one and one-half years. Some of that time was during his and my employment with AFS.
- 4. While Perry was under my supervision, I would observe him approximately four times per day. I never observed him taking Lortabs or other medications.
- 5. I am aware that Perry had rheumatoid arthritis, but I do not recall any time that he was accommodated with any restrictions or accommodations.
- 6. Had Perry been taking Lortabs with permission, that is something I would have been involved in, but I am not aware of any such instance.
- 7. AFS's policy is that employees are not to take narcotics on the job or within six hours before starting work. This policy was, and is, strictly observed in our area. I brief employees on this policy regularly.

Case 1:06-cv-00723-MHT-CSC

Document 36-8

Filed 06/15/2007

Page 3 of 3

Further, Affiant saith not.

Tom Thomasino

Sworn to and subscribed to before me on this the

before me on this the day of June 2007.

[Affix Notarial Seal]

My Commission Expires:

11/20/2007

EXHIBIT H

Page 2 of 3

STATE OF ALABAMA

COUNTY OF DALE

AFFIDAVIT OF THOMAS E. FORD

Thomas E. Ford, after being first duly sworn, deposes and says as follows:

- 1. My name is Thomas E. Ford. I am over the age of majority and competent to testify to the matters stated herein. This Affidavit is based on my personal knowledge.
- 2. I am a Records Specialist Lead for Army Fleet Support, LLC at Hanchey Field, Fort Rucker, Alabama. I have held this position at AFS since December 1, 2003. when AFS began its contract with the military.
- 3. In all, I have worked for AFS and previous aircraft maintenance contractors at Fort Rucker a total of approximately twenty-three years, six months. Twenty of those years were in some capacity as a Records Clerk, three of those years as a Production Control Clerk and six months as a Monitor. I have never worked as an aircraft mechanic.
- 4. I was injured in a job-related accident while working for Sikorsky in the mid-eighty=s. In 2005, I was out for five months on short term disability for medical issues related to those injuries. When I returned to work, I was temporarily accommodated by AFS for four weeks with no lifting over twenty-five pounds.
 - 5. I have not been accommodated in any manner since that date. Further, Affiant saith not.

Sworn to and subscribed to before me on this the ______ day of June, 2007.

NOTARY PUBLIC

[Affix Notarial Seal]

My Commission Expires:

EXHIBIT I

PDR® Electronic Library

This report is based solely on product labeling as published by Physicians' Desk Reference ®. Copyright © 2006 Thomson PDR. All rights reserved.


Report generated 01/05/2007 at 09:48 am

Kadian Capsules(Alpharma Branded Products)

DESCRIPTION

KADIAN® capsules 20, 30, 50, 60 and 100 mg contain identical polymer coated sustained release pellets of morphine sulfate for oral administration.

Chemically, morphine sulfate is 7,8-didehydro-4,5 (alpha)- epoxy-17-methyl-morphinan-3,6 (alpha)- diol sulfate (2:1) (salt) pentahydrate and has the following structural formula:



Morphine sulfate is an odorless, white, crystalline powder with a bitter taste and a molecular weight of 758 (as the sulfate). It has a solubility of 1 in 21 parts of water and 1 in 1000 parts of alcohol, but is practically insoluble in chloroform or ether. The octanol: water partition coefficient of morphine is 1.42 at physiologic pH and the pK $_{\rm b}$ is 7.9 for the tertiary nitrogen (mostly ionized at pH 7.4).

Each KADIAN® sustained release capsule contains either 20, 30, 50, 60, or 100 mg of Morphine Sulfate USP and the following inactive ingredients common to all strengths: hypromellose, ethylcellulose, methacrylic acid copolymer, polyethylene glycol, diethyl phthalate, talc, corn starch, and sucrose. The 20 mg capsule shell contains gelatin, silicon dioxide, sodium lauryl sulfate, D&C yellow #10, titanium dioxide, and black ink SW-9009. The 30 mg capsule shell contains gelatin, silicon dioxide, sodium lauryl sulfate, FD&C red #3, FD&C blue #1, titanium dioxide and black ink S-1-8114 or S-1-8115. The 50 mg capsule shell contains gelatin, silicon dioxide, sodium lauryl sulfate, D&C red #28, FD&C red #40, FD&C blue #1, titanium dioxide, and black ink SW-9009. The 60 mg capsule shell contains gelatin, silicon dioxide, sodium lauryl sulfate, D&C red #28, FD&C red #40, FD&C blue #1, titanium dioxide and black ink S-1-8114 or S-1-8115. The 100 mg capsule shell contains gelatin, silicon dioxide, sodium lauryl sulfate, D&C yellow #10, FD&C blue #1, titanium dioxide, and black ink SW-9009.

CLINICAL PHARMACOLOGY

Morphine is a natural product that is the prototype for the class of natural and synthetic opioid analgesics. Opioids produce a wide spectrum of pharmacologic effects including analgesia, dysphoria, euphoria, somnolence, respiratory depression, diminished gastrointestinal motility, altered circulatory dynamics, histamine release and physical dependence.

Exhibit I

Filed 06/15/2007

Page Page 2 8f 17

Morphine produces both its therapeutic and its adverse effects by interaction with one or more classes of specific opioid receptors located throughout the body. Morphine acts as a pure agonist, binding with and activating opioid receptors at sites in the peri-aqueductal and peri-ventricular grey matter, the ventro-medial medulla and the spinal cord to produce analgesia.

Effects on the Central Nervous System

The principal therapeutic actions of morphine are analgesia, sedation and alterations of mood. Opioids of this class do not usually eliminate pain, but they do reduce the perception of pain by the central nervous system.

Morphine produces respiratory depression by reducing the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension (or to direct electrical stimulation).

Morphine depresses the cough reflex by direct effect on the cough center in the medulla. Antitussive effects may occur with doses lower than those usually required for analgesia.

Morphine causes miosis, even in total darkness, and little tolerance develops to this effect. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g. pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked mydriasis rather than miosis may be seen due to severe hypoxia in overdose situations.

Effects on the Gastrointestinal Tract

Gastric, biliary and pancreatic secretions are decreased by morphine. Morphine causes a reduction in motility associated with an increase in tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone is increased to the point of spasm. The end result is constipation. Morphine can cause a marked increase in biliary tract pressure as a result of spasm of the sphincter of Oddi.

Effects on the Cardiovascular System

Morphine produces peripheral vasodilation which may result in orthostatic hypotension or syncope. Release of histamine may be induced by morphine and can contribute to opioid-induced hypotension. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes and sweating.

Pharmacodynamics

The relationship between the blood level of morphine and the analgesic response will depend on the patient's age, state of health, medical condition, and the extent of previous opioid treatment.

A minimum effective concentration (MEC) of morphine for pain relief has been reported as 27.2 ± 14.5 ng/mL (mean \pm SD) in cancer patients treated with morphine solution. These results compare with the MEC for plasma morphine reported as 14.7 ± 4.8 ng/mL (mean \pm SD) in patients with postoperative pain. The high degree of variation is of clinical significance as it may result in either under-dosing or over-dosing if the dosage is not adjusted to the patient's clinical status and analgesic response (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).

For opioid-tolerant patients the situation is much more complex. Some patients will become rapidly tolerant to the analgesic effects of morphine, and will require high daily oral morphine doses for adequate pain control. Since the development of tolerance to both the therapeutic and adverse effects of opioids is highly individualized, the dose of morphine should be individualized to the patient's condition and should not be based on an arbitrary choice of a dose or blood level to be achieved.

Pharmacokinetics

KADIAN® capsules contain polymer coated sustained release pellets of morphine sulfate that release morphine significantly more slowly than from morphine sulfate tablets and shorter-acting controlled-release oral morphine sulfate preparations. KADIAN® activity is primarily due to morphine. One metabolite, morphine-6-glucuronide, has been shown to have analgesic activity, but poorly crosses the blood-brain barrier.

Following oral administration, the extent of absorption is essentially the same for immediate or sustained release formulations, although the time to peak blood level (T $_{max}$) will be longer and the C $_{max}$ will be lower for formulations that delay the release of morphine in the gastrointestinal tract.

Elimination of morphine is primarily via hepatic metabolism to glucuronide metabolites (55 to 65%) which are then renally excreted. The terminal half-life of morphine is 2 to 4 hours, however, a longer term half-life of about 15 hours has been reported in studies where blood has been sampled up to 48 hours.

The single-dose pharmacokinetics of KADIAN® are linear over the dosage range of 30 to 100 mg. The single dose and multiple dose pharmacokinetic parameters of KADIAN® in normal volunteers are summarized in Table 1.

Table 1:Mean pharmacokinetic parameters (% coefficient variation) resulting from a
fasting single dose study in normal volunteers and a multiple dose study in patients with
cancer pain.

Regimen/ Dosage Form	AUC #, + (ng.h/mL)	C _{max} + (ng/mL)	T _{max} (h)	C _{min} + (ng/mL)	Fluctuation *
Single Dose (n=24)					
KADIAN® Capsule	271.0 (19.4)	15.6 (24.4)	8.6 (41.1)	na ^	na
Controlled-Release Tablet	304.3 (19.1)	30.5 (32.1)	2.5 (52.6)	na	na
Morphine Solution	362.4 (42.6)	64.4 (38.2)	0.9 (55.8)	na	na
Multiple Dose (n=24)					
KADIAN® Capsule q24h	500.9 (38.6)	37.3 (37.7)	10.3 (32.2)	9.9 (52.3)	3.0 (45.5)
Controlled-Release Tablet q12h	457.3 (40.2)	36.9 (42.0)	4.4 (53.0)	7.6 (60.3)	4.1 (51.5)

[#] For single dose AUC = AUC $_{0-48h}$, for multiple dose AUC = AUC $_{0-24h}$ at steady state

Absorption

Following the administration of oral morphine solution, approximately 50% of the morphine absorbed reaches the systemic circulation within 30 minutes. However, following the administration of an equal amount of KADIAN® to healthy volunteers, this occurs, on average, after 8 hours. As with most forms of oral morphine, because of pre-systemic elimination, only about 20 to 40% of the administered dose reaches the systemic circulation.


Food Effects: While concurrent administration of food slows the rate of absorption of KADIAN®, the extent of absorption is not affected and KADIAN® can be administered without regard to meals.

<u>Steady State:</u> When KADIAN® is given on a fixed dosing regimen to patients with chronic pain due to malignancy, steady state is achieved in about two days. At steady state, KADIAN® will have a significantly lower C _{max} and a higher C _{min} than equivalent doses of oral morphine solution and some other controlled-release preparations (see Graph 1).


⁺ For single dose parameter normalized to 100 mg, for multiple dose parameter normalized to 100 mg per 24 hours

^{*} Steady-state fluctuation in plasma concentrations = C_{max} - C_{min} / C_{min}

[^] Not applicable



When given once-daily (every 24 hours) to 24 patients with malignancy, KADIAN® had a similar C _{max} and higher C _{min} at steady state in clinical usage, when compared to twice-daily (every 12 hours) controlled-release morphine tablets (MS Contin®), given at an equivalent total daily dosage (see Graph 2 and Table 1). Drug-disease interactions are frequently seen in the older and more gravely ill patients, and may result in both altered absorption and reduced clearance as compared to normal volunteers (see Geriatric, Hepatic Failure, and Renal Insufficiency sections).



Distribution

Once absorbed, morphine is distributed to skeletal muscle, kidneys, liver, intestinal tract, lungs, spleen and brain.

The volume of distribution of morphine is approximately 3 to 4 L/kg. Morphine is 30 to 35% reversibly bound to plasma proteins.

Although the primary site of action of morphine is in the CNS, only small quantities pass the blood-brain barrier.

Morphine also crosses the placental membranes (see PRECAUTIONS - Pregnancy) and has been found in breast milk (see PRECAUTIONS - Nursing Mothers).

Metabolism

The major pathway of the detoxification of morphine is conjugation, either with D-glucuronic acid in the liver to produce glucuronides or with sulfuric acid to give morphine-3-etheral sulfate. Although a small fraction (less than 5%) of morphine is demethylated, for all practical purposes, virtually all morphine is converted to glucuronide metabolites including morphine-3-glucuronide, M3G (about 50%) and morphine-6-glucuronide, M6G (about 5 to 15%). Studies in healthy subjects and cancer patients have shown that the glucuronide metabolite to morphine mean molar ratios (based on AUC) are similar after both single doses and at steady state for KADIAN®, 12-hour controlled-release morphine sulfate tablets and morphine sulfate solution.

M3G has no significant analgesic activity. M6G has been shown to have opioid agonist and analgesic activity in humans.

Excretion

Approximately 10% of morphine dose is excreted unchanged in the urine. Most of the dose is excreted in the urine as M3G and M6G. A small amount of the glucuronide metabolites is excreted in the bile and there is some minor enterohepatic cycling. Seven to 10% of administered morphine is excreted in the feces.

The mean adult plasma clearance is about 20-30 mL/minute/kg. The effective terminal half-life of morphine after IV administration is reported to be approximately 2.0 hours. Longer plasma sampling in some studies suggests a longer terminal half-life of morphine of about 15 hours.

Special Populations

Geriatric: The elderly may have increased sensitivity to morphine and may achieve higher and more variable serum levels than younger patients. In adults, the duration of analgesia increases progressively with age, though the degree of analgesia remains unchanged. KADIAN® pharmacokinetics have not been investigated in elderly patients (>65 years) although such patients were included in the clinical studies.

Nursing Mothers: Morphine is excreted in the maternal milk, and the milk to plasma morphine AUC ratio is about 2.5:1. The amount of morphine received by the infant depends on the maternal plasma concentration, amount of milk ingested by the infant, and the extent of first pass metabolism.

Pediatric: Infants under 1 month of age have a prolonged elimination half-life and decreased clearance relative to older infants and pediatric patients. The clearance of morphine and its elimination half-life begin to approach adult values by the second month of life. Pediatric patients old enough to take capsules should have pharmacokinetic parameters similar to adults, dosed on a per kilogram basis (see **PRECAUTIONS - Pediatric Use**).

Gender: No meaningful differences between male and female patients were demonstrated in the analysis of the pharmacokinetic data from clinical studies.

Race: Pharmacokinetic differences due to race may exist. Chinese subjects given intravenous morphine in one study had a higher clearance when compared to caucasian subjects (1852 ± 116 mL/min versus 1495 ± 80 mL/min).

Hepatic Failure: The pharmacokinetics of morphine were found to be significantly altered in individuals with alcoholic cirrhosis. The clearance was found to decrease with a corresponding increase in half-life. The M3G and M6G to morphine plasma AUC ratios also decreased in these patients indicating a decrease in metabolic activity.

Renal Insufficiency: The pharmacokinetics of morphine are altered in renal failure patients. AUC is increased and clearance is decreased. The metabolites, M3G and M6G accumulate several fold in renal failure patients compared with healthy subjects.

Drug-Drug Interactions: The known drug interactions involving morphine are pharmacodynamic, not pharmacokinetic (see

PRECAUTIONS - Drug Interactions).

Clinical Studies

A total of 177 healthy subjects and 337 patients with cancer pain participated in a total of 15 studies (10 pharmacokinetic and 6 clinical; one study reported both pharmacokinetic and clinical data). Of these individuals, 158 healthy subjects and 268 patients received KADIAN®. In the controlled clinical studies patients were followed for a median duration of 7 days and in the open label studies patients were followed for up to 12-24 months. KADIAN® was compared to oral morphine solution and to either MS Contin® or to a 12-hour controlled-release morphine tablet bioequivalent to MS Contin® using trial designs that followed the clinical and pharmacokinetic performance of each treatment in cancer patients receiving chronic opioid therapy.

In two controlled studies, patients with moderate to severe cancer pain were titrated with immediate-release morphine (IRM) solution or tablets to a stable total daily dose of morphine for at least three consecutive days, then randomized to KADIAN® or 12-hour controlled-release morphine for seven days of observation. KADIAN® given once a day proved similar to the same total dose of morphine given in divided doses in a 12-hour dosage form, with respect to pain relief, use of rescue medication, patient and investigator global assessment, and quality of sleep. Individual patient differences in the pattern of pain control emphasize the need to individualize both dose and dosing interval (see **DOSAGE AND ADMINISTRATION**).

INDICATIONS AND USAGE

KADIAN® is indicated for the management of moderate to severe pain where treatment with an opioid analgesic is indicated for more than a few days (see CLINICAL PHARMACOLOGY; Clinical Studies).

KADIAN® was developed for use in patients with chronic pain who require repeated dosing with a potent opioid analgesic, and has been tested in patients with pain due to malignant conditions. KADIAN® has not been tested as an analgesic for the treatment of acute pain or in the postoperative setting and is not recommended for such use.

CONTRAINDICATIONS

KADIAN® is contraindicated in patients with a known hypersensitivity to morphine, morphine salts or any of the capsule components.

KADIAN® is contraindicated in patients with respiratory depression in the absence of resuscitative equipment, and in patients with acute or severe bronchial asthma.

KADIAN® is contraindicated in any patient who has or is suspected of having paralytic ileus.

WARNINGS

(See also CLINICAL PHARMACOLOGY)

Impaired Respiration

Respiratory depression is the chief hazard of all morphine preparations. Respiratory depression occurs more frequently in elderly and debilitated patients, and those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction (when even moderate therapeutic doses may significantly decrease pulmonary ventilation).

Morphine should be used with extreme caution in patients with chronic obstructive pulmonary disease or cor pulmonale, and in patients having a substantially decreased respiratory reserve (e.g. severe kyphoscoliosis), hypoxia, hypercapnia, or pre-existing respiratory depression. In such patients, even usual therapeutic doses of morphine may increase airway resistance and decrease respiratory drive to the point of apnea.

Head Injury and Increased Intracranial Pressure

The respiratory depressant effects of morphine with carbon dioxide retention and secondary elevation of cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure. Morphine produces effects which may obscure neurologic signs of further increases in pressure in patients with head injuries. Morphine should only be administered under such circumstances when considered essential and then with extreme care.

Hypotensive Effect

KADIAN®, like all opioid analgesics, may cause severe hypotension in an individual whose ability to maintain blood pressure has already been compromised by a reduced blood volume, or a concurrent administration of drugs such as phenothiazines or general anesthetics. (see also PRECAUTIONS - Drug Interactions). KADIAN® may produce orthostatic hypotension and syncope in ambulatory patients.

KADIAN®, like all opioid analgesics, should be administered with caution to patients in circulatory shock, as vasodilation produced by the drug may further reduce cardiac output and blood pressure.

Gastrointestinal Obstruction

KADIAN® should not be given to patients with gastrointestinal obstruction, particularly paralytic ileus, as there is a risk of the product remaining in the stomach for an extended period and the subsequent release of a bolus of morphine when normal gut motility is restored. As with other solid morphine formulations diarrhea may reduce morphine absorption.

PRECAUTIONS (See also CLINICAL PHARMACOLOGY)

General

KADIAN® is intended for use in patients who require continuous treatment with a potent opioid analgesic. As with any potent opioid, it is critical to adjust the dosing regimen for KADIAN® for each patient, taking into account the patient's prior analgesic treatment experience. Although it is clearly impossible to enumerate every consideration that is important to the selection of the initial dose of KADIAN®, attention should be given to the points under DOSAGE AND ADMINISTRATION.

Cordotomy

Patients taking KADIAN® who are scheduled for cordotomy or other interruption of pain transmission pathways should have KADIAN® ceased 24 hours prior to the procedure and the pain controlled by parenteral short-acting opioids. In addition, the post-procedure titration of analgesics for such patients should be individualized to avoid either oversedation or withdrawal syndromes.

Use in Pancreatic/Biliary Tract Disease

KADIAN® may cause spasm of the sphincter of Oddi and should be used with caution in patients with biliary tract disease, including acute pancreatitis. Opioids may cause increases in the serum amylase level.

Special risk groups

KADIAN® should be administered with caution, and in reduced dosages in elderly or debilitated patients; patients with severe renal or hepatic insufficiency; patients with Addison's disease; myxedema; hypothyroidism; prostatic hypertrophy or urethral stricture.

Caution should also be exercised in the administration of KADIAN® to patients with CNS depression, toxic psychosis, acute alcoholism and delirium tremens, and convulsive disorders.

Driving and operating machinery

Morphine may impair the mental and/or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Patients must be cautioned accordingly. Patients should also be warned about the potential combined effects of morphine with other CNS depressants, including other opioids, phenothiazines, sedative/hypnotics and alcohol (see Drug Interactions).

Information for Patients

If clinically advisable, patients receiving KADIAN® should be given the following instructions by the physician:

1. KADIAN® capsules should be swallowed whole (not chewed, crushed, or dissolved). Alternatively, KADIAN® capsules may be opened and the entire contents sprinkled on a small amount of applesauce immediately prior to ingestion. The pellets should NOT be chewed, crushed, or dissolved due to risk of overdose. When prescribing KADIAN® by the sprinkle method, details of proper technique should be explained to the patient. KADIAN® capsules may also be opened and the entire contents sprinkled over about

10 mL of water in a beaker then flushed with swirling through a pre-wetted 16-French gastrostomy tube fitted with a plastic funnel at the port end. The beaker is rinsed with additional aliquots of water as necessary to transfer all of the pellets to flush the tube. NASOGASTRIC TUBES SHOULD NOT BE USED. (also see DOSAGE AND ADMINISTRATION)

2. The dose of KADIAN® should not be adjusted without consulting the physician.

- 3. Morphine may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g. driving, operating machinery). Patients started on KADIAN® or whose dose has been changed should refrain from dangerous activity until it is established that they are not adversely affected.
- 4. Morphine should not be taken with alcohol or other CNS depressants (sleeping medication, tranquilizers) because additive effects including CNS depression may occur. A physician should be consulted if other medications are currently being used or are prescribed for future use.
- Women of childbearing potential who become or are planning to become pregnant, should consult a physician.
- Upon completion of therapy, it may be appropriate to taper the morphine dose, rather than abruptly discontinuing it.
- While psychological dependence ("addiction") to morphine used in the treatment of pain is very rare, morphine is one of a class of drugs known to be abused and should be handled accordingly.
- As with other opioids, patients taking KADIAN® should be advised that severe constipation could occur and appropriate laxatives, stool softeners and other appropriate treatments should be initiated from the beginning of opioid therapy.

Drug Interactions

CNS Depressants: Morphine should be used with great caution and in reduced dosage in patients who are concurrently receiving other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, other tranquilizers and alcohol because of the risk of respiratory depression, hypotension and profound sedation or coma. When such combined therapy is contemplated, the initial dose of one or both agents should be reduced by at least 50%.

Muscle Relaxants: Morphine may enhance the neuromuscular blocking action of skeletal relaxants and produce an increased degree of respiratory depression.

Mixed Agonist/Antagonist Opioid Analgesics: From a theoretical perspective, mixed agonist/antagonist analgesics (i.e. pentazocine, nalbuphine and butorphanol) should NOT be administered to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic. In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.

Monoamine Oxidase Inhibitors (MAOIs): MAOIs have been reported to intensify the effects of at least one opioid drug causing anxiety, confusion and significant depression of respiration or coma. We do not recommend the use of KADIAN® in patients taking MAOIs or within 14 days of stopping such treatment.

<u>Cimetidine:</u> There is an isolated report of confusion and severe respiratory depression when a hemodialysis patient was concurrently administered morphine and cimetidine.

Diuretics: Morphine can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Morphine may also lead to acute retention of urine by causing spasm of the sphincter of the bladder, particularly in men with prostatism.

Food: KADIAN® capsules should be swallowed whole (not chewed, crushed, or dissolved). Alternatively, KADIAN® capsules may be opened and the entire contents sprinkled on a small amount of applesauce immediately prior to ingestion. The pellets in KADIAN® should NOT be chewed, crushed, or dissolved due to risk of overdose. (see DOSAGE AND ADMINISTRATION, and INFORMATION FOR PATIENTS)

Carcinogenicity/Mutagenicity/Impairment of Fertility

Long-term studies in animals to evaluate the carcinogenic potential of morphine have not been conducted. There are no reports of carcinogenic effects in humans.

In vitro studies have reported that morphine is non-mutagenic in the Ames test with Salmonella, and induces chromosomal aberrations in human leukocytes and lethal mutation induction in Drosophila . Morphine was found to be mutagenic in vitro in human T-cells, increasing the DNA fragmentation. In vivo, morphine was mutagenic in the mouse micronucleus test and induced chromosomal aberrations in spermatids and murine lymphocytes.

Chronic opioid abusers (e.g., heroin abusers) and their offspring display higher rates of chromosomal damage. However, the rates of chromosomal abnormalities were similar in nonexposed individuals and in heroin users enrolled in long term opioid maintenance programs.

Pregnancy

Teratogenic effects (Pregnancy Category C)

Teratogenic effects of morphine have been reported in the animal literature. High parental doses during the second trimester were teratogenic in neurological, soft and skeletal tissue. The abnormalities included encephalopathy and axial skeletal fusions. These doses were often maternally toxic and were 0.3 to 3-fold the maximum recommended human dose (MRHD) on a mg/m ² basis. The relative contribution of morphine-induced maternal hypoxia and malnutrition, each of which can be teratogenic, has not been clearly defined. Treatment of male rats with approximately 3-fold the MRHD for 10 days prior to mating decreased litter size and viability.

Nonteratogenic effects

Morphine given subcutaneously, at non-maternally toxic doses, to rats during the third trimester with approximately 0.15-fold the MRHD caused reversible reductions in brain and spinal cord volume, and testes size and body weight in the offspring, and decreased fertility in female offspring. The offspring of rats and hamsters treated orally or intraperitoneally throughout pregnancy with 0.04- to 0.3-fold the MRHD of morphine have demonstrated delayed growth, motor and sexual maturation and decreased male fertility. Chronic morphine exposure of fetal animals resulted in mild withdrawal, altered reflex and motor skill development, and altered responsiveness to morphine that persisted into adulthood.

There are no well-controlled studies of chronic in utero exposure to morphine sulfate in human subjects. However, uncontrolled retrospective studies of human neonates chronically exposed to other opioids in utero, demonstrated reduced brain volume which normalized over the first month of life. Infants born to opioid-abusing mothers are more often small for gestational age, have a decreased ventilatory response to CO 2 and increased risk of sudden infant death syndrome.

Morphine should only be used during pregnancy if the need for strong opioid analgesia justifies the potential risk to the fetus.

Labor and Delivery

KADIAN® is not recommended for use in women during and immediately prior to labor, where shorter acting analgesics or other analgesic techniques are more appropriate. Occasionally, opioid analgesics may prolong labor through actions which temporarily reduce the strength, duration and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilatation which tends to shorten labor.

Neonates whose mothers received opioid analgesics during labor should be observed closely for signs of respiratory depression. A specific opioid antagonist, such as naloxone or nalmefene, should be available for reversal of opioid-induced respiratory depression in the neonate.

Neonatal Withdrawal Syndrome

Chronic maternal use of opiates or opioids during pregnancy coexposes the fetus. The newborn may experience subsequent neonatal withdrawal syndrome (NWS). Manifestations of NWS include irritability, hyperactivity, abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, weight loss, and failure to gain weight. The onset, duration, and severity of the disorder differ based on such factors as the addictive drug used, time and amount of mother's last dose, and rate of elimination of the drug from the newborn. Approaches to the treatment of this syndrome have included supportive care and, when indicated, drugs such as paragoric or phenobarbital.

Nursing Mothers

Low levels of morphine sulfate have been detected in human milk. Withdrawal symptoms can occur in breast-feeding infants when maternal administration of morphine sulfate is stopped. Because of the potential for adverse reactions in nursing infants from KADIAN®, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

There are studies from the literature reporting the safe and effective use of both immediate and sustained release oral morphine preparations for analgesia in pediatric patients who were dosed on a per kilogram basis. However, the safety of KADIAN®, both the entire capsule and the pellets sprinkled on applesauce, have not been directly investigated in pediatric patients below the age of 18 years. The range of doses available is not suitable for the treatment of very young pediatric patients or those who are not old enough to take capsules safely. The applesauce sprinkling method is not an appropriate alternative for these patients.

ADVERSE REACTIONS

Serious adverse reactions that may be associated with KADIAN® therapy in clinical use are those observed with other opioid analgesics and include: respiratory depression, respiratory arrest, circulatory depression, cardiac arrest, hypotension, and/or shock (see OVERDOSAGE, WARNINGS).

The less severe adverse events seen on initiation of therapy with KADIAN® are also typical opioid side effects. These events are dose dependent, and their frequency depends on the clinical setting, the patient's level of opioid tolerance, and host factors specific to the individual. They should be expected and managed as a part of opioid analgesia. The most frequent of these include drowsiness, dizziness, constipation and nausea. In many cases, the frequency of these events during initiation of therapy may be minimized by careful individualization of starting dosage, slow titration, and the avoidance of large rapid swings in plasma concentrations of the opioid. Many of these adverse events, will cease or decrease as KADIAN® therapy is continued and some degree of tolerance is developed, but others may be expected to remain troublesome throughout therapy.

Management of Excessive Drowsiness

Most patients receiving morphine will experience initial drowsiness. This usually disappears within 3-5 days and is not a cause of concern unless it is excessive, or accompanied by unsteadiness or confusion. Dizziness and unsteadiness may be associated with postural hypotension, particularly in elderly or debilitated patients, and has been associated with syncope and falls in non-tolerant patients started on opioids.

Excessive or persistent sedation should be investigated. Factors to be considered should include: concurrent sedative medications, the presence of hepatic or renal insufficiency, hypoxia or hypercapnia due to exacerbated respiratory failure, intolerance to the dose used (especially in older patients), disease severity and the patient's general condition.

The dosage should be adjusted according to individual needs, but additional care should be used in the selection of initial doses for the elderly patient, the cachectic or gravely ill patient, or in patients not already familiar with opioid analysesic medications to prevent excessive sedation at the onset of treatment.

Management of Nausea and Vomiting

Nausea and vomiting are common after single doses of morphine or as an early undesirable effect of chronic opioid therapy. The prescription of a suitable antiemetic should be considered, with the awareness that sedation may result (see **Drug Interactions**). The frequency of nausea and vomiting usually decreases within a week or so but may persist due to opioid-induced gastric stasis. Metoclopramide is often useful in such patients.

Management of Constipation

Virtually all patients suffer from constipation while taking opioids on a chronic basis. Some patients, particularly elderly, debilitated or bedridden patients may become impacted. Tolerance does not usually develop for the constipating effects of opioids. Patients must be cautioned accordingly and laxatives, softeners and other appropriate treatments should be used prophylactically from the beginning of opioid therapy.

Adverse Events Probably Related to KADIAN® Administration

In controlled clinical trials in patients with chronic cancer pain the most common adverse events reported by patients at least once during therapy were drowsiness (9%), constipation (9%), nausea (7%), dizziness (6%), and anxiety (6%). Other less common side effects expected from morphine or seen in less than 3% of patients in the clinical trials were:

Body as a Whole: Asthenia, accidental injury, fever, pain, chest pain, headache, diaphoresis, chills, flu syndrome, back pain, malaise, withdrawal syndrome

Cardiovascular: Tachycardia, atrial fibrillation, hypotension, hypertension, pallor, facial flushing, palpitations, bradycardia, syncope

Central Nervous System: Confusion, dry mouth, anxiety, abnormal thinking, abnormal dreams, lethargy, depression, tremor, loss of concentration, insomnia, amnesia, paresthesia, agitation, vertigo, foot drop, ataxia, hypesthesia, slurred speech, hallucinations, vasodilation, euphoria, apathy, seizures, myoclonus

Endocrine: Hyponatremia due to inappropriate ADH secretion, gynecomastia

Gastrointestinal: Vomiting, anorexia, dysphagia, dyspepsia, diarrhea, abdominal pain, stomach atony disorder, gastro-esophageal reflux, delayed gastric emptying, biliary colic

Filed 06/15/2007 Page 12 of 18 17

Hemic & Lymphatic: Anemia, leukopenia, thrombocytopenia

Metabolic & Nutritional: Peripheral edema, hyponatremia, edema

Musculoskeletal: Back pain, bone pain, arthralgia

Respiratory: Hiccup, rhinitis, atelectasis, asthma, hypoxia, dyspnea, respiratory insufficiency, voice alteration, depressed cough reflex,

non-cardiogenic pulmonary edema

Skin and Appendages: Rash, decubitus ulcer, pruritus, skin flush

Special Senses: Amblyopia, conjunctivitis, miosis, blurred vision, nystagmus, diplopia

Urinary abnormality, amenorrhea, urinary retention, urinary hesitancy, reduced libido, reduced potency, prolonged labor

DRUG ABUSE AND DEPENDENCE

Morphine is the prototype of opioid agonist drugs, and may be subject to misuse, abuse and addiction. Addiction to opioids prescribed for pain management is rare, but requests for opioids from patients addicted to opioids are common and physicians should take appropriate care in prescribing this controlled substance.

Opioid analgesics may cause physical dependence. Physical dependence results in withdrawal symptoms in patients who abruptly discontinue the drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity, e.g. naloxone, nalmefene, or mixed agonist/antagonist analgesics (pentazocine, butorphanol, nalbuphine), (see also OVERDOSAGE).

Physical dependence usually does not occur to a clinically significant degree until after several weeks of continued opioid usage. Tolerance, in which increasingly large doses are required in order to produce the same degree of analgesia, is initially manifested by a shortened duration of analgesic effect, and subsequently, by decreases in the intensity of analgesia.

In chronic pain patients, and in opioid-tolerant cancer patients, the administration of KADIAN® should be guided by the degree of tolerance manifested. Physical dependence, per se, is not ordinarily a concern when one is dealing with a patient in pain, and fear of tolerance should not deter using adequate doses to adequately relieve pain.

If morphine is abruptly discontinued an abstinence syndrome may occur. This is usually mild and is characterized by rhinitis, myalgia, abdominal cramping and occasional diarrhea. Most observable symptoms disappear in 5-14 days without treatment; however, there may be a phase of secondary or chronic abstinence which may last for 2-6 months characterized by insomnia, irritability and muscular aches.

If treatment of physical dependence of patients taking morphine is necessary, the patient may be detoxified by gradual reduction of the dose. Gastrointestinal disturbances or dehydration should be treated with supportive care.

KADIAN® has no role in the management of opioid addiction.

OVERDOSAGE

Symptoms

Acute overdosage with morphine is manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, sometimes, pulmonary edema, bradycardia, hypotension and death. Marked mydriasis rather than miosis may be seen due to severe hypoxia in overdose situations.

Treatment

Primary attention should be given to the re-establishment of a patent airway and institution of assisted or controlled ventilation. Gastric contents may need to be emptied to remove unabsorbed drug when a sustained release formulation such as KADIAN® has been taken. Care should be taken to secure the airway before attempting treatment by gastric emptying or activated charcoal.

The pure opioid antagonists, naloxone or nalmefene, are specific antidotes to respiratory depression which results from opioid overdose. Since the duration of reversal would be expected to be less than the duration of action of KADIAN®, the patient must be carefully

monitored until spontaneous respiration is reliably re-established. KADIAN® will continue to release and add to the morphine load for up to 24 hours after administration and the management of an overdose should be monitored accordingly. If the response to opioid antagonists is suboptimal or not sustained, additional antagonist should be given as directed by the manufacturer of the product.

Opioid antagonists should not be administered in the absence of clinically significant respiratory or circulatory depression secondary to morphine overdose. Such agents should be administered cautiously to persons who are known, or suspected to be physically dependent on KADIAN®. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute abstinence syndrome.

Opioid Tolerant Individuals: In an individual physically dependent on opioids, administration of the usual dose of the antagonist will precipitate an acute withdrawal. The severity of the withdrawal produced will depend on the degree of physical dependence and the dose of the antagonist administered. Use of an opioid antagonist should be reserved for cases where such treatment is clearly needed. If it is necessary to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be begun with care and by titration with smaller than usual doses.

Supportive measures (including oxygen, vasopressors) should be employed in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation.

DOSAGE AND ADMINISTRATION

KADIAN® CAPSULES SHOULD BE SWALLOWED WHOLE (NOT CHEWED, CRUSHED, OR DISSOLVED).

ALTERNATIVELY, KADIAN® CAPSULES MAY BE OPENED AND THE ENTIRE CONTENTS SPRINKLED ON A SMALL AMOUNT OF APPLESAUCE IMMEDIATELY PRIOR TO INGESTION. THE PELLETS IN KADIAN® CAPSULES SHOULD NOT BE CHEWED, CRUSHED, OR DISSOLVED DUE TO RISK OF OVERDOSE.

TAKING CHEWED OR CRUSHED KADIAN® CAPSULES OR PELLETS WILL LEAD TO THE RAPID RELEASE AND ABSORPTION OF A POTENTIALLY TOXIC DOSE OF MORPHINE.

KADIAN® CAPSULES MAY BE OPENED AND THE ENTIRE CONTENTS SPRINKLED OVER ABOUT 10 ML OF WATER AND FLUSHED WITH SWIRLING THROUGH A PRE-WETTED 16 FRENCH GASTROSTOMY TUBE FITTED WITH FUNNEL AT THE PORT END. ADDITIONAL ALIQUOTS OF WATER ARE USED TO TRANSFER ALL PELLETS AND TO FLUSH THE TUBE. THE ADMINISTRATION OF KADIAN® PELLETS THROUGH A NASOGASTRIC TUBE SHOULD NOT BE ATTEMPTED.

The sustained release nature of KADIAN® allows it to be administered on either a once-a-day or twice-a-day schedule. KADIAN® produces analgesia similar to that produced by conventional immediate-release and controlled-release formulations for the same total daily dose of morphine. However, peak and trough blood levels depend on the release characteristics of each specific formulation, and other oral morphines may not be therapeutically equivalent to KADIAN® for an individual patient.

KADIAN® capsules have the same extent of absorption (AUC) as immediate-release oral formulations and controlled-release oral formulations of morphine sulfate. However, key pharmacokinetic parameters (e.g. C max, T max) for KADIAN® are significantly different from other controlled-release oral formulations.

As with any potent opioid drug product, it is critical to adjust the dosing regimen for each patient individually, taking into account the patient's prior analgesic treatment experience. In the selection of the initial dose of KADIAN®, attention should be given to:

- 1. the total daily dose, potency and kind of opioid the patient has been taking previously;
- 2. the reliability of the relative potency estimate used to calculate the equivalent dose of morphine needed;
- 3. the patient's degree of opioid tolerance;
- 4. the general condition and medical status of the patient;
- concurrent medication;
- 6. the type and severity of the patient's pain.

The following dosing recommendations, therefore, can only be considered suggested approaches to what is actually a series of clinical decisions over time in the management of the pain of an individual patient.

Conversion from Other Oral Morphine Formulations to KADIAN®

Patients on other oral morphine formulations may be converted to KADIAN® by administering one-half of the patient's total daily oral morphine dose as KADIAN® capsules every 12 hours (twice-a-day) or by administering the total daily oral morphine dose as KADIAN® capsules every 24 hours (once-a-day). KADIAN® should not be given more frequently than every 12 hours.

Conversion from Parenteral Morphine or Other Parenteral or Oral Opioids to KADIAN®

KADIAN® can be administered to patients previously receiving treatment with parenteral morphine or other opioids. While there are useful tables of oral and parenteral equivalents in cancer analgesia, there is substantial interpatient variation in the relative potency of different opioid drugs and formulations. For these reasons, it is better to underestimate the patient's 24 hour oral morphine requirement and provide rescue medication, than to overestimate and manage an adverse event. The following general points should be considered:

Parenteral to oral morphine ratio: It may take anywhere from 2-6 mg of oral morphine to provide analgesia equivalent to 1 mg of parenteral morphine. A dose of oral morphine three times the daily parenteral morphine requirement may be sufficient in chronic use settings.

Other parenteral or oral opioids to oral morphine sulfate: Physicians are advised to refer to published relative potency data, keeping in mind that such ratios are only approximate. In general, it is safest to give half of the estimated daily morphine demand as the initial dose, and to manage inadequate analgesia by supplementation with immediate-release morphine. (See discussion which follows.)

The first dose of KADIAN® may be taken with the last dose of any immediate-release (short-acting) opioid medication due to the long delay until the peak effect after administration of KADIAN®.

Use of KADIAN® as the First Opioid Analgesic

There has been no evaluation of KADIAN® as an initial opioid analgesic in the management of pain. Because it may be more difficult to titrate a patient to adequate analgesia using a sustained release morphine, it is ordinarily advisable to begin treatment using an immediate-release morphine formulation.

Individualization of Dosage

The best use of opioid analgesics in the management of chronic malignant and non-malignant pain is challenging, and is well described in materials published by the World Health Organization and the Agency for Health Care Policy and Research which are available from Alpharma upon request. KADIAN® is a third step drug which is most useful when the patient requires a constant level of opioid analgesia as a "floor" or "platform" from which to manage breakthrough pain. When a patient has reached the point where comfort cannot be provided with a combination of non-opioid medications (NSAIDs and acetaminophen) and intermittent use of moderate or strong opioids, the patient's total opioid therapy should be converted into a 24 hour oral morphine equivalent.

KADIAN® should be started by administering one-half of the estimated total daily oral morphine dose every 12 hours (twice-a-day) or by administering the total daily oral morphine dose every 24 hours (once-a-day). The dose should be titrated no more frequently than every-other-day to allow the patients to stabilize before escalating the dose. If breakthrough pain occurs, the dose may be supplemented with a small dose (less than 20% of the total daily dose) of a short-acting analgesic. Patients who are excessively sedated after a once-a-day dose or who regularly experience inadequate analgesia before the next dose should be switched to twice-a-day dosing.

Patients who do not have a proven tolerance to opioids should be started only on the 20 mg strength, and usually should be increased at a rate not greater than 20 mg every-other-day. Most patients will rapidly develop some degree of tolerance, requiring dosage adjustment until they have achieved their individual best balance between baseline analgesia and opioid side effects such as confusion, sedation and constipation. No guidance can be given as to the recommended maximal dose, especially in patients with chronic pain of malignancy. In such cases the total dose of KADIAN® should be advanced until the desired therapeutic endpoint is reached or clinically significant opioid-related adverse reactions intervene.

Alternative Methods of Administration

In a study of healthy volunteers, KADIAN® pellets sprinkled over applesauce were found to be bioequivalent to KADIAN® capsules swallowed whole with applesauce under fasting conditions. Other foods have not been tested. Patients who have difficulty swallowing whole capsules or tablets may benefit from this alternative method of administration.

- 1. Sprinkle the pellets onto a small amount of applesauce. Applesauce should be room temperature or cooler,
- 2. Use immediately.
- 3. Rinse mouth to ensure all pellets have been swallowed.
- 4. Patients should consume entire portion and should not divide applesauce into separate doses.

The entire capsule contents may be administered through a 16 French gastrostomy tube.

1. Flush the gastrostomy tube with water to ensure that it is wet.

- 2. Sprinkle the KADIAN® Pellets into 10 mL of water.
- 3. Use a swirling motion to pour the pellets and water into the gastrostomy tube through a funnel.
- 4. Rinse the beaker with a further 10 mL of water and pour this into the funnel.
- 5. Repeat rinsing until no pellets remain in the beaker.

THE ADMINISTRATION OF KADIAN® PELLETS THROUGH A NASOGASTRIC TUBE SHOULD NOT BE ATTEMPTED.

Considerations in the Adjustment of Dosing Regimens

If signs of excessive opioid effects are observed early in the dosing interval, the next dose should be reduced. If this adjustment leads to inadequate analgesia, that is, if breakthrough pain occurs when KADIAN® is administered on an every 24 hours dosing regimen, consideration should be given to dosing every 12 hours. If breakthough pain occurs on a 12 hour dosing regimen a supplemental dose of short-acting analgesic may be given. As experience is gained, adjustments in both dose and dosing interval can be made to obtain an appropriate balance between pain relief and opioid side effects. To avoid accumulation the dosing interval of KADIAN® should not be reduced below 12 hours.

Conversion from KADIAN® to Other Controlled-Release Oral Morphine Formulations

KADIAN® is not bioequivalent to other controlled-release morphine preparations. Although for a given dose the same total amount of morphine is available from KADIAN® as from morphine solution or controlled-release morphine tablets, the slower release of morphine from KADIAN® results in reduced maximum and increased minimum plasma morphine concentrations than with shorter acting morphine products. Conversion from KADIAN® to the same total daily dose of controlled-release morphine preparations may lead to either excessive sedation at peak or inadequate analgesia at trough and close observation and appropriate dosage adjustments are recommended.

Conversion from KADIAN® to Parenteral Opioids

When converting a patient from KADIAN® to parenteral opioids, it is best to calculate an equivalent parenteral dose, and then initiate treatment at half of this calculated value. For example, to estimate the required 24 hour dose of parenteral morphine for a patient taking KADIAN®, one would take the 24 hour KADIAN® dose, divide by an oral to parenteral conversion ratio of 3, divide the estimated 24 hour parenteral dose into six divided doses (for a four hour dosing interval), then halve this dose as an initial trial.

For example, to estimate the required parenteral morphine dose for a patient taking 360 mg of KADIAN® a day, divide the 360 mg daily oral morphine dose by a conversion ratio of 1 mg of parenteral morphine for every 3 mg of oral morphine. The estimated 120 mg daily parenteral requirement is then divided into six 20 mg doses, and half of this, or 10 mg, is then given every 4 hours as an initial trial dose.

This approach is likely to require a dosage increase in the first 24 hours for many patients, but is recommended because it is less likely to cause overdose than trying to establish an equivalent dose without titration.

Opioid analgesic agents may not effectively relieve dysesthetic pain, post-herpetic neuralgia, stabbing pains, activity-related pain, and some forms of headache. This does not mean that patients suffering from these types of pain should not be given an adequate trial of opioid analgesics. However, such patients may need to be promptly evaluated for other types of pain therapy.

Safety and Handling

KADIAN® consists of closed hard gelatin capsules containing polymer coated morphine sulfate pellets that pose no known handling risk to health care workers. Oral morphine products are not known to be associated with a high risk of diversion, but all strong opioids are liable to diversion and misuse both by the general public and health care workers, and should be handled accordingly.

HOW SUPPLIED

KADIAN® capsules contain white to off-white or tan colored polymer coated sustained release pellets of morphine sulfate and are available in five dose strengths:

20 mg size 4 capsule, yellow opaque cap imprinted KADIAN and yellow opaque body imprinted with 20 mg. Capsules are supplied in bottles of 30 (NDC 63857-322-03), 60 (NDC 63857-322-06), and 100 (NDC 63857-322-11).

30 mg size 4 capsule, blue violet opaque cap imprinted KADIAN and blue violet opaque body imprinted with 30 mg. Capsules are supplied in bottles of 30 (NDC 63857-325-03), 60 (NDC 63857-325-06), and 100 (NDC 63857-325-11).

Filed 06/15/2007

Page 15 of 17

50 mg size 2 capsule, blue opaque cap imprinted KADIAN and blue opaque body imprinted with 50 mg. Capsules are supplied in bottles of 30 (NDC 63857-323-03), 60 (NDC 63857-323-06), and 100 (NDC 63857-323-11).

60 mg size 1 capsule, pink opaque cap imprinted KADIAN and pink opaque body imprinted with 60 mg. Capsules are supplied in bottles of 30 (NDC 63857-326-03), 60 (NDC 63857-326-06), and 100 (NDC 63857-326-11).

100 mg size 0 capsule, green opaque cap imprinted KADIAN and green opaque body imprinted with 100 mg. Capsules are supplied in bottles of 30 (NDC 63857-324-03), 60 (NDC 63857-324-06), and 100 (NDC 63857-324-11).

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). Protect from light and moisture.

Dispense in a sealed, tamper-evident, childproof, light-resistant container.

CAUTION

DEA Order Form Required.

Rx only

KADIAN® is a licensed trademark of Alpharma Branded Products Division Inc.

MS Contin® is a registered trademark of The Purdue Frederick Company

Manufactured for: Alpharma Branded Products Division Inc.

One New England Avenue

Piscataway, NJ 08854

by: Purepac Pharmaceutical Co.


Elizabeth, NJ 07207 USA


40-8984Revised--November 2004

PRODUCT PHOTO(S):

NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual or relative size.

The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a quick-reference identification aid. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected overdosage, the drug's identity should be verified by chemical analysis.





Filed 06/15/2007

Page 18 of 18 17

Copyright© 2006 Thomson PDR

EXHIBIT J

PDR® Electronic Library

This report is based solely on product labeling as published by Physicians' Desk Reference ®. Copyright © 2006 Thomson PDR. All rights reserved.

Report generated 01/05/2007 at 09:49 am

Lortab 10/500 Tablets, Lortab 5/500 Tablets, Lortab 2.5/500 Tablets, Lortab 7.5/500 Tablets(UCB)

DESCRIPTION

Hydrocodone bitartrate and acetaminophen is supplied in tablet form for oral administration.

WARNING: May be habit forming (see PRECAUTIONS, Information for Patients, and DRUG ABUSE AND DEPENDENCE).

Hydrocodone bitartrate is an opioid analgesic and antitussive and occurs as fine, white crystals or as a crystalline powder. It is affected by light. The chemical name is 4,5(alpha)-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5). It has the following structural formula:

Acetaminophen, 4'-hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula:

CH₃CONH—OH
$$C_8H_9NO_2$$
M.W. 151.16

Each Lortab 2.5/500 tablet contains:

Hydrocodone Bitartrate 2.5 mg

Acetaminophen 500 mg

In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, crospovidone, microcrystalline cellulose, povidone, pregelatinized starch, stearic acid and sugar spheres which are composed of starch derived from corn, sucrose, and FD&C Red #3. Meets USP dissolution test 1.

Exhibit J

Each Lortab 5/500 tablet contains:

Hydrocodone Bitartrate 5 mg

Acetaminophen 500 mg

In addition, each tablet contains the following inactive ingredients: cornstarch, FD&C Blue # 1 Lake, gelatin, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, sodium starch glycolate, and sugar spheres. Meets USP dissolution test 1.

Each Lortab 7.5/500 tablet contains:

Hydrocodone Bitartrate 7.5 mg

Acetaminophen 500 mg

In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, crospovidone, microcrystalline cellulose, povidone, pregelatinized starch, stearic acid, and sugar spheres which are composed of starch derived from corn, sucrose, FD&C Blue #1 and D&C Yellow #10. Meets USP dissolution test 1.

Each Lortab 10/500 tablet contains:

Hydrocodone Bitartrate 10 mg

Acetaminophen 500 mg

In addition, each tablet contains the following inactive ingredients: D&C Red No. 27 Aluminum Lake, D&C Red No. 30 Aluminum Lake, colloidal silicon dioxide, croscarmellose sodium, crospovidone, microcrystalline cellulose, povidone, pregelatinized starch, starch (corn), and stearic acid. Meets USP dissolution test 1.

CLINICAL PHARMACOLOGY

Hydrocodone is a semisynthetic narcotic analgesic and antitussive with multiple actions qualitatively similar to those of codeine. Most of these involve the central nervous system and smooth muscle. The precise mechanism of action of hydrocodone and other opiates is not known, although it is believed to relate to the existence of opiate receptors in the central nervous system. In addition to analgesia, narcotics may produce drowsiness, changes in mood and mental clouding.

The analgesic action of acetaminophen involves peripheral influences, but the specific mechanism is as yet undetermined. Antipyretic activity is mediated through hypothalamic heat regulating centers. Acetaminophen inhibits prostaglandin synthetase. Therapeutic doses of acetaminophen have negligible effects on the cardiovascular or respiratory systems; however, toxic doses may cause circulatory failure and rapid, shallow breathing.

Pharmacokinetics: The behavior of the individual components is described below.

<u>Hydrocodone</u>: Following a 10 mg oral dose of hydrocodone administered to five adult male subjects, the mean peak concentration was 23.6 ± 5.2 ng/mL. Maximum serum levels were achieved at 1.3 ± 0.3 hours and the half-life was determined to be 3.8 ± 0.3 hours. Hydrocodone exhibits a complex pattern of metabolism including O-demethylation, N-demethylation and 6-keto reduction to the corresponding 6-(alpha)- and 6-(beta)-hydroxymetabolites.

See OVERDOSAGE for toxicity information.

Acetaminophen: Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. The plasma half-life is 1.25 to 3 hours, but may be increased by liver damage and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug.

See OVERDOSAGE for toxicity information.

INDICATIONS AND USAGE

Lortab Tablets are indicated for the relief of moderate to moderately severe pain.

CONTRAINDICATIONS

This product should not be administered to patients who have previously exhibited hypersensitivity to hydrocodone or acetaminophen.

Patients known to be hypersensitive to other opioids may exhibit cross sensitivity to hydrocodone.

WARNINGS

Respiratory Depression: At high doses or in sensitive patients, hydrocodone may produce dose-related respiratory depression by acting directly on the brain stem respiratory center. Hydrocodone also affects the center that controls respiratory rhythm, and may produce irregular and periodic breathing.

Head Injury and Increased Intracranial Pressure: The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a preexisting increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.

Acute Abdominal Conditions: The administration of narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.

PRECAUTIONS

General: Special Risk Patients: As with any narcotic analgesic agent, Lortab Tablets should be used with caution in elderly or debilitated patients, and those with severe impairment of hepatic or renal function, hypothyroidism, Addison's disease, prostatic hypertrophy or urethral stricture. The usual precautions should be observed and the possibility of respiratory depression should be kept in mind.

<u>Cough Reflex</u>: Hydrocodone suppresses the cough reflex; as with all narcotics, caution should be exercised when Lortab Tablets are used postoperatively and in patients with pulmonary disease.

Information for Patients: Hydrocodone, like all narcotics, may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery; patients should be cautioned accordingly.

Alcohol and other CNS depressants may produce an additive CNS depression, when taken with this combination product, and should be avoided.

Hydrocodone may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.

Laboratory Tests: In patients with severe hepatic or renal disease, effects of therapy should be monitored with serial liver and/or renal function tests.

Drug Interactions: Patients receiving narcotics, antihistamines, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone bitartrate and acetaminophen tablets may exhibit an additive CNS depression. When combined therapy is contemplated, the dose of one or both agents should be reduced.

The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.

Drug/Laboratory Test Interactions: Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.

Carcinogenesis, Mutagenesis, Impairment of Fertility: No adequate studies have been conducted in animals to determine whether hydrocodone or acetaminophen have a potential for carcinogenesis, mutagenesis, or impairment of fertility.

Pregnancy:

Teratogenic Effects: Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Lortab Tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects: Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on the best method of managing withdrawal.

Labor and Delivery: As with all narcotics, administration of this product to the mother shortly before delivery may result in some degree of respiratory depression in the newborn, especially if higher doses are used.

Nursing Mothers: Acetaminophen is excreted in breast milk in small amounts, but the significance of its effects on nursing infants is not known. It is not known whether hydrocodone is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocodone and acetaminophen, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Safety and effectiveness in the pediatric population have not been established.

Geriatric Use: Clinical studies of hydrocodone bitartrate and acetaminophen tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosage range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

Hydrocodone and the major metabolites of acetaminophen are known to be substantially excreted by the kidney. Thus the risk of toxic reactions may be greater in patients with impaired renal function due to the accumulation of the parent compound and/or metabolites in the plasma. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Hydrocodone may cause confusion and over-sedation in the elderly; elderly patients generally should be started on low doses of hydrocodone bitartrate and acetaminophen tablets and observed closely.

ADVERSE REACTIONS

The most frequently reported adverse reactions are light-headedness, dizziness, sedation, nausea and vomiting. These effects seem to be more prominent in ambulatory than in non-ambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down.

Other adverse reactions include:

Central Nervous System: Drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, psychic dependence, mood changes.

Gastrointestinal System: Prolonged administration of Lortab Tablets may produce constipation.

Genitourinary System: Ureteral spasm, spasm of vesical sphincters and urinary retention have been reported with opiates.

Respiratory Depression: Hydrocodone bitartrate may produce dose-related respiratory depression by acting directly on brain stem respiratory centers (see **OVERDOSAGE**).

Special Senses: Cases of hearing impairment or permanent loss have been reported predominantly in patients with chronic overdose.

Dermatological: Skin rash, pruritus.

The following adverse drug events may be borne in mind as potential effects of acetaminophen: allergic reactions, rash, thrombocytopenia, agranulocytosis.

Potential effects of high dosage are listed in the OVERDOSAGE section.

DRUG ABUSE AND DEPENDENCE

Controlled Substance: Lortab Tablets are classified as a Schedule III controlled substance.

Abuse and Dependence: Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of narcotics; therefore, this product should be prescribed and administered with caution. However, psychic dependence is unlikely to develop when hydrocodone bitartrate and acetaminophen tablets are used for a short time for the treatment of pain.

Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued narcotic use, although some mild degree of physical dependence may develop after a few days of narcotic therapy. Tolerance, in which increasingly large doses are required in order to produce the same degree of analgesia, is manifested initially by a shortened duration of analgesic effect, and subsequently by decreases in the intensity of analgesia. The rate of development of tolerance varies among patients.

OVERDOSAGE

Following an acute overdosage, toxicity may result from hydrocodone or acetaminophen.

Signs and Symptoms:

<u>Hydrocodone</u>: Serious overdose with hydrocodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis) extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, cardiac arrest and death may occur.

Acetaminophen: In acetaminophen overdosage: dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect. Renal tubular necrosis, hypoglycemic coma and thrombocytopenia may also occur.

Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.

In adults, hepatic toxicity has rarely been reported with acute overdoses of less than 10 grams, or fatalities with less than 15 grams.

Treatment: A single or multiple overdose with hydro-codone and acetaminophen is a potentially lethal polydrug overdose, and consultation with a regional poison control center is recommended.

Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. Vomiting should be induced mechanically, or with syrup of ipecac, if the patient is alert (adequate pharyngeal and laryngeal reflexes). Oral activated charcoal (1 g/kg) should follow gastric emptying. The first dose should be accompanied by an appropriate cathartic. If repeated doses are used, the cathartic might be included with alternate doses as required. Hypotension is usually hypovolemic and should respond to fluids. Vasopressors and other supportive measures should be employed as indicated. A cuffed endo-tracheal tube should be inserted before gastric lavage of the unconscious patient and, when necessary, to provide assisted respiration.

Meticulous attention should be given to maintaining adequate pulmonary ventilation. In severe cases of intoxication, peritoneal dialysis, or preferably hemodialysis may be considered. If hypoprothrombinemia occurs due to acetaminophen overdose, vitamin K should be administered intravenously.

Naloxone, a narcotic antagonist, can reverse respiratory depression and coma associated with opioid overdose. Naloxone hydrochloride 0.4 mg to 2 mg is given parenterally. Since the duration of action of hydrocodone may exceed that of the naloxone, the patient should be kept under continuous surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. A narcotic antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular depression.

If the dose of acetaminophen may have exceeded 140 mg/kg, acetylcysteine should be administered as early as possible.

Serum acetaminophen levels should be obtained, since levels four or more hours following ingestion help predict acetaminophen toxicity. Do not await acetaminophen assay results before initiating treatment. Hepatic enzymes should be obtained initially, and repeated at 24-hour intervals.

Methemoglobinemia over 30% should be treated with methylene blue by slow intravenous administration.

The toxic dose for adults for acetaminophen is 10 g.

DOSAGE AND ADMINISTRATION

Dosage should be adjusted according to severity of pain and response of the patient. However, it should be kept in mind that tolerance to hydrocodone can develop with continued use and that the incidence of untoward effects is dose related.

The usual adult dosage for Lortab® 2.5/500 tablets is one or two tablets every four to six hours as needed for pain. The total daily dosage should not exceed 8 tablets.

The usual adult dosage for Lortab® 5/500 tablets is one or two tablets every four to six hours as needed for pain. The total daily dosage should not exceed 8 tablets.

The usual adult dosage for Lortab® 7.5/500 tablets is one tablet every four to six hours as needed for pain. The total daily dosage should not exceed 6 tablets.

The usual adult dosage for Lortab® 10/500 tablets is one tablet every four to six hours as needed for pain. The total daily dosage should not exceed 6 tablets.

HOW SUPPLIED

Lortab® 2.5/500 tablets (Hydrocodone Bitartrate and Acetaminophen Tablets, USP, 2.5 mg/500 mg) contain hydrocodone bitartrate 2.5 mg and acetaminophen 500 mg. They are supplied as white with pink specks, capsule-shaped, bisected tablets debossed "ucb" on one side and "901" on the other side, in containers of 100 tablets NDC 50474-925-01 and 500 tablets NDC 50474-925-50.

Lortab® 5/500 tablets (Hydrocodone Bitartrate and Acetaminophen Tablets, USP, 5 mg/500 mg) contain hydrocodone bitartrate 5 mg and acetaminophen 500 mg. They are supplied as white with blue specks, capsule-shaped, bisected tablets debossed "ucb" on one side "902" on the other side, in containers of 100 tablets NDC 50474-902-01, 500 tablets NDC 50474-902-50, and in hospital unit-dose packages of 100 tablets [4 × 25] NDC 50474-902-60.

Lortab® 7.5/500 tablets (Hydrocodone Bitartrate and Acetaminophen Tablets, USP, 7.5 mg/500 mg) contain hydrocodone bitartrate 7.5 mg and acetaminophen 500 mg. They are supplied as white with green specks, capsule-shaped, bisected tablets debossed "ucb" on one side and "903" on the other side, in containers of 100 tablets NDC 50474-907-01, 500 tablets NDC 50474-907-50, and in hospital unit-dose packages of 100 tablets [4 × 25] NDC 50474-907-60.

Lortab® 10/500 tablets (Hydrocodone Bitartrate and Acetaminophen Tablets, USP, 10 mg/500 mg) contain hydrocodone bitartrate 10 mg and acetaminophen 500 mg. They are supplied as pink, capsule-shaped, bisected tablets, debossed "ucb" on one side and "910" on the other side, in containers of 100 tablets NDC 50474-910-01, 500 tablets NDC 50474-910-50, and in hospital unit-dose packages of 100 tablets [4 × 25] NDC 50474-910-60.

Storage: Store at 20 to 25°C (68 to 77°F). [see USP Controlled Room Temperature]

Dispense in a tight, light-resistant container with a child-resistant closure.

A Schedule CIII Narcotic.

Manufactured for


UCB Pharma, Inc.

Smyrna, GA 30080

Lortab® 2.5/500, Lortab® 7.5/500

Manufactured by

Mikart, Inc.



Lortab® 5/500, Lortab® 10/500

Manufactured by

Mallinckrodt Inc.

Hobart, New York 13788

3E 03/2004

Current as of 05/2005

Copyright© 2006 Thomson PDR

EXHIBIT A

STATE OF ALABAMA

COUNTY OF DALE

AFFIDAVIT OF JOHN L. HAMLIN

John L. Hamlin, after being first duly sworn, deposes and says as follows:

- 1. My name is John L. Hamlin. I am over the age of majority and competent to testify to the matters stated herein. This affidavit is based on my personal knowledge.
- 2. I am Director, Business and Contracts, for Army Fleet Support, LLC ("AFS"). I have held this position since December 2005.
- 3. In September, 2003, AFS was notified that it was the successful bidder in response to the US Army Aviation & Missile Command's ("the Government's") Request for Proposals to provide maintenance and logistics support, effective December 1, 2003, to aircraft assigned to the US Army Aviation Center, Aviation Technical Test Center ("ATTC"), US Army Aeromedical Research Laboratory and other tenant and satellite units on Fort Rucker, Alabama. The primary objective of the contract awarded to AFS ("the Contract") by the Government was, and is, to provide aircraft maintenance in support of the flight training programs at Fort Rucker.
- 4. AFS was awarded this Contract through competitive bidding that involved the incumbent contractor, DynCorp Technical Services, LLC, Sikorsky Support Services Incorporated ("SSSI"), a previous contractor, and others.
- 5. This Contract is the largest aircraft maintenance contract in the Department of Defense. More than 3,200 people are employed by AFS in its maintenance and

logistics program at Fort Rucker.

- 6. The services performed by AFS under the Contract are on a Cost
 Reimbursable Plus Award and Incentive Fee basis, as provided in the Request for
 Proposal upon which all bidders bid. In other words, AFS is reimbursed by the
 Government for its costs, plus an agreed percentage of the savings below target costs and
 the opportunity for incentive fees, based on performance. The base period of the Contract
 was for one year, with options to extend up to a total of ten years, three months.
 Currently, the Contract has been extended by the Government through September 30,
 2008.
- 7. Per the contract terms dictated by the Government in its Request for Proposals, "[a]ll work will be performed in government furnished facilities at Fort Rucker, Alabama, and other locations as required." (See § C.1 of Attachment 1 (Continuation Sheet) of the Performance Work Statement attached to my affidavit.) The Government's Contract further provides that "[t]he Government will furnish the materials, supplies, equipment, machinery, [and] tools specified in the exhibits [to the Contract]." (See § C.10.1 of Attachment 1 (Continuation Sheet) of the Performance Work Statement attached to my Affidavit.) These materials, supplies, etc. include: existing aircraft maintenance facilities; Government-owned vehicles; new equipment training for the maintenance of new equipment that AFS is required to support; protective and flight clothing; utilities; aviation and motor vehicle fuels, oils, and petroleum

products required in the execution of the Contract; and reproduction (duplication) services. (See §§ C.10.1.1. - C.10.7 and Attachments 9, 9a, 10, 11 & 14.) AFS is accountable to return the facilities and non-expendable property to the Government, or turn them over to the successor contractor, at the conclusion of this Contract.

- 8. The furnishing of the above property pursuant to the Contract is not a subsidy or gift to AFS by the Government. These provisions were in the Request for Proposal issued by the Government and on which AFS and all other bidders submitted their Proposals. As a practical matter, since the objective of the Contract is to provide aircraft maintenance in support of the flight training programs at Fort Rucker, and the Government owns all of the real property and facilities comprising Fort Rucker, the successful bidder must maintain its operation on Fort Rucker to accomplish its mission in a timely manner. The facilities on Fort Rucker and most of the equipment there that are used by AFS, pre-existed the onset of the Contract and were used by previous contractors.
- 9. It is my understanding that the Government has entered similar contracts with other maintenance contractors over, approximately, the last fifty years. Were the Government not to furnish the property and services listed, the successful bidder would have to furnish that property and, in turn, charge the Government for same on a "cost-plus" basis.
 - 10. The Government's furnishing of certain facilities and property for AFS's

use does not increase AFS=s profits. If anything, it reduces AFS=s profits since the Contract is a Acost-plus@ one, and AFS has no opportunity to earn a profit on the cost of the facilities and property furnished by the Government.

11. In performing its Contract with the Government, AFS is subject to the regulations listed in § C.12 of Attachment 1 (Continuation Sheet) of the Performance Work Statement attached to my affidavit. Those regulations include regulations of The Department of Defense and The Department of the Army.

Further, Affiant saith not.

JOHN L. HAMLIN

Sworn to and subscribed to before me on this the 15 H day of June, 2007.

NOTARY PUBLIC

Affi Notatial Seal]

My Commission Expires:

ATTACHMENT 1	Deference Alace Day	·
CONTINUATION SHEET	Reference No. of Document Being Continued	
	PHN/SINN DAAH23-03-C-0345 MOD/AMD	Page i
SECTION C.1	DESCRIPTION/SPECIFICATIONS/WORK STATEMENT	
	INTRODUCTION	SECTION C.1
Name of Offeror or Contractor:	INTRODUCTION	
	I	

C.1	NTRODUCTION
C.1.1	- Trot marce Work Objective and the control of the
C.1.2	Changes to the Available Aircraft Requirement
C.1.3	Apprease Documents
C.1.4	restormance inspection Criteria
C.1.5	Tasks in Performance Work Statement (PWS)

	Reference No. of Document Being Continued	
CONTINUATION SHEET	PIIN/SINN DAAH23-03-C-0345 MOD/AMD	Page 1
SECTION C.1	DESCRIPTION/SPECIFICATIONS/WORK STATEMENT	SECTION C.1
	INTRODUCTION	

C.1 INTRODUCTION

The purpose of this contract is to provide quality maintenance support to the aircraft assigned as reflected in Attachment 2 to the US Army Aviation Center, Aviation Technical Test Center (ATTC), US Army Aeromedical Research Laboratory and other tenant and satellite units on Fort Rucker, Alabama. All work will be performed in government furnished facilities at Fort Rucker, Alabama, and other locations as required.

C.1.1 Performance Work Objective

The primary objective of this contract is to provide aircraft maintenance in support of the flight training at Fort Rucker, Alabama. For each month during the fiscal year (FY), the Government will provide the Contractor a fixed percentage of aircraft fleet required to be available for each day of the month having flight operations. The required number of available aircraft will vary by aircraft type. Contractor must execute aircraft maintenance to meet the available aircraft requirement for the month. The monthly projected available aircraft required for FY04 is provided in Attachment 2. Contractor must develop and execute a maintenance program to ensure the specified numbers of aircraft listed are available for launch. The Contractor shall maintain aircraft in accordance with appropriate Technical Manuals, Federal Aviation Regulations, and US Army Aviation Center (USAAVNC) Regulations and all Army Regulations.

C.1.2 Changes to the Available Aircraft Requirement

Changes to Attachment 2 may be made by the Contracting Officer Representative (COR) and provided to the Contractor two (2) weeks prior to the beginning of the month. After the two (2) week point, the requirement for available aircraft is fixed. Configuration and number of aircraft required shall be provided to the Contractor on a daily basis. Changes to aircraft configuration and configuration quantity only will be submitted no later than 3:00 pm the day prior to the actual requirement. Changes in configuration do not affect the number of aircraft required to be available.

C.1.3 Applicable Documents

- a. Where specific version of a document is called out as a reference, no other version shall be used without prior written consent of the Contracting Officer. The applicable version of subsidiary (second-tier) documents listed below shall be that version dated either concurrent with or just prior to the date of the listed documents.
- b. The Contractor shall generate and/or provide documentation as required by this Performance Work Statement, and the Contract Data Requirements List (CDRL) at Exhibit A. Exhibit A shall also apply to all options years.
- c. The documents listed on the Document Summary List (DSL) at Attachment 7 form a part of this contract to the extent invoked by specific reference in other paragraphs of this contract. Revision letters, amendment indicators, notices, supplements, tailoring, and dates are omitted when listed in other parts and sections of the contract. Documentation identified on the DSL shall be made available upon request for Government review in its current available format.
- d. Deliverable and non-deliverable data shall be capable of electronic transmission and storage to Government facilities or Government access electronically to the data at Contractor facilities. The Contractor shall maintain a system that provides electronic delivery/access to the Government. Data not developed under this contract will be provided in its currently available format.

C.1.4 Performance Inspection Criteria

For this acquisition, the Government desires to emphasize mission, performance, quality of maintenance, supply management, limited depot repair of parts, and cost effectiveness. The performance inspection criteria for this contract are established in Attachment 8.

	Reference No. of Document Being Continued	
CONTINUATION SHEET	PIIN/SINN DAAH23-03-C-0345 MOD/AMD	Page 2
SECTION C.1	DESCRIPTION/SPECIFICATIONS/WORK STATEMENT	SECTION C.I
	INTRODUCTION	SECTION C.J

C.1.5 Tasks in Performance Work Statement (PWS)

The Contractor shall perform the entire spectrum of tasks as described in this PWS. Tasks include the following areas:

- **C.2** AIRCRAFT MAINTENANCE C.3MAINTENANCE OF COMPONENTS AND EQUIPMENT C.4 AUTOMATION **C.5** OTHER SERVICES C.6 SUPPLY C.7 UNIQUE ATTC REQUIREMENTS C.8 MANAGEMENT AND PERSONNEL C.9 GENERAL PROVISIONS C.10 GOVERNMENT FURNISHED PROPERTY AND SERVICES C.11 **DEFINITIONS AND ACRONYMS** C.12 REFERENCES
- **ATTACHMENTS**
- 1 Performance Work Statement
- 2 Required Aircraft Table
- 3 Assigned Aircraft
- 3a Projected Assigned Aircraft FY 04 FY13
- 4 US Army Aviation Center (USAAVNC) Flying Hour Program
 Critical Flight Hour Program
- 5 US Army Aviation Technical Test Center (ATTC) Estimated Flight Hours
- 6 ATTC Projected Maintenance Man hour Requirements Satellite Units
- 6a Fort Rucker Historical Maintenance Man hour Requirements Satellite Units and Other Specific Tasks
- 7 Document Summary List/Regulations
- 8 Incentive Fee Determination Criteria
- 9 Government Furnished Property Material and Supplies
- 9a Government Furnished Property Equipment
- 10 Government Furnished Property Facilities
- Government Furnished Property General Service Agency (GSA) Vehicle Density List
- 12 Contract Security Classification Specification (DD Form 254)
- 13 Inter/Intraservice Support Agreement or Other Approved
- 14 Government Furnished Property ATTC
- 15 Projected National Maintenance Program

EXHIBITS

Exhibit A Contract Data Requirements List (CDRL)

SECTION C.10 DESCRIPTION/SPECIFICATION STATE PRODUCTION PRODUCTION PRODUCTION SPECIFICATION STATE PRODUCTION SPECIFICATION STATE PRODUCTION SPECIFICATION SP	ATTACHMENT 1 CONTINUATION SHEET SECTION C.10	Page 1 SECTION C.10
--	--	------------------------

C.10. GOVERNMENT FURNISHED PROPERTY (GFP) AND SERVICES

C.10.1 Government Property

The Government will furnish the materials, supplies, equipment, machinery, tools specified in the exhibits. The Government will also provide repair parts and components for all Army aircraft, except the TH-67 through DoD Supply System (See Part C.6). Property provided by the Government will be in accordance with current Table of Distribution and Allowance (TDA) or as approved by the KO. The Contractor shall accomplish all maintenance functions relating to Government provided equipment under the terms of this contract as required by the Government Property clause.

C.10.1.1 Government Facilities

The Government will furnish for use by the Contractor existing aircraft maintenance facilities, reserving for its own use such facilities as are required for flight operations, maintenance inspections, and supply and storage. The maintenance of facilities, commonly referred to as "repairs and utility" functions, will be the responsibility of the Government. For all alterations, modifications, or additions to facilities, a Facilities Engineering Work Request (DA Form 4283) shall be submitted through the Property Administrator (PA) to the Directorate of Engineering and Logistics (DEL). The Government will provide facilities listed in Attachment 10 Lists Facilities. The Contractor shall not perform any modifications to Government facilities without approval of the PA and the KO.

C.10.1.2 Government-Owned Vehicles

The Government will furnish vehicles for official use by the Contractor. Government furnished non-tactical vehicles (NTV) will be furnished and maintained by the Government Services Administration (GSA) from GSA Interagency Fleet Management System (IFMS). All other types of Government-owned vehicles, i.e., fuel trucks, 5-ton wrecker, electric golf carts, etc., shall be furnished by the Government, but Contractor shall perform all maintenance. These Government-owned vehicles shall not be used to transport contractor employees between their homes and places of employment or for any personal business or benefit. All contractor employees operating Government-owned vehicles shall have a valid appropriate state operator's permit. Whenever possible, gas or electric powered "golf carts" shall be utilized in place of trucks, sedans, vans, or other "on-road" vehicles. The GSA Vehicle Density List at Attachment 11 contains trucks, sedans, and vans provided by the Government for contractor use. The Equipment List at Attachment 4a contains other type vehicles provided by Government for contractor's use. Contractor shall maintain a management information system on all vehicles and provide status IAW DI-MISC-80508.

C.10.1.3 Government-Owned Aircraft

Title and control of Government-owned aircraft shall remain in and with the Government.

C.10.2 Calibration Service and Maintenance

The Government will furnish only that calibration service and maintenance on Test, Measurement, and Diagnostic Equipment (TMDE), which is determined to be beyond the capability, responsibility and authority of the Contractor in accordance with those references cited in C.5.5 of this PWS.

C.10.3 New Equipment Training (NET)

The Government will, when required, provide NET to the Contractor for the maintenance of new equipment introduced which the Contractor is required to support. Upon notification by the KO or COR that training is available, the Contractor shall provide personnel who require the training for performance of duties. Each person provided such training will incur a minimum two (2) year obligation, after completion of training, to serve in the job classification/position for which the training was received, provided the person remains employed by the Contractor. Persons receiving NET of two weeks or longer will not be eligible for additional formal training during the two (2) year obligation, unless such additional training is on equipment for the same aircraft system or there is a requirement to train an employee on more than one type aircraft during this period.

P
0
0
0
5
3

ATTACHMENT 1	Reference No. of Document Being Continued	
	PIIN/SINN DAAH23-03-C-0345 MOD/AMD P00053	Page 2
SECTION C.10	DESCRIPTION/SPECIFICATIONS/WORK STATEMENT	SECTION C.10
	GOVERNMENT FURNISHED PROPERTY AND	, , , , , , , , , , , , , , , , , , , ,
	SERVICES	

C.10.4 Protective and Flight Clothing

The Government will furnish protective and flight clothing, which shall be utilized by contractor personnel in areas requiring such in the performance of the contract. The Contractor shall submit requests for protective and flight clothing to the PA for approval.

C.10.5 Utilities

The Government will furnish utility related services currently available in the facilities to be provided. These utilities include heating fuels, gas, electricity, water, and sewage. The Contractor shall abide by installation regulations on energy conservation.

C.10.6 Mobility Fuels

The Government will furnish all aviation and motor vehicle fuels, oils, and petroleum products required in the execution of the contract.

C.10.7 Reproduction Service

The Government shall provide, if available, all reproduction (duplication) required under the Government printing and binding regulations. If the Government cannot provide required services within the necessary

timeframe, the contractor is authorized to utilize commercial sources. The contractor shall select the most economical means of obtaining services, considering overall quality services provided.

C.10.8 Contractor Provided Equipment

The Contractor will provide all facilities, equipment, repair parts, supplies, and materials required by this contract except as otherwise designated as GFP/GFE. The Contractor shall assume property responsibility for Aircraft Basic Issue List Items (DA Form 2408-17 and DA Pam 738-751). Mechanics' hand tools as appearing on approved tool lists and supplies required to maintain said tools in functional condition are specifically excluded from provision as GFE under this contract.

C.10.9 Utilization of Government Furnished Equipment

The GFE shall be utilized in accordance with and utilization data shall be collected and reported on GFE as required by the FAR, DFARS, AFARS, and AR 71-13.

C.10.10 Status Report

Vehicle and Equipment Deadline Status Report shall be prepared IAW DI-MISC-80508.

ATTACHMENT 1 CONTINUATION SHEET	Reference No. of Document Being Continued PIIN/SINN DAAH23-03-C-0345 MOD/AMD P00053	Page 1
SECTION C.12	DESCRIPTION/SPECIFICATIONS/WORK STATEMENT REFERENCES	SECTION C.12
Name of Offeror or Contractor:		

C.12 REFERENCES

C.12.1 Primary Reference Documents

C.12.2 Reference Publications

Government and commercial references required in support of this PWS total approximately 85,000 separate publications, precluding their being listed individually. Therefore, upon request, a copy of the most current DA Form 12 series, Adjutant General Publication Center Printout, and available indexes of commercial publications maintained by the present contractor will be made available. Also, upon request, the master library and engineering technical data library maintained in Building 415 by the present contractor will be available for review. Also, the contractor shall maintain a complete set of Army Approved Directives (C.12.3.3) in Building 412 designated reference library.

C.12.3 Publications List

Specific types of government and commercial publications required, but not limited to, in support of this PWS are as follows:

C.12.3.1 Government Publications

Department of the Army Regulations (AR)

Department of the Army Pamphlets (DA Pam)

Department of the Army Circulars (DA Cir)

Department of the Army Memorandums (DA Memo)

Department of Defense Regulations (DOD Reg)

Department of Defense Manuals

Federal Information Processing Standards (FIPS)

Common Tables of Allowance (CTA)

Department of the Army Field Manuals (DA FM)

Department of the Army Technical Manuals (DA TM)

Department of the Army Modification Work Orders (DA MWO)

Department of the Army Technical Bulletins (DA TB)

Department of the Army Training Circulars (DA TC)

Table of Organizational Equipment (TOE)

Federal Supply Classification (FSC)

Letter Orders (LOS)

Supply Bulletins (SB)

Department of Defense Specifications and Standards (DOD Specs & Stds)

Depot Maintenance Work Requirements

Department of Defense Flight Information Publications (DOD FLIPS)

US Army Aviation Center Regulations (USAAVNC Reg)

ATTACHMENT I CONTINUATION SHEET	Reference No. of Document Being Continued PIIN/SINN DAAH23-03-C-0345 MOD/AMD P00053	Page 2
SECTION C.12	DESCRIPTION/SPECIFICATIONS/WORK STATEMENT REFERENCES	SECTION C.12
Name of Offeror or Contractor:		

US Army Aviation Center Circulars (USAAVNC Cir)

US Army Aviation Center Pamphlets (USAAVNC Pam)

DA Regulations (USAAVNC Suppl to DA Reg)

Federal Aviation Administration Regulation (FAR)

Federal Aviation Administration Type Certificates

Federal Aviation Administration Advisory Circulars

Federal Aviation Administration Airworthiness Directives

Federal Aviation Administration Summary of Supplement Type Certificates

Military Specifications and Standards (MIL Specs & Std)

Other Miscellaneous Publications

US Army Test and Evaluation Command Regulations (ATEC Reg)

US Army Test and Evaluation Command Pamphlets (ATEC PAM)

US Army Materiel Command Regulations (AMC Reg)

US Army Materiel Command Pamphlets (AMC Pam)

US Army Developmental Test Command Regulations (DTC Reg)

US Army Developmental Test Command Pamphlets (DTC Pam)

US Army Developmental Test Command Circulars (DTC Cir)

US Army Aviation Technical Test Center Regulations (ATTC Reg)

US Army Aviation Technical Test Center Pamphlets (ATTC Pam)

US Army Aviation Technical Test Center Circulars (ATTC Cir)

ATTC Supplements to AMC Regulations (ATTC Suppl to AMC Reg)

ATTC Supplements to DTC Regulations (ATTC Suppl to DTC Reg)

ATTC Supplements to DA Regulations (ATTC Suppl to DA Reg)

C.12.3.2 Commercial Publications

Manufacturers' Information Letters

Manufacturers' Service Letters

Manufacturers' Service Notices

Manufacturers' Service Instructions

Manufacturers' Service Bulletins

Manufacturers' Sales Letters

Manufacturers' Operator's Manuals

Manufacturers' Services Manuals

Manufacturers' Maintenance Manuals

ATTACHMENT 1 CONTINUATION SHEET	Reference No. of Document Being Continued PIIN/SINN DAAH23-03-C-0345 MOD/AMD P00053	Page 3
SECTION C.12	DESCRIPTION/SPECIFICATIONS/WORK STATEMENT REFERENCES	SECTION C.12
Name of Offeror or Contractor:		

Manufacturers' Repair Parts Listings

Manufacturers' Overhaul Manuals

Manufacturers' Parts Price Lists

Manufacturers' Engineering Drawings

Commercial Publications.

Manufacturers' Engineering Specifications

Manufacturers' Special Service Tools

Manufacturers' Test Specifications

Other Miscellaneous Publications

C.12.3.3 Army Approved Directives.

Contractor Procedural Manuals

Contractor Process Controls

Contractor Engineering Standards

Contractor Engineering Change Memos

Depot Level Maintenance Authorizations

Technical Directive Routers

DA Form 2028 Responses, Approved Pending Manual Changes

Other Miscellaneous Publications

MATERIALS AND SUPPLIES

PIIN/SIIN: I	DAAH23-03-C-0345
MOD/AMD	

The materials and supplies listing consists of the following:

- (a) Authorized Stockage List (ASL)
 - 1. RIC ALD
 - 2. RIC W0H
 - 3. TH 67
- (b) Prescribed Load List (PLL)
 - 1. AH-64A
 - 2. AH-64D
 - 3. CH-47
 - 4. OH-58C
 - 5. OH-58D
 - 6. UH-1
 - 7. UH-60
- (c) Shop Stock Level (SSL)
 - 1. AMSS
 - 2. AMSS TH-67
 - 3. Cairns Field TH-67
 - 4. Hanchey Field
 - 5. Lowe Field

EQUIPMENT

DAAH23-03-C-

- 1. The Defense Property Accounting System (DPAS) listing contains the Industrial Property List ti consists of Table of Distribution and Allowances (TDA) property and other equipment that are authorized for performance under the contact and the quantities currently on hand. The contractor is authorized to requisition th authorized quantities on this listing. Deliveries will be subject to availability from the appropriate commodity con Changes to the authorized quantities will be considered effective upon written approval by the PBO.
- 2. The Government shall approve and provide the necessary Department of Defense Activity Addi Codes (DODAAC) for the Contractor to perform the activities and acquisitions of the mission assignment.
- 3. The TDA items hand-receipted from other property books for use on the contract are clearly ide as such.
- 4. A joint inventory will be made during Phase-In/Phase-Out in accordance with the contract claus "Continuity of Services".

PIIN/SINN:	DAAH23-03-C-0345
MOD/AME	

Page 1 of 2

GOVERNMENT FURNISHED PROPERTY - FACILITIES

The facilities identified with this Performance Work Statement will be provided to the Contractor by the Government. (*indicates shared with Government)

FACILIT 405	DESCRIPTION - RIVIN	TOTAL AREA
412	AC Comp Maintenance-Ground Equip Shop-Main Post	12400
413	Admin General Purpose-ACLC	14602
414	Flam Material Storage-Motor Pool-Main Post	120
415	Tech Publication Storage - Main Post	288
416	AC Comp Maintenance - AMSS - Main Post	71176
423	AC Paint Shop - AMSS - Main Post	3800
424	Storage General Purpose Inst-AMSS - Main Post	400
426	Storage General Purpose Inst-AMSS - Main Post	48
427	QA/CAL General Purpose-X-Ray - Main Post	638
429	AC Parts Storage - AMSS - Main Post	1800
1003	Storage General Purpose - AMSS - Main Post	288
1004	Storage General Purpose - Main Post (STAMIS)	6000
1005	Storage General Purpose - Main Post (STAMIS)	9000
1013	Storage General Purpose - Main Post (STAMIS)	9000
1106	AC Comp Maintenance - Trans Run Stand - Main Post	3000
1206	Mgmt General Purpose - QDR	3000
1206	Flam Material Storage - Main Post	1200
	AC Parts Storage -	780
1302	Gear - Warehouse	
1303	Storage General Purpose -Ind Property Warehouse	9000
1305	Storage General Purpose - Shipping Warehouse	9100
1401	Storage General Purpose - Receiving Warehouse	9000
1401	Storage General Purpose - AMSS Warehouse	9000
7205	Storage General Purpose - AMSS Warehouse	9320
10401	Flam Material Storage	9000
10406	AC Engine Test Cell - Tank Hill	120
25105	Sep Toilet/Shower - Tank Hill	240 64
25161	AC Maintenance Hanger - Knox	21801
5162	Maintenance General Purpose - Knox Motor Pool	
25165	Ir tam Material Storage - Knox	3000
25166	AC Maintenance Hanger - Knox	1,200
25641	Storage Bldg - Knox Warehouse	58,713
5642	Ammo Break Down Area - Molinelli Range	14,000
3642 25645	Storage Bldg - Molinelli Range	400
.5646	General Storage + Break Room - Molinelli Range	352
5647	Lauine – Molinelli Range	1,200
0101	Jet Fuel Storage ABV - Molinelli Range	352
	AC Maintenance Hanger - Cairns	1,120
0103 0113	AC Maintenance Hanger - Cairns	37,989
0301	AC Maintenance Hanger - Cairns	35,392
	AC Maintenance Hanger - Cairns	4,000
0302	AC Maintenance Hanger - Cairns	24,616
0303	AC Maintenance Hanger - Cairns	5,670
0304	AC Maintenance Hanger - Cairns	24,436
0306	AC Parts Storage - Cairns	4,000
0308	Storage Shed General Purpose - Cairns	1,000
0105	Storage General Purpose - Lowe	64

PIIN/SINN:	DAAH23-03-C-0345
MOD/AMI)

Page 2 of 2

GOVERNMENT FURNISHED PROPERTY - FACILITIES

FACILITY 40106		TOTAL AREA
	Navy Building, Air - Lowe	36
40108	Storage Shed General Purpose - Lowe	120
40113	AC Maintenance Hanger - Lowe	25,058
40114	AC Comp Maintenance-Avionics & Supply - Lowe	2,000
40115	AC Parts Storage - Lowe	3,452
40116	Flam Material Storage - Lowe	120
40117	AC Maintenance Hanger - Lowe	35,392
40119	Storage Shed-Paint - Lowe	140
40120	AC Maintenance Hanger - Lowe	34,220
40128	Maintenance-Vehicle & Ground Equip Shop - Lowe	1,000
40135	AC Paint Shop - Lowe	7,273
40137	Storage Shed Gen Purpose - Lowe	
40139	AC Plastic Media Stripping - Lowe	5,000
40146	Flam Material Storage - Lowe	3,200
40152	Flam Material Storage - Lowe	200
40188	Admin General Purpose-by Washrack - Lowe	
5004T	Admin General Purpose-Trailer - Hanchey	480
5005T	Admin General Purpose-Trailer - Hanchey	840
5006T	Admin General Purpose-Trailer - Hanchey	840
50130	Hanger Shop Space-Avionics - Hanchey	1,440
50132	Storage Shed General Purpose - Hanchey	7,500
50201	AC Maintenance Hanger - Hanchey	288
50202	AC Maintenance Hanger - Hanchey	35,213
50203	AC Parts Storage - Hanchey	15,607
50204	AC Maintenance Hanger - Hanchey	14,400
50205	Flam Material Storage - Hanchey	15,164
50207	AC Maintenance Hanger - Hanchey	925
50208	AC Comp Maintenance-Supply/Armament Repair	14,500
50209	AC Maintenance Hanger - Hanchey	15,638
50210	Flam Material Storage - Hanchey	18,585
50211	Storage General Purpose-Motor Pool/Eng Shop	232
60104	AC Maintenance Bay - Shell Field	2,530
60105	AC Maintenance Bay - Shell Field	8,471
60106	POL Storage - Shell Field	8,471
60110	Avionics/Flight Line (right side only)- Shell	120
60113	QC/PC/Test Flight/Records - Shell	1,620
60118	Motor Pool/Sheet Metal - Shell	4,000
60126	Supply/Storage - Shell	4,000
L2840		4,000
	Admin General Purpose-Data Processing - Daleville	5,000

PIN/SINN: E	AAH23-03-C-0345
MOD/AMD	

Page 1 of 4

GSA VEHICLE DENSITY LISTING

Listed below are the vehicles provided by GSA. A joint inventory will be made on the contract clause "Continuity of Services" during the Phase-In-Phase-Out (PIPO)

GSA#	TMP#	Year	
G12-13221	D001	1999	Model
G32-00969	D200	2001	BREEZE
G41-33045	D007	1997	TCFE2409
G41-33048	D048	1997	ASTRO
G41-33049	D049	1997	S10
G41-33050	D045		S10
G41-33051	D051	1997	\$10
G41-33052	B 5 7 5	1997	S10
G41-33053	D012	1997	S10
G41-33054		1997	S10
G41-33055	D035	1997	S10
G41-33056	D005	1997	S10
G41-33057	D005	1997	S10
G41-33058	D038	1997	S10
G41-34376		1997	S10
G41-34377	D041	1997	S10
G41-34383	D043	1997	S10
G41-34384	D026	1997	F150
G41-34388	D029	1997	F150
G41-34395	D055	1997	F150
G41-34395 G41-36919	D036	1997	AEROSTAR
G41-42914	D042	1998	S10
	D021		WINDSTAR
G41-42938	D056	1999	RAM 1500
G41-42945	D006	1999	CARAVAN
G41-42971	D050	1999	RAM 1500
G41-42972	D022	1999	RAM 1500
G41-42976	D024	1999	RAM 1500
G41-42978	D028	1999	CARAVAN
G41-43001	D030	1999	CARAVAN
G41-43002	D034	1999	CARAVAN
G41-43023	D032	1999	RANGER
G41-43024	D014	1999	RANGER
G41-43025	D011	1999	RANGER
G41-43026	D037	1999	RANGER
G41-43027	D033	1999	RANGER
G41-43030	D052	1999	RANGER
G41-43031	D059	1999	RANGER
G41-43034	D003	1999	RANGER
G41-43035	D004	1999	RANGER
G41-43037	D010	1999	RANGER
G41-43038	D015	1999	RANGER
G41-43039	D002	1999	RANGER
G41-43042	D031	1999	RANGER

PIN/SINN: D	AAH23-03-C-0345
MOD/AMD	
	Bass 2 of 4

GSA VEHICLE DENSITY LISTING

GSA#	TMP#	Year	Model
G41-43046	D017	1999	RANGER
G41-43047	D008	1999	RANGER
G41-43049	D020	1999	RANGER
G41-43050	D023	1999	RANGER
G41-43051	D061	1999	RANGER
G41-43052	D044	1999	RANGER
G41-43053	D063	1999	RANGER
G41-49389	D013	2000	S10
G41-49394	D046	2001	RAM 1500
G41-49395	D040	2001	RAM 1500
G41-49396	D166	2001	RAM 1500
G41-49403	D161	2001	RAM 1500
G41-49406	D128	2001	RAM1500
G41-49441	D163	2001	RAM1500
G41-49442	D160	2001	RAM1500
G41-49443	D168	2001	RAM 1500
G41-49444	D165	2001	RAM 1500
G41-49445	D064	2001	RAM 1500
G41-57057	D007	2001	S10
341-57087	D065	2001	WINSTAR
341-65066	D009	2002	S10
341-65069	D025	2002	\$10
341-65074	D019	2002	S10
342-39802	D111	2000	B2500
342-39803	D067	2000	B2500
G42-43730	D114	2001	1500
342-43731	D127	2001	1500
342-43734	D102	2001	1500
342-43737	D066	2001	RAM1500
342-45174	D093	2001	1500
342-45177	D133	2001	RAM1500
G42-45198	D099	2001	1500
G42-48441	D081	2002	RAM1500
G42-48462	D158	2002	C1500
342-48466	D159	2002	C1500
G42-80642	D164	1997	E150
342-80647	D110	1997	E150
G43-05263	D090	1999	RAM 2500
G43-05264	D092	1999	
343-05268	D074	1999	RAM 2500
G43-05284	D079	1999	2500
G43-05487	D094	1999	RAM 2500
G43-05495	D108		P30
G43-09206	D108	1999	2500
G43-09210	D112	2000	3500
G43-09221		2000	3500
J7J-UJZZ I	D095	2000	`P30

PIN/SINN: C	AAH	123-03-	C-	034	15
MOD/AMD					
		Don	- 1	-4	7

GSA VEHICLE DENSITY LISTING

GSA#	TMP#	Year	Model
G43-14161	D097	2001	RAM 2500
G43-14166	D073	2001	F350
G43-20543	D087	2002	E350
G43-63168	D096	1997	C3500
G43-67534	D107	1997	P30
G43-67569	D071	1997	F250
G43-67570	D076	1997	F250
G43-67571	D077	1997	F250
G43-67572	D078	1997	F250
G43-67573	D080	1997	F250
G43-67574	D070	1997	F250
G43-67575	D075	1997	F250
G43-67576	D082	1997	F250
G43-67577	D083	1997	F250
G43-67578	D068	1997	F250
G43-67580	D069	1997	F250
G43-67582	D085	1997	P30
G43-67585	D084	1997	P30
G43-67586	D088	1997	P30
G43-67587	D089	1997	P30 6
G61-04860	D134	1999	CHEROKEE
G61-08952	D126	2001	CHEROKEE
G61-34843	D125	1997	CHEROKEE
G62-05084	D129	1999	RAM 1500
G62-26956	D124	1996	BRONCO
G62-29570	D091	1997	F250
G63-07360	D113	2001	IF350
G63-11633	D105	2002	K3500
G63-28089	D104	1997	C3500
G63-28091	D103	1997	C3500
G63-28092	D106	1997	C3500
G63-28093	D109	1997	C3500
G63-28095	D101	1997	C3500
G63-28096	D098		C3500
G63-30151	D100	1997	F350
G71-00018	D119	1998	F-800
G71-00021	D121	1998	F-800
G71-00023	D120	1998	F-800
G71-00026	D122	4000	F-800
G71-00027	D116	1998	F-800
G71-00028	D115	1998	F-800
G71-00552	D130	2000	C6500
G71-01215	D177	2001	S&P
G71-01824	D178	2003	4200 S & P
G71-17367	D117	1998	F-800
G71-17368	D176	1998	F-800

PIN/SINN:	DAAH23-03-C-0345
MOD/AME	
	Page 4 of 4

GSA VEHICLE DENSITY LISTING

GSA#	TMP#	Year	Model
G71-17369	D118	1998	F-800
G71-17376	D170	1998	F-800
G71-17743	D123	2002	4700
G82-00050	D132	1992	F900 T/T
G82-01986	D400	1990	7100 4X2
G90-01420	D131	1991	WRECKER
G91-04543	D406	1994	28'F/BED S&P

PHNINNS DAAH23-09-C-0945 MOD/AMD

Page t of 30

As of 3/17/03	i		
BAR	SERIAL	The state of the s	
CODE	NUMBER	NOMENCLATURE	COST
00057	J2874	Dieplay Station 3278-902 w/keytocad (BC:05008)	
00099	58063	Printer Type 3287-001	2,860.00
00100	H3453	Display Station wheyboard-rad 3278-002	6,015.00
X0110	C7533	Display Station wikeyboard mid 3279-03X	2,950.00
0121	(00121	80ard Magnetic Change A Board	2,574.00
10169	G-20809	Multimeder (Ng AMPSM-45	100,00
0179	43662	Printer Type 3287-002	145.00
0185	C9074	Printer IBM 3297-002	6,015 00
0187	C9073	Provior 3287NA002	6,015.00
00188	C7534	Cisplay Station 3279-03X	6.015.00
0190	S1381	Display Station 3278-002	2,574.00
0191	G6651	Printer 3287-C02	2,960,00
0501	48M72	Display 51s6cm 3278-005	5,924.74
0502	J2873	The same of the sa	2,967 (8)
0506	48M74	Display Station 3278-002 wkeyboard (8C:03940)	2,980.00
0508	54500	Ospany Station 3278-035	2,967,00
0510	43663	Control Unit, Mell 3276-002	6,207.00
0514	14916	Display Station wikeyooxard-nut 3278-iki2	6,015.00
0517	48M73	Printer Typ Mot 6	40,985.00
0518	C7535	Display Station 3278-005	2.967.00
0519	B013724	Olsplay Station 3279-034	2,374.00
0523	B178791	Manifor Storage Display Mdl Telesconic 618	10,850 (J)
0600	4 4 4 4 1 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Terminal Hard CopyUnii	4,495.00
0600	1380	Display Station 3278-002	2,960.00
0602	58063	Printer, Type 3387-001	6,015.00
0002 0675	J2869	Display Station 3278-002	2,960.00
0676	23331	Redio Set AN/PRC-90	517.31
0683	14066	Radio Set AN/PRC-90	517.31
0710	14501	Radio Set ANYPRC-90	517.31
0710 0711	D2396	Dual Disketin (comp of 00711)	
0714	D3876	Chaptery Stallon 6580-AO8	11,824.00
)/14)/15	B9214	Printer 5219-a(r4	2,000.00
	27009	Display Station 3276-005	2.967.00
0723	0045336	Computer 3270 PC Mdl 5271-008	10,842.00
724	37937	Keyboard for 3270 PC	200 00
0725	07364	Printer 5218 A04	2,000.00
1726	34704	Manitor Color Olsplay MOL 6272-001	300.00
0731	37945	Keyboard, PC	200.00
1732	32178	Manilar, Cator Display	300.00
733	D7368	Printer 5218-A04	2,576.00
734	0045337	Computer, Mdl 5271-006	10,842.00
738	29717	Color Display Mdf 5272-000 t	300.00
825	00825	Chair Typisl Airliff, Borge	371.00
827	00827	Char Airlit Beige	371.00
1855	408034	Calculator, Canon Elec	232.97
1857	420274	Calcutator, Cenon Elec	232.97
1915	A890919	Stud Driver	465.00
997	00997	Chair Arist	371.00
000	01000	Chair	145.00

PUN/SINN: DAAH23-03-C-0345 MOD/AMB

Page 2 of 36

As of 3/17/03			
BAR	SERIAL		
CODE	NUMBER	NOMENCLATURE	COST
01484	0927	Power Supply 40-25	800.00
01522	WTC1257575	Tricycle Transporter	515.50
01819	000124	Control Unit 3274-CB1	4.591.00
01820	000126	Control Unit 3274-C61	4,981.00
01984	01984	Cabinet Terminal/PC Workstation	833.00
01985	61736	Printer Pacemetor 2410	2,010,00
01990	01990	Keyboard Zerith	150.00
01992	01992	Koytopott, Zenith	150.00
)1993	XXX00964	Suma Graphica	200.00
01995	113783	Printer Okidata 93	320.00
02000	06108A4717	Computer Exec Set	2,300.00
02101	D2388	Disketin Dual 6360-22	200,00
02108	58062	Printer 3287-001	
02109	02109	Rayboed (comp of DOSCZ)	მ,815.00
J2114	02114	SheetFeeder 7870 (comp of 00711)	
02121	02121	Keybeard/Operator Console	
02125	0051051	The state of the s	100 00
02126	46568	Corrouter System 3270	9,142.00
12127	E4725	Oual Diskette \$380-22 (comp of \$2127)	1
2128	02128	Display Station 6580-A10	13,012.00
2129	E2647*	Keyboard (comp of (X2127)	
02130	E2647	SheotFeeder 7870	576.00
)2131	02131	Printer 5218-A64	2,000,00
02132		Keyboard (comp of 00188)	
02133	40970	Keyboard for 3270 PC (comp of 02125)	
)2134	30813	Color Olsplay ,Mdl 5272-0001	1,000.00
)2135	02134	ShoelFeeder 7870 (comp of 02135)	
	D7365	Printer 5218-A04	2,000.00
2138	02138	Keyboard (comp of 08501)	
)2140	27005	Display Station 3278-005	2,767.00
2141	004120	Controller 3725	76,758.00
2142	00A4896	Console 3727-7(ii)	2,174.00
12151	34019	Disketie Dual 6360-22	200.00
2176	0045303	Computer System 3270	10,242.00
12194	E6442	Diskette Dual 5360-22	350.00
2196	1051804	SheelFaedar 7870	00.00
2197	31651	Printer 5218-A02	2,000.00
12235	02235	Table,Computer,Pulty, Adjustable 66*	380.00
2253	02253	Terminal Workstation 18" adjustable Purty	420.00
2256	02256	Table Terminal Workstation Split level	557 25
2257	02257	Side Extension (comp of 02256)	
2260	02260	Terminal Workstation 48° adjustable Putty	420.00
2262	02262	Termiant Stand spiri-Lovel	370.00
2263	02263	Skin Extension	120.00
2285	85525	Engraveograph ITF-V	2.817.60
2286	00008989	Boyeler 8-4 (comp of 02285)	
2287	100595	Saw Safety (comp of 0/2/86)	
2319	02319	Redio Console w/Microphone M-80 (SN: 05828)	3,004.30
2354	1231649	Safe APP Sec Container	770.00

PHN/SINN:	BAAH23-03-03-0345
MOREAMD	
	Page 3 of Ja

As of 3/17/03			
BAR	SERIAL	The state of the s	
CODE	NUMBER	NOMENCLATURE	COST
02418 (comp)	20198	RM Cont UT VID VS200F	100.00
12419 (comp)	10262	Cont 9X Vid AV VS100G	100.00
02585	02585	Board Mark & Wipe 4'x6'	230.50
02630	02630	Magnetic 5-Yr Planning Calondar	673 50
02650	02650	Cover Frinter Acoustic Mill 287	311.92
32979	02979	Table Weinut corner Step 30"x30"x24"	36.75
03011	03011	Dispenser, 115V60H, 9.5G PH	242.90
33019	03019	Table End Step	45.00
03403	01580	Power Sup FP-4606(3)(3)	1,988.00
03510	03510	MAG plan catendar	122.96
03553	30150	Foster (light Head gear	1,490.20
)3 5 56	04181	Teal Sel Ballery TS-2530A	452.56
) 3590	14612	Transmitting Std Hadio, ANKSRT-22	2,280.00
03591	12121	Receiver Radio, AN/GRR-24	8,000.00
3592	16436	Transmilling Set Radio, AN/GRT-21	2,000.00
3594	14422	Receiver Radio, ANIGRR-23	8,000,00
3628	3882H	Paper, Smedder Machine	
3648	298	Test Set Radio, AN/PRM-32	751.00
03712	2455202	Multimeter Catt Mat# 80 KIA	290.00
3713	03713	Test MOB	289.00
3857	03857	Keyboard IBM (comp of 00/190)	125,00
13940	03940	Keybosed (comp of 00502)	
14262	848	Power Sup PP-4606()/G	
M297	10A8	The state of the s	600.00
4302	2830	Mullimeter Digital Air Purifier Desktop	79.95
4427	A-EC5104	The same of the sa	127.96
M656	04656	AMMETER VOLT-OHM	140.50
14695	6761	Refrigerator, Lefthand	150.00
14696	8782	Air Purtter Deskhop	127 96
4723	SVRPS-521	Air Purifier Desklop	127.96
4724	SVRPS 541	STLB Van STOR M750(C)	32,982.60
5008	05008	STLR Van STOR M750(C)	32,952,00
5012	05012	Knytoard (comp of 00057)	
5028	05012	Keyboard (comp of 60600)	
5029		SheelFeeder 7870 (comp of 00711)	
	05029	Kayboard for 5580-A06 (comp of 00711)	- CONTRACTOR
15031 Engo	0192529	Expansion Unit PC-XT	1,358.00
5039 Ensa	0192527	Expansion Unit PC-XT	1,358.00
5041	05041	SineetFeeder 7870 (comp of 00733)	
5088 even	0192429	Expansion Unit PC-XT willxed disk	1,359.00
5099	40980	Keyboard F/3270	200.00
5101	07776	Dual Distone 6360-22 (comp of 05102)	
5102	E4721	Display Station 6580-A10	9,764.00
5103	9381	Printer 6215-001 (comp of 05103)	
5105	05105	Keyboard (comp of 05102)	
5117	D192487	Expansion Unit PC-XT, WiFored Disk	1,358.00
5123	B0442	Computer Compaq Portable widoal disk drive	1,581.80
5182	51BB	TS-3651/ALO-136(V)1	203,608.00
5185	34622	Color Display 5272-001	300.00

PHINISINN:	DAAH234BAC4B45
MODEANED	
	Page 4 of 14

As of 3/17/09			
BAR	SERIAL	The second secon	•
CODE	NUMBER	NOMENCLATURE	COST
05403	805455		
05187	0051091	Computer 3270	10,242.00
05232	7027	Scale Benefit withiny PK	481.00
05238	2659	Oven, Convention	798.93
05367	G6652	Printer,3287-C02	5,724.74
05396	1290	Radio Set AN/PRC-90	517.31
05397	F6943	Андо Sir ANPRC-90	517.31
05399	F06596	Radio Set AN/PRC-90	517.31
05400	3356	Radio Set AN/PRC-90	517.31
05406	107410	Radio Set ANIFRC-90)	517.31
25408	17106	Radio Set ANPRC-90	517.31
25410	6114	Hadio Set ANYPRC-90	517,31
05425	05425	Chair Airlift	371.00
25482	05482	Cher Airlit Brown	105.26
)5483	05483	Chair Airlift Brown	106.26
15484	05484	Cheer Airlitt Brown	105.26
1 5 485	05485	Chair Aidill Brewn	106.26
)549 8	05498	Stand Terminal widewers 60"x30"	597.30
5608	92170	Monitor Cofor	200.00
15622	723AC0995	Computer, Micro	3,915.00
5623	05823	Keyboard Zenith	200.00
15632	7A6224697Y	Printer Dat Regula	300.00
5633	05633	Keyboard Zen#n	200.00
5637	7A6224692Y	Pontor Dot Mastix	٠
15642	723AC1001	Computer Micro Mdl 62	528.00
05643	92170823	Manitar RG8 Calor	3,015,00
15645	05645	Keybos≰d	200.00
5646	723AC0963	Computer, Compaq	200.00
15647	7A6219618Y	Printer Dor Matrix	2.715.00
15655	2718J29665	Printer, Lasoriel	628.00
15657	2718J29809	Printer, Laserjei	2.458.90
5661	2728A54731	Terminal HP150II	2,480.90
5662	2727A54602	the state of the s	1,548.70
15674	2728A54735	Terrinal HP150II	1,540.70
5665	2719840556	Texmenal HP150II	1,549.70
5686	2719540549	Keyboard HP	200.00
5702	2719\$40567	Keyboard HP	200.00
5708	2719S40565	Koytosart HP	200.00
5745	er errigina i i i i da desi a diador laglacas co como que con	Keyboard HP	200.00
5746	0022	Test Sat Elec Sys M91	600.00
5747	05746	Settee, Metal Frame	405.00
	05747	Settoe, Metal Frame	435 00
5748 5749	05748	Solloe, Molal Frame	435.00
	05749	Settee, Metal Frame	435 00
5751	23-2618	ROO FM MT500 HNIXITEKI	1,161.54
575 2	23-2619	RDO FM MT500 HNDITLKI	1,161.54
5753	23-2620	ROO FM MT800 HNDNTLKI	1,161,54
5816	2709-A26536	Power Malar 436A (comp to 05817)	
5817	2636A11447	Frequency Counter Micro	6,499,80
5818	2702A55772	Power Sensor HP8481A (Comp of 05818)	1

PHN/SINN:	DAAHAD-03-C-0345
MODEW AMID	
	Page 5 ad 37

As of 3017.013			
BAR	SERIAL.		
CODE	NUMBER	NOMENCLATURE	COST
05828	05828	Radio Console WilMerophone M-88C/JU	3,004.30
)5844	05844	Cabinet Terminal PC Workstellon	833.00
J5846	05846	Cebinet Terminal/PC Workstation	B33.00
05848	05848	Cabinet,Tenraral/PC Workstation	833.00
05901	05901	Cobinet TeamanaVPC Workstation	833.00
05904	05904	Table Computer, MDL 8267 (DeVake)	840.00
05910	4435776	MUR (NGIT ANIPSM-45/4/C)	115.00
05968	49981	Multimeter DIG AANPSM-45(C)	145.00
05971	2974	TEST STAND ELEC ACFT(C)	27,220.00
05973	3791	Balancing KILPRPO (C)	8,160,00
05980	0532	Compr RCP P4R15GJ	
05982	B0178	the control of the complete control of the control	14,501.80
05984	B0072	GEN ST HSWTHJHGV7	2,186.00
05987	43255	GEN ST MEPO16AMC)	(4,491.00
05988	43254	Power Supply	1,988.06
	the same transfer was a second	Power Supply	1.988.00
05993 05094	49794	TST STAND HYD(C)	16,728.60
05994	B0403	(TEST STAND ACFT(C)	591.0X)(I-0
05997	10170020	TRUE GAS HYS HISOF(C)	27,414.00
06003	39946	GEN ANIURM-127(C)	189.70
06005	B8978	MANT KEE MK-1004/ARC(C)	1,233.00
08006	B8987	Multimer TS-585ABC/U(C)	159.46
06007	B0397	Multimer T8-585ABCiU(C)	158.46
06008	43421	Multimer TS-585ABC/U(C)	159.46
06009	42304	Oscii Anaism-281A(C)	1,420.00
06010	49985	Multimeter DIG ANIPSM-45(C)	145.00
06011	49982	Multimeter DIG AN/PSM-45(C)	145.00
06012	B0499	Resist Decad ZM-16/U(C)	51.01
06013	B8748	Resist Decad ZM-16/U(C)	51.01
06014	B0616	TST FAC KT MK-994/AR(C)	10,827.00
06015	8086	Test Sel Fuel TF20 1(C)	6,007.89
06016	38256	TST ST DIR AMARM-RAC)	2,230.00
06017	138980	TST ST DIR ANIARM-83(C)	2,230.00
06020	51519	TS Redar ANTEM-25A(C)	27,000.00
06021	51526	TS Radar AN/TPM-25A(C)	27,000.00
06022	39599	TST ST ANARM-92B REC(C)	4,400.00
06023	39597	FST FAC KT MK-994/AR(C)	10,627.00
06026	38284	TST ST TR ANIAPM-23BA(C)	21,630,00
06027	B8924	CHARGER BTY PP-1451/G	784.00
06028	49983	Multimeter DIG AM/PSM-45(C)	145.00
06029	49988	Mullimeter OIG AMPSM 45(C)	
16030	49986	Mullimeter DIG AMPSM-45(C)	145.00
06032	B8096	The state of the s	145.00
16033	8988	TST ST AMP ANIASM-121(C)	13,356.00
0003-3 060034	8954	SAM ACFT D ANYASM-120(C)	5,274.00
06035		SAM AMP OP SM-335/ASM(C)	1,417.00
	8951	MT KE MK-731/ARC-51X(C)	9,592.00
16036	49984	Mullimeter 13K5 AWPSM-45(C)	145.00
06038	49989	Mullimeter BIG AN/PSM-45(C)	145.00
0603 9	49990	Millimeter DIG ANIPSM-45(C)	145.00

PUN/SINN: DAAH23-03-C-0348 MODYAMD

Page 6 of 36

As at 3/17/03			
BAR	SERIAL.	The second secon	
CODE	NUMBER	NOMENCLATURE	COST
06040	49991	Mattinieter DIG ANIPSM-45(C)	
6042	49993	Mullimeter DWG AN/PSM-45(C)	145,00
6047	B8027		145.00
16051	41075	Shaper CTGHZTL(C) SAW Band Metal Cutt(C)	44,871.0
6052	B8024		
6053	43926	Labre ENG Floor MDT(C)	15,550.0
X8071	PC903	SAW Pwr Hack Hoxiz TY(C) Krytoserd, Behdan	349.75
6073	PC904	Keyboard	200.00
16074	B1820	the second secon	200.00
6075	0192411	Computer Desktop 386 Expansion Unit PC-XT	8,118.00
15085	2743J99737	The second secon	1,358.00
6089	06089	Printer LeserJel	2,316,00
6090	06090	Chair, Straight Wicusthone	21104
16091	06091	Cherr, Straight Woushions	211.04
6092	08092	Settee, Metal Framo	435.00
6101	06106A4712	Settes, Missai Frame	435.00
6127	43185	Computer Eusc Sel	2.300.00
6133	B3184	Public Artidross Systems(C)	200 00
6134	38265	16ST STAND PM /189-1(C)	27,270.00
6135	B0013	TS TRANS AN/APM-305(C)	18,422 00
6136	38266	TST TRANSP AN/APM-123(C)	7,881.00
8137	38605	TST TRANSP AN/APM-123(C)	7,881.00
3138	39689	TST ST AN/ARM-92B REC(C)	4,400.00
6142	95080402	TST EL PWr AN/UPM-93(C)	892.00
6145	95080668	Moniky RG8 Cotor	300.00
5156	812AE3243	Monitor RGB Color	200.00
6164	8A6410357Y	Computer PC Zeniën	1,528.00
3167	8A6411889Y	Printer Dot Matny	250.00
3172	42047	Primler Oot Medrix	\$28.00
3173	80153	Oschoscope AMUSM(C)	2,326.97
3174	49498	Osoli AN/UBM-281A(C)	1,420.00
3175	49497	Mullinwiter AIMLESM-486(C)	480.00
183	06106A4715	Mullimaser ANNUSM 48(%(C)	490.00
192	B9401	Compuler Exéc Sol	2,300.00
195		Printer 5218-A04 (comp of 00711)	
243	710016 2702A26241	Monitor Culor Display	500,00
246	The same of the sa	Diek Drive 9153A	1,299.80
247	2702A28236	Disk Orive 9153A	1,298,80
250	2702A26231	Disk Drive 9163A	1,299,80
251	2816550018	Keyboard HP	200.00
253	2816550019	Keybosed HP	200.60
254	2010830008 2010840236	Keykowa HP	200 (н)
257		Keytoerd HP	200.00
259	2720Y06051	Femilia HP 1500	1.548.70
261	2720Y06053	Terminal HF 150II	1.561 10
271	2720Y06050	[eminal HP 160]]	1,548.70
288	11508363	Modem Starkt Alone	110,60
	8370106	Fling cabinet widrawers	2,228.76
311	68190888	Cart, Electric E-Z	4,252,00

PHN/SINN ₁	DAAH21-09-C-034
MOWAMB	
	11 T - f 1

के का उपारिकार्थ के बात कर कर के किए हैं कि उस के का किए की का का किए की				
BAR	SERIAL	The state of the s		
CODE	NUMBER	NOMENCLATURE	COST	
06332	502-00381	PN Modulator HP87348(C)	1,754.00	
06339	USA45562	Airning Circle M2A2(C)	1,797.00	
06340	USA-1246	SIM FEMPASPEEDS	4,803.00	
05341	USA42248	TST Set Instrument(C)	29,838.00	
06342	USAB0645	TST Synchro TTU-231E(C)	5,308.00	
06343	USA41241	TST Set Instrument(C)	10,303.00	
06365	ACO	TST Audio TS-1598/VAI(C)	1,258.00	
D6374	06374	Cabinel strg 12 DRW	753.12	
06379	06379	Cabinet,Storage 9 dwr 30x57 MDL SEP3155	621.77	
06381	06381	Cabinet strg 3 Drw	100.00	
06366	1024	Signal Salector (comp of 97418)		
06432	23-2616	ROO FM MT500 HNOIT(R)	1,161 54	
06433	06433	CHRGR SNGL (comp of RDO FR MT508)	9, 10, 2 24	
06434	23-2617	ROO FM MT500 HNDITLKI	1,16154	
08435	06435	CHRGR SNGL (comp of RDO FR MT50B)	8, 1014 SP4	
06436	06436	CHROR SNGI. (comp of RDO FR MTS00)		
06437	06437	CHRGR SNGL (comp of RDO FR MT500)		
06438	06438	CHROR SNOL (comp of RDO FR M1500)	Commercial and the second seco	
05439	23-2621	ROO FM MT560 HNDITLKI	1,161.54	
06440	06440	CHRGR SNGL (comp of RDO FR MT500)	1,101.34	
06456	3400153587	Modern	100.00	
06459	20F1017887	Montter WY-530-02	200.00	
06498	12798	Cantrol Unit ASC II		
08502	9371081202	Compuler Lepheki Micro	12,295.00 1,524.00	
06521	65750588	Trick 4040x968 IN MAX	THE PARTY OF THE P	
06524	39AC077717	Competer Advanced 2VVX	3,707.85 2,084.00	
06530	39AC077021	Computer Advanced ZWX	2,084.00	
06535	9626727	Keyboard,Zenith	200.00	
06542	8A6464971Y	Printer Ook Meerlx	528,00	
08545	8A6465024Y	Printer Dot Matrix	528.00	
06559	8A6464972Y	Prenter, ALPS	528.00	
08561	9626728	Keyboard Zesith	200.00	
06628	06106A4748	Computer Exec Set	2,300.00	
06634	0058837	DISK DRIVE FLOPPY		
06692	06692	Cablnet,Terminat/PC Workstation	833.00	
06732	109088	Speech Security EQ		
06733	10429	Tape Reader GP	1,929.81	
06734	10430	Tape Reader GP	161.00	
06735	23524	Tape Reader GP	161.00	
06736	31406	Tape Reader GP	161.00	
06737	42635	Elec. Transfer Keying	235.45	
06738	42636	Elec. Transfer Keying	235.45	
06739	42637	Elec. Transfer Keying	235.45	
08740	98658	Histor Transfer Keying	235.45	
08741	D05269	Interface Adapter	857.08	
06742	24339	Spench Security EQ	2,820.37	
06743	24340	Speech Security EQ	the transfer of the second	
06744	24341	Speech Security EQ	2.820.37 2.820.37	

PHAGURA:	DAAH23-03-C-0345
мююлано	
	Pene S of 36

As of \$/17/03			ļ
BAR	SERIAL.	The state of the contraction of the state of	
CODE	NUMBER	NOMENCLATURE	COST
08745	24342	Speech Security EQ	2,820.37
Q5746	24343	Speech Security EO	2,820.37
06747	24344	Speech Security EQ	2,820.37
06748	24345	Speech Security EQ	2,820,37
08749	24346	Special Security EQ	2,820.37
06750	24347	Speech Security EQ	2.820.37
06751	24346	Spoors Security EQ	2,620.37
06752	E01857	Interface Adapter	852.08
06753	D05270	Interface Adapter	062.08
06754	D05260	Interface Adapter	852.08
06756	D05287	Interface Adapter	052.08
06757	D05268	Interface Adapter	852.08
06758	D05278	Interface Adapter	052.00
06759	D05253	Interface Adapter	852.08
06760	D05255	Interface Adapter	852.08
06761	D05257	Interface Adapter	857 08
06762	005328	Remote Control Unit	579.67
06763	D05368	Remote Control Unit	579.67
36764	D05414	Remote Control Unit	579.67
06765	D05404	Remote Control Unit	579.67
06766	D05431	Remote Control Unit	579.67
06767	D05301	Remote Control Unit	de-
06768	D05401	Remote Control Unit	579.67
06789	D05312	Remote Control Unil	579.67
06770	D05265	Remote Control Unit	579.67
D6771	D05429	Remote Control Unit	579.67
06832	0080A	MNT K KM-1035/ARC-131(C)	57967
06850	20016	Read VIDO V-1000AB-F	4,195.00
06851 (comp)	20030	RM Cont UT VID VS200F	2,000.00
16891	1826A16641	Power Motor ME-441/L/(C)	100.00
06907	SVRPS-540		117.75
06913	28989	STLR Ven STOR M750(C)	32,952.03
)6915	B8552	COMPRIROP HGR5-9M1(C)	3,805.00
26921	2002	Stand Maint ACFT Pw(C)	54,338.00
)6922	41010	Shiriking Stretch Mach(C)	5,865.00
06024	0475	Shinking-Streich Machitol	5,665.00
)6928	42292	PNCHG MACH MTL HDTUR(C)	1,324.60
06930	149597	Tester ANUSMIZUTA	2.610.71
6931	45598	Pathon	2,663.00
6973	2706840922	Pistigen	2,060.00
6979	80802026	Keykoard HP	200.00
6996	ENI89071	Moralize Casar	200.00
7012	36AJ077856	Test Set Sec Sys M92	3,669,00
7051		Computer, Advanced	1,497.00
7068	07051	Keytboard Zentih	\$00.00
7069	36AJ077846	Computer, Advanced	1,497,00
7089	07069	Keybourd Zanith	200.00
	0371416813	Computer, Lapheld	1,524.00
7095	0371348813	Computer, Lapheld MICRO	1,511.00

PUNBINK:	DAAH23-09-C-0345
MODIAMO	-

Page 9 of 36

As of 3/17/05			
BAR	SERIAL.		
CODE	NUMBER	NOMENCLATURE	COST
07155	07155	Cabinat Mullimedia 84	511.88
37156	07156	Cabinet Mullimedia 84	511.85
07157	07157	Cabinet Mullimedia 84	511.86
77195	9A6448492Y	Printer Oct Matrix	528.00
07199	9A644B477Y	Printer Ock Matrix	528.B0
07200	9A6448460Y	Printer Dot Matrix	528.60
07205	9A6448487Y	Ponter Dot Mairix	529.00
07207	B2005	Compressor Unit RCP, AIR PR	1,034.00
07208	USA#41580	GEN SIG SG 1144/U(C)	4,734.00
07209	88995	MNT KIT MK-733/ARC-54(C)	4,625.00
07210	USA41252	TST Amalyzer(C)	15,007.00
07211	USA#41251	Test Set TS-3920/ASM(C)	27,571 0x
37239	105973	Radio Set AMPRC 90	
07240	15875	Redio Set ANAPRC-90	51731 51731
07241	9649	Radio Set AMPRC-90	
07242	F6389	Radio Set AN/PRC-90	517.31
7244	9614608	Keyboard Zenith	517.31
77245	937NN2104	Montky	200.00
77249	2311543	Keyboard F/3270	500.00
77303	44311	Frager AGFT Marring)	200.00
17312	00182175F	Monitor Color Unisys	1,748.00
17315	00182138F	Monitor-Color Unisys	200.00
17332	00181627F	Monitor Color Unisys	200.00
07333	A626945	Compular PC Unitys	200.00
7334	3554821	Keyboard, Unisys	2,152.00
7335	00182041F	and the state of t	200.00
7341	00181922F	Monitor, Color Unitrys Menitor, Color	200.00
77366	A629019	The state of the s	200.00
7367	3555849	Gomputer, PC	2,152.00
7368	00182228F	Keytoard	200.00
7390	48657	Menitor, Calar	200.00
77394	83-380A014	Power Supply	1,988.00
7411	911001704	Power Unit Aux, Aviation	250.000.00
77417	1009	Monitor 19' Color	7,690.00
7418	1140	Test Sel Fire ConSub(C)	24,946.00
17419		Analyzer Bearkx Sya	32,719.62
7420	1335 1449	Arrahyzer Bathor Sys (comp of 07418)	
17421	1303	Stostex Mrd 135M12 (comp of 07418)	<u>.</u>
17426	01606A4695	Printer MdW 8510-1 (comp of 07418)	
7434	THE MENTING IN THE PROPERTY OF STREET, AND ADDRESS OF A SHALL ASSES.	Compater Exac Sets	2,300.00
7435	07434	Workslation, Double	8,678.00
7436	07435	Workslation, Single	4,931.00
7437	07436	Workslatton, Single	4,931.00
	07437	Workstation Double	10,043.00
7438	07438	Workstallon Single	5,640.00
7439 7440	07439	Workstalion, Single	4,931.00
7440	07440	Workstalkus, Single	4,931.00
7441	07441	Workstellon, Single	5,370.00
7442	07442	Tablo, Rectangular	612.00

PHASINN:	DAAFI23-63-C-0345
MANDON	
	Page 10 of 36

As of 3/17/03			
BAR	SERIAL.		
CODE	NUMBER	NOMENCLATURE	COST
7443	07443	Table, Rectangular	049.00
7444	07444	Workslation, Single	612.00
7445	07445	Workstallon, Single	4,931.00
7446	07446	Workstaliun, Single	4,931.00
7447	07447	Workstation, Spale	4,931.00
7448	07448	Workstation, Single	5.370.00
7449	07449	Workstation, single	4,931 00
7450	07450	Workstallon, Double	4,931.00
7452	07452	Workstalkin, angle	10.043.0
7453	07453	Wantstallon, single	4,451.00
7454	07454	Workstation, single	4,931.00
7455	07455		4,931.00
7456	07456	Worksteller State	4,931.00
7457	07457	Workstation Single	4,931.00
7458	07458	Workstallon Single	4,931.00
7465	348639469	Chear Aidift	371.00
7466	348536392	Printer Unlays	454.00
7471	348590753	Printer Unisys	454.00
7477	017261	Printer Linesys AP1329	454.00
499	LA01901734	Printer Unisys Mid# 37	2.050.00
7553	07563	Reingorator, Household	318.96
7554	07554	Ноексаве 84″ и Э0°	1,300.00
7555	07555	Beakcasa 84° x 30°	1,300.00
7556		Fable, Reclangular	B12.00
7557	07556	Table, Roctargolai	410.00
7558	07557	Cleaner Vaccarin	291.44
592	1083374	Modern, Smart, Mdl 2400	337.00
7593	07592	Dispensor Water 115V	519,50
594 '594	32080024	Moentar, Digitel Sys	200.00
	07594	Board Letter W/Stand	430.10
749	33310913	Oven 120V 60HZ	349.00
766	84100	Balancing Kill PROP (C)	8,180.00
771	9008037933	Over Microwava Redera	173.88
889	170	MINT ACS K MK-1192/ARM(C)	5,737.00
89 	RD801075	Reing 120V 50valletz	326,51
908	397	TRAILER ACFT MAINT	1,748.00
924	3191001225	Facsinale Machine Digasi	1,373.00
125	08125	Workstation Single	3,198.65
129	08129	Workstation Single	3,198.65
130	08130	Desk Occide Pedatal 72"	640.80
131	08131	Credenza 72"	1,065.60
132	08132	Storage Unit, Vertical	318.80
135	08135	Cabinet ADP 22x18x79	306.00
136	08136	Fable Executive	576.D0
139	08139	Workstation Single	* * * * * * * * * * * * * * * * * * *
140	08140	Teshio Lamanale	2.338.70
141	08141	Workstation Single	410.40
46	150-0228	Filing Cati Security	3,175,90
225	08225	Light Desk fluoracers	1,264.00 340.00

PHNISINN: DAAHDI-03-C-03-65 MODIAMD

Page 11 of J&

As of 3/17/03			
BAR	SERIAL.	The second secon	
CODE	NUMBER	NOMENCLATURE	COST
08226	08226	Scale beam & dial PTB	354.25
08227	08227	Fable drawing wistool	228.36
08229	08229	Truck, HAND	206,91
08235	8708036943	Oven 120V, 60 HZ	565.17
08278	08278	Table, Reclangular	410.00
08279	08279	Table, Rectangular	410.00
09200	06280	Table, Reclangular	410.00
08282	18-05611	Arsaiyat, Television	533.80
08283	W10226	Machine, Wing & Multip	2,830.00
08284	4860-01D	Exposure Unit,3M	427.00
Q8286	0112	Bicycle, Heavy-duty	561.96
08303	08303	Workelstion Single	3,135.85
08313	08313	Workstation Single	3,207.60
08314	08314	Workstation Double	5,994.24
08315	08315	Workstation Single	3,21280
08316	08316	Workstation Single	3,212 80
08317	08317	Slorage Unit, Vertical	319.80
08318	08318	Workstation Double	6,282.24
08320	08320	Workstation Single	3,212.80
08321	08321	Workslation Single	3,235 84
08322	08322	Workstation Single	3,235.84
08323	08323	Workstation Double	6,007.04
08324	08324	Workstation Single	3,098.24
08325	08325	Workstellon Quad	10,801.92
08326	08326	Workstation Single	2,992.64
08328	08328	Storage Unit, Vertices	emi i i a september este como con con
08329	08329	Storage Unit, Vertical	316.80
08330	08330	Slerage Unit, Vertical	316.80
08331	08331	Sicrage Unit Vertical	316.80
08335	B196528	Osallasage Logic AN	316.80
08336	B011138	The state of the second contract of the second of the seco	15,800.00
08337	B161705	Camera Oscilloscope (comp of 08335)	
08338	B024017	Ampélior Dual Channel (comp of 08335)	the state of the s
08339	B160412	Analyzer & Displey (comp of 08335)	
08340	B237095	Ampélier Buai Channel (comp of (98335)	
08341	08341	Oual Time Base 7853A (comp of 08335)	
08342	08342	Adapter Camera (comp. of 08335)	
08343	08343	Cert OsciPoscope (comp of 08335)	
08344	3965164	Case Camera (comp of 08335)	
08345	11-40669	Mullinusier Mrg V7	230.00
08347	and the state of t	Generator Set Porteble	450.00
08348	151100050 989	Monter 15" B&W wand	937.00
08349		Generator Films Code	5,250.00
26348 28350	E6TC00130	Recorder Reproducer	1,516.20
	8101273	Oual Time Base 7853A (comp of 08335)	
38351 38352	1699	Generator Time Code	3,182.00
38352 30353	1689	Generator Time Code	3,382,00
08353	1700	Generator Time Code	3.382.00
08354	1719	Generator Time Code	3,382.00

PHN/S68N: BAAH23-03-C-0348 Page 12 of 36

As of 3/17/03	•		
BAR	SERIAL	A CONTRACTOR OF THE PARTY OF TH	
CODE	NUMBER	NOMENCLATURE	COST
08355	889	Inserier Airtigrae VID	
8356	890	Inserter Airbame VII)	4,026 75
18357	888	Inserter Althorne ViD	₫,026.75
¥8358	870	Priserter Airborne VID	4,026,75
8359	309105	Manitor Video 28/VDC	2,616.25
18380	299414	Monitor Video 28VCC	226.25
8361	309107	Machillar Victor 28VDC	228.25
18362	309104	Montor Video 28VDC	226.25
8363	Ma	Mount Assembly	228,25
8364	M10	Mount Assembly	535.80
636 5	N4	The state of the s	535 80
18366	M8	Mount Assembly	636.60
8367	A94848	Mount Assently	535.80
18368	B001310	Prover Supply DC	591.60
8369	8001393	Camera Video closed C	3 18.00
8370	8001323	Camera Video racsad C	918.00
0371	⊞001350	Carnera Video closed C	318.00
8372	6910105	Camera Video dosed C	314.00
8373	69244	Recorder Video Cassette	12,610.00
8374	692006	Recorder Vicino Artorne	12,600,00
8375	692005	Recorder Video Cassette	12,610.00
8376	and assessment and a property of the contract of	Recorder Video Cassotte	12.610.00
8377	6950 222	Recordor Video Aldonne	12,600.00
8378		CMRA Sys wiPeriscope	11,990.00
8379	242	Cararol Unit (comp of 08377)	
8380	20658	Recorder VTI3	18,400.00
	20210	Remote Cantral (comp of 06379)	
8381 8382	10296	Control Bax (comp of 18379)	" -
6383	131	Transducer Airspeed (1,400.00
	49	Corwerter Power FREQU	9,652.00
3 38 4	4927-037	Tost Set T AN/AFIX-424(V)	15,965.00
3397	262	Display Remote	300,00
3398	259	Display Remotes	300.00
3399	1002	Generator Time Code	5,250.00
3400	08400	Sokiering Station TMP	118.78
3401	08401	Soldering Station TMP	115.75
1405	08405	Test Kill Ball Trag	6,852.00
1406	08408	Test Fot Bal Fring	6,852.00
432	E0015	TST Set Bench ADVFLT(C)	1,263.15
1433	30347	Tape Reader GP	161.00
436	80589	Eloc Transler Keying	235.45
437	85850	Elec: Transfer Koying	235.45
463	387581101	Printer Oat Matris UN	371.00
475	387581218	Printer Dot Mairix Unisys	371.00
499	387611379	Printer Ook Moens	371.60
504	387581192	Printer Oct Makik Uneys	371.00
527	39543574	Computer, PC Unisys	1,296.00
528	000373948	Monitor, 14° Color	500.00
529	0024418	Keyboard Unisys	200.00

PITNISINN:	DAAH23-03	-C-0345
MODIAMID		
	Page	L3 of 36

As of 3/17/03			
BAR	SERIAL.		
CODE	NUMBER	NOMENCLATURE	COST
08531	395943590	Computer, PC Unity's	1,296.00
08532	000410368	Monitor, 14" Cafor	500.00
08537	0000747	Keyboard Unlays	200.00
08538	387581184	Printer Det Matrix	371.00
08545	0000058	Keyboard, Urasys	200.00
08556	395916794	Computer PC Unisys	1,796.00
08557	000370058	Monitor, Color 14" w/ Titl	500 00
08574	0000059	Keyboard Unisys	100.00
08585	00035327B-	Montou, 14" Color	50000
08586	395916562	Computer, PC Unisys	1,895.00
06688	387612104	Printer Dat Matris UN	
08600	38712237	Printer Ook Matrix	371.00
08623	21988	Test Sel Radio Frequency	371 (0) 1,601,00
08690	387489867	Printer Ook Matrix	1. 3. 4. 4. 4.
08763	AN0003237	Saktering Slation	371 00
08764	AN0003254	Soklering Station	250.00
08805	1075799	Modern, Externet Baud	250.00
08825	00107251	par and a second communication and a second control of the second	255.00
38828	34CF(X)33934	Keyboard Zerrilla	200.00
20020 28864		Computer, Desktop	2,879.00
)8866	06108A4710	Computer Exec Set	2,300.00
28887	106220-916	Montor 14" VGA	281.81
	106220-636	Monitor 14" VGA	291.90
08874	E331900634	Graphic Toblet Summa Sketch II	8 25.00
08930	F06843	Radio Set ANPRC-90	517,31
08955	7771340087	Disk Drive Bernouli	2,219.60
)8969	814544A019	Months Vitteo Graphic	898.00
08970	31HAL70554	Computer Md 84PC	3,189.00
28971	08971	Keyboerd, Enherced	200 00
09005	B011374	OSCILLOSCOPE OS-288/G	3,621.60
9006	8011377	OSCILLOSCOPE OS 288/G	3,621,99
09031	0E11344376	Printer 9-PM Epson	483.00
09034	0€11344377	Printer 9-PW Epson	493.00
0904 0	0E11344380	Printer S-PWI Epson	CO.EB4
00044	Ø€11344361	Printer 8-PWN Epson	483.00
29 055	0E11344356	Printer 9-PSN Epson	483.00
9059	0E11344350	Printer 9-PM Epson	483.00
99064	3127J20038	Printer (,सञ्जूर्व (III)	7.728.00
9088	110913076	Saw Banu Horizontal	4,500.00
9104	ACX01352	Drawing Board	400.00
X9106	1GMATJ21138	Printer, Panssonic	1,200.00
9107	1070110238	Monitor, Clamend Scan Color	300,00
9106	W910917564	Power Supply, Uninternaptible	300.00
29120	¥¥910918405	Power Supply 450	306.00
9124	GMAT#22196	Printer, 24-Pen Multi	300 OKI
9143	19A	Test Sel Et, SY AWALM-178	9,477,00
) 9144	40A	T ST EL SY ANALM-178	9,477.00
99241	USA#WL09WB	TRK LF CBD 4000 LB	10,884.00
)9242	09242	Sprayer Paint Airless	1,950.00

PHASINA:	OAAH23-09-C-0945
MODAMII	
	Page 14 of 36

As af 3/17/03			}
BAR	SERIAL.	The second secon	Í
CODE	NUMBER	NOMENCLATURE	COST
09257	USA58092	VLTMTR EL ANAJRM-1450	372.00
09319	F2190	Radio Set AWPRC-90	547.31
09320	14924	Radio Set AN/PRC-90	
09321	1796A	Radio Set ANPRO-Se	517.31
09322	F3538	Radio Set AMPRC 90	517.31
09370	69370	Dispersor, Weter	517.31
09373	0116868	Teléphone, Answering	506-00
39393	AT21000928	Сапърива, Місто	79.95
09394	4122090	The same of the sa	1,241300
39395	M920605888	Months, 14" VGA Calar	300.00
19397	4116344	Keybaard IBM Compital	(200.00
09402	AT21001528	Montler, 14" VGA Calar	345.00
39404	M920605842	Minicongruter 486	1,241.00
09407		Keyboard IBM Compibi	200.00
09426	M920605816	Keylaxeti, iBb/	200.00
09427	AT21001128	Computer, Micro	345.00
	4122198	Monitor 14" VGA Celer	345.00
09428	M920605883	Keyboent IBM Comptbl	200.00
29432	AT21002228	Computer Micro	1,241.00
19433	4116603	Manilor 14" VGA Coka	345.00
1943 4	M920605817	Keyboard IBM Compilib	200.00
19435	AT21000328	Computer, Micro	1,241.00
9440	M920605841	Keyboard, IBM	200.00
19442	4117637	Monitor, WIN	345.00
9443	M920604769	Keybodard Zerath	200.00
9456	ATZ1001928	Minicomputer 485	1,241.00
9457	4117616	Moritor, 14" VGA Color	345.00
09458	M920605904	Keryboard, IBM Compalible	500.00
9459	AT21001328	Minicompuler 486	1,241.00
9461	M920605908	Keybourd, IBM Competible	200.00
9463	4117218	Manilor, 14" VGA Calar	346.00
19467	N/9/206/04513	Keyboard, IBM Competitie	200.00
9488	4116555	Moniker, 14" VGA Colur	345.00
9469	4117477	Monitor 14" VGA Cofor	345.00
9477	0024520	Koytoard, Unisya	
9502	20057680	Monitor, MDL TE1458	200.00
9503	686588	Minicomputer 486	300.00
9504	1529A132	The state of the s	1,942.00
9524	9215601EF	Keyboard, Compusedd Ractio Sei	150.00
9557	09557	The second secon	4,010.00
9570	14577	Sheet Feeder 7870	200.00
9571	14141	Radio Sel ANTERO OR	517.31
9572	11715	Radio Set ANIFEC-90	517.31
9573	territoria de la compansión de la compan	Radio Set AN/PRC-90	517.31
9584	387812112	Prenter (XOT Maskix LRV)	371.00
	20228498	Monitor #4" VGA	281.00
9609	41177771	Monitor 14" VGA Cotor	345.00
9664	85-25344	Manual, Crew	144.00
9693	AT30814928	Computer Micro	1,241.00
9702	812AE3284	Computer PC, Zenith	1,028.00

PHAISINN:	DAAH23-03-C-0345
MURVANID	
	Page 15 of 36

As of 3/17/83			}
BAR	SERIAL	The state of the s	
CODE	NUMBER	NOMENCLATURE	COST
09708	6128	Radio Set ANFRC-90	517.31
9740	8010416	DISTORT ANA TS-4084/G	2,596,00
X9741	USBC154498	Printer, Lesserjet	1,336.00
19763	09763	Gun, Long John Ext	199 00
9778	32805-0461	Mexicon, Minitraver FAX	179.00
9779	3051003636	FAX, Smart Modern	379 OU
)978¢)	3051003462	FAX, Smart Modern	379.00
99792	09792	Power Supply	269.00
09793	09793	Power Supply	369.00
1980 6	9308150000	Switch, Auto-Dista	239 00
1981 i	ZAA69196	Drawing Board	248.00
9912	MHX908162	Manilor, Calor Mdl MX-17F	S\$19.00
39813	09813	Corrector, MDL 468DX266 W/Keyboshd	2,272,00
19857	US88499029	Printer, Lascolat 4L	669.00
J9879	USBC130205	Printer, Lassadet 4L	1.336.00
09914	A0125100K034	Modern, Fax Smart	:400.95
09923	USTC044753	Frinter, Lasseflet 4 Mot C2001a	1,446.80
19933	09933	Computer Cominade	7
19934	182738142	Keyboard Fujiau	11,750,00
)9965	AC0-35005041	Monitor, Color 15', Midk CMS-1861LFC	
19966	18276359	Keyboard, 101	300.00
9967	09967	Computer, Mdl 486002-86	65.00
19972	3593A	the contract of the contract o	1,995 (KI
09976	3337A52639	Deciloscope DC-100MHZ: AN/USM-488	2,084.00
19977	119414	Scanner, Scangel I-P, Mdi C2500A	949.00
39983	USB8560417	Shed feeder, Automatic	499.00
10008		Printer, Laserjat MP	845.00
10009	USB8601512	Printer Laserjet 4, Mdf C2003A	664.00
	USBB191864	Printer Lanerjet 4, Mdl C2001A	1,389.00
10014	USBB607124	Printer, Lasorjet 41.	664.60
10018	10018	Building Portable, ATTC 901	2,370.18
10068	188TUED504	Radio, Two-Way, Mdi P43QLC20A2AA	440.90
10069	188TUED624	Radio, Two-Way, Mdl P43QLC20A2AA	440.00
10070	188TUEE581	Radio, two Way, Mdl P400)LC20A2AA	440.00
10087	USBB726553	Printer Lacenet HP	664.00
10103	USBB682267	Printer, Laserjet HP	664.00
10106	10105	Computer,486-335X	1,175.00
10107	M940102859	Keyboard	100.00
10108	A90-41300823	Moreon, W3A 14"	374 (0)
10109	13311	Printer, Sharer Mct SB-310	479.95
0123	188TUA0288	Racko Two-Viey	500.00
10128	10128	Tricycle	633.22
10142	10142	Square, Machinist (tocally fabricated)	100.00
10175	BY7MM31201	Graphics Tablel Micro	217.00
10182	940408564	Keytoand	56.00
0185	10185	Computer Pantium PAK	1,959.00
0186	TCE4400355	Keyboard	100.00
0190	1198	Analyzer, Army Whrelton	12,339.00
0191	4123	Adapter Sel, AVA CH-47	3,093.00

PEROSONN:	DAAH23-03-C-0345
MCHWAMD	
	Page 16 of 36

Asi ali 3/17/03			
BAR	SERIAL	1	· ····
CODE	NUMBER	NOMENCLATURE	COST
10192	10192	Flower Supply Unintermiptable	478.00
0197	42104834	Monitor 14" Color	255 00
0199	42104824	Monitor 14" Color	255.00
0203	1333001677	Manitor, 17" Mag Golor	855.00
0243	3342588H40	Monitor Cotor Compan	378.00
0327	0003892	Keyboard Md M2	100.00
0329	36410329	Meritor-Color 14"	378.00
10350	46U170100	Radio, Handheld	450 00
10351	430140073	Recto, Hardheld	450.00
0393	1402	Radio Set AMPRC-90	517 32
0422	10422	Modern, Deda/Fex	114.95
10424	1901	Accuratear	51,179.00
0433	47()180041	Racko Harodhoed, Mrš HX241V	450.00
10434	47U180044	Redfo, Hendheld, Wolf HX241V	450.00
10435	47U180050	Radio, Handheld, Mol HX241V	450.00
104B4	4104131811	Power Supply	179.95
10520	1179AA	Program Loader Radio Sel,KY813/PRC112	1,807,00
0521	1180AA	Program Loader Radio Set,KY913/FRC112	1,807.00
0525	177	Power Supply PP-2953/U	2,551.60
0538	JS111	Eallye, Mdl 1440-3F6H	5,445.00
0563	38103733	Morator 14" Color	
0564	3470096	Keyboard MdI M2	378.00
10597	38581214	Monitor 14" Color	100.00
10808	R4V-075	Milling Mechine McDAM STAR 1500	378.00
10626	JPBF006455	Printer, Laseriel 4V	39,770.00
10643	USCC410479	Printer, Laserier 4V	1,863.80
10644	USGC478294	Printer, Laserjet 4L	633.00
0656	USCC477827	Printer, Laserjet 41.	633.00
10678	407332		693.00
10692	450290794	Television, Color 19* Recceder, Video Midl VR327	179.99
10713	50082		179.99
10714	50081	Scale, Weighting Aircraft Top of Jack	2,900.00
10717	05898	Scale, Weighting Aircraft Top of Jack	2,900.00
10744	AV2944000184	Redio, AirBand VHF Mdl#IC-22 Mersitor Color 15"	599 00
0758	JPDD105939	of the statement of the	356.00
0766		Printer, Laserjet Color	5,551.00
1.5714 %	095040122868	Power Supply MdI BK400B	148,98
10767 10768	(095040122933	Power Supply Mdi 8K400B	148.50
10768 Insens	095020068022	Power Supply Mill 8K4008	148.98
0802 0824	USBB014027 155092175	Printer, Lasenet 6L	633.00
		Keyboard, Mid FDA1021	100.00
0825 0828	50684914 48591283	Moritor, EVGA Mill CM201	320.00
10830		Monitor, EVBA Mill CM201	320 00
	CD3143167	Keyinasd, Md FDA1021	100.00
10848	039Z05Z	Plotter Artisten PLUS 1023	1,200.00
	TGKB50904393	Keytoard, Md FDA1021	100.00
10854	48591287	Montor, EVGA Mill CM201	320.00
0862	CD3143176	Keyloosed, Mdl FDA1021	100 00
0863	48591252	Montor, EVGA Mdl CM201	320.00

PITMISINN:	DAAHIJ-03-C-034:
MODVAMO	
	Paule Pine in

4×4[3/[7/0]			
BAR	SERIAL,	All a former of Many that is a second of the	
Adoz	NUMBER	NOMENCLATURE	COST
0865	CO3143203	(Kayboard, Mill FDA 1021	
0066	50684535	Monitor, EVGA Met CM291	100.00
0908	10908	Test Set Stabilator Line/SAS	320.60
0909	324681	Electromp Assembly	26,477.0
0915	10915	Gun, Soldering Cardiass Mdl Z-50	116.96
0916	10918	Gur, Soldanng Contless Met 2 50	116.96
096 t	U9CC717471	Printer Lageriet 42.	935,00
0963	USCC717474	Printer Lasorial 4L	487.00
0964	USCC731712	Printer Lasared 4L	487.00
0965	USCC717434	Printer, Laseries 4L	487 00
0966	USCC718998	Printer, Lassenet 4L	487.00
0967	JPDF032653	Printer, Lascelet 41	487,00
0968	JP0F032654	Printer, Lasage	1,834.60
1090	5509	The state of the s	1,834 (%)
1108	551CA10AD310	Fiberscope, Mdl Al,S-156U	8,135.00
1113	6625H5N3D560	Monitor, Corresay, Cression	971.00
1114	55ACA10AD303	Computer, Mdi XL5133	4,325,90
133	11133	Monitor, Compsq, Ovision	971.00
1134	A34265	Scale, Aircraft Weighing	25,000.00
135	A34289	Weight Cells (comp of 11133)	
136	A34298	Weight Calls (comp of 11133)	
1137	A34273	Weight Cells (comp of 11133)	
138		Weight Cells (comp of 11133)	/
139	799215 A34285	Cantral Processing Unit AC100 (comp of #1133)	
140		Weight Cells (comp of 11133)	
141	A34295	Weight Cells (comp of 11123)	
142	A34264	Weight Cells (comp of 11133)	
143	A34284	Weight Colls (comp of 11133)	
144	799216	Central Processing Unit AC180 (comp of 11133)	1
145	502023	Platform Scales (comp of 11133)	1
	502028	Platform Scales (comp of 11133)	
146	502027	Platform Scales (comp of 11133)	
150	MI43GA008123	Monitor, 17", MAG	549.00
178	JPCD172762	Printer, Lassorjat St.	443.00
181	11181	Jack Hyd Tripod 12 F	1,625.09
182	11182	Jack Hyd Tripod 12 T	1,555.09
183	11183	Jack Hyd Tripod 12 T	1,955,00
184	11184	Jack Hyd Tripod 12 T	1.555.06
94	7116446BYK0411A	Computer, Notebook, DELL	3,486.00
195	7118446BYK0425A	Compuler,Notebook, 0€LL	
196	7118446BYK0407A	Computer, Notebook, DELL	3,466.00 3,466.00
197	71184468YK0409A	Computer, Noteback, OELL	3,456.00
198	7118446BYK0233A	Computer, Natabook, DELL	3.456.00
199	7118446BYK0376A	Computer, Notebook, DELL	3,466.00
200	7118446BYK0227A	Computer Notebook	
201	7118446BYK0426A	Computer, Notebook, OELL	3,465,00
02	7118446BYK0335A	Computer, Nobelbook, DELL	3,486.00
03	7118448BYK0408A	Computer, Natebook, DELL	3,466.00
204	7118446BYK0385A	Computer, Nalebook, DELL	3,466.60

PHN/STNN: DAAH23-01-C-6345 MODIAMB
Page 18 of 36

As of 3/17/03			
BAR	SERIAL		- seems and analysis of the seems of the see
CODE	NUMBER	NOMENCLATURE	cost
1205	7118446BYK0410A	Campuler,Nalebook, DELL	
1207	7118446BYK0445A	Computer, Notebook, DELL	3,466.00
1208	7118446BYK0447A	Computer Notebook, UECL	3,466.00
1217	FB7160901	Monitor, 17"	3,466.00
1223	FB7160645	Mantor, 17*	1,930,00
1225	F87160652	Morsior, 17	1,030.00
1236	H23W28	Computer, Pentium, Dossop	1.030.00
1239	H23W2D	Computer, Pentium, Desktop	3,000.00
1255	U03736349	VCR, Symphonic	3,000 00
1256	V7150714828354	The second of th	299.00
1259	66746J22L087	Television 31" Senyo	469.00
1265	BLINX	Manitor, 17"; Dell	399.00
1268	M354H809915	Computer, P233M; Dell	2,000.00
1269	M154H8099919	Monitor,17" MAG	490.00
1270	MI54148099918	Monitor,17" MAG	490 00
1286	8067412	Menibor, 17" MAG	490.00
1287	The second secon	Monitor, Color	279.(K)
1289	JPH,8037077	Printer, Lasonet 6L	389,99
1298	JPHJ037095	Pranter, Lassesjet &L	389.59
1301	CBF41	Computer,P233MLDell	2,000.00
302	H2BCEV	CPU, P233M,Integraph	2,100.00
304	HZBCEJ	CPU, P233M,Intergraph	2,100.00
	FB7211282	Montler, 17", Intergraph	1,030,00
305	PB7211285	Monitor, 17", Intergraph	1,000.00
306	FB7211284	Monitor, 17", Intergraph	1,030.00
325	H2BCEZ	Computer #233M	2,000,00
335	H2BCEX	Computer,P233M	8,000.00
336	FB7212342	Monitor, 17", Intergraph	374.00
359	H2BCF4	Computer,P233M	2,000.00
365	H2BCDD	Conipuler,P233M	2,000.00
366	FB7211733	Monator, 17", Interpresph	374.00
368	JPHL121374	Printer, Lasence 61	367.00
369	JPML121373	Printer, Lesenet 6L	267.00
372	FB7211731	Montter, 17", Intergraph	The second second second
373	H2BCDH	Computer,P233M, DELL	374.00 2,000.00
378	DBYR6	Computer, P233Mt, DELL	1,500.00
387	FB8140292	Munitor, 17", Intergraph	
390	H292ZY	Computer, Desklop	499.00
392	H293AG	Compuler, Prenium, Desktop	2,470.00
394	H2F900	Computer, Design	2,470.00
101	0009660450	Computer, PII-206M	2,470.00
102	17004A368170	Monitor, 17; Gateway	2,480.00
109	M2FAEC	Consputer, Pentium	500.0k)
113	H2FB53	Computer, Pontium	1.486.00
115	H2FB4X	Computer, Desktop	1,486.00
16	FB8140153	Moretor, 17°, Intergraph	1,486.00
118	FB8140155	The state of the s	499.00
19	H2FB6G	Monitor, 17*, intergraph	499.00
21	H2F8KX	Computer, Doskiop	1,466.00
_ ·	THE DION	Computer, Desklop	1,485.00

PHN/SINN: DAAH20-03-C-0348 MOD/AND

Page 19 nf 36

As of 3/17/03	V.		
BAR	SERIAL.		
CODE	NUMBER	NOMENCLATURE	COST
11422	FB7641553	Moditor, 17', Intergraph	499.00
1425	92DJ601907	Computer, Desktop	1,564.00
1438	92GJ700068	Computer, Deaklop	1,546.00
1457	B92GJ700707	Computer, Desklop	1,540.00
1463	692GJ701072	Consputer, Mattlewer	1,540,06
1474	B92GJ700558	Computer, Desklop	1,540.00
1483	B92GJ701749	Computer, Desktop	1,540.90
11484	B92GJ700523	Computer, Desklep	contract the contract of the c
1494	FG8250668	The state of the s	1,540.00
11495	FG8250666	Monthly, 17	303.00
	The same of the same and the same of the s	Moniker, #7"	203.00
11509	F88210234	Montter 17"	303.00
11512	F88210231	New Hur, 17°	209.00
11530	FG8250961	Monitor, 17*	O0.E0E
11532	FG8250953	Monitor,17"	303.00
11533	FG8250947	Manisor, 17 ⁵	303.00
11535	FG8250946	Monäer,17*	303.00
11537	J305B88	Printer, Laserjet Color	2,299 00
11556	B92GJ701543	Computer, Desktop	1,540.00
11557	B92GJ701394	Computer, Desidop	1,540.00
11560	FK8153107	Monitor, 17°	298:00
11563	FK8153485	Monitor, 17°	269.00
11587	MY91GAZ0T4	Mullinacion Machine HP710	469.00
11623	H3NK600279R	Monstor, 19*, Intergraph	410.00
11655	GC01410993	Monitor, 17" DAEWOO	386.00
11659	R0074	TST ST PILOT AST NULL	14,201 00
11664	10E01041110769	Printer, Color, Lexmerk	2,114.00
11698	340000010000	Printer, Bar Code	1,800.00
2019	S9543	Keyboard, Enhanced	100.00
2075	US5881308V	Printer Deskjet 855C	
12078	US588110BD	Printer Deskjet 8550	479.99
12088	60207125		499.99
12189	EKA60902815	Oven Microwave	119.00
12192	· · · · · · · · · · · · · · · · · · ·	Camera,Zoom,Mill DC 50	1,200.06
12192	38103750	Monllor 14" Color	378.00
	A0075	Tost Sor TS-3896/L/V	8.415.00
12206	980922650	Dispanser Wir 115v	375.00
12211	A1768	CNTR ELC R AWUSM-459	6,418.00
12242	08859912	Feavy Mixer w/Caba, Standa, Mixeophore	1,530.00
2254	F83446116	Multifunction Genter	799,00
2280	1611096002220000	l'elephone, Cordesa	179.99
2327	H13839	Display Unit PN 125200-001	3,317.00
2328	H13988	Display Unit PN 125200-001	3,317.00
2329	H13848	Display Unit PN 125200-001	3,317.00
2330	H13982	Display Unit PN 125200-001	3,317.00
12333	3GNEK18R5VG132237	Vehicle, Non-Tactical; Chev TAHOE	31,232.96
2382	12382	Board,Magnetic 4" x 6"	592.75
2392	6569	Crane Piper Pibl 2 Ton	668.00
2405	8057CD	Telephone, Cordiess	
2410	U\$BD006814	Printer Laseriet 6P	379.99 721.00

PHNISINN:	DAAH23-03-C-0345
MODRAMO	
	Page 20 of 36

As of 3/17/03			
BAR	SERIAL		
CODE	NUMBER	NOMENCLATURE	COST
12416	20063	Short Light.	
12417	20064	Cart, Utility	8,225.04
2420	0283A	Carl, Ultity	8,225.04
12452	320988B	Ohmmeter: ANIPSM-43	312.00
12453	720423	Carriera, Silt 35MM	486.00
12454	3422498	Lens, Camera 28-200MM	330.00
12463	10567-730018	Flash, Carriera Nikon	210.00
12454	181	Test Set Line Advanced	66,064.00
2465	062	Tester, Fuel Quarkity Digit	4,416,00
	L = - T	Tester, Fixel Quantity Digs	4,686.00
2481	FA725N013780	Scanner, Color Strobe	289.00
12483	FA725N013866	Scanner, Color Strobe	299.00
12488	12488/TR1221	CH58,Bladis Repair Kit	10.135.20
2489	730140/7171123	Test Set Line Advanced	69,064.00
2491	12491	Cydra, Michanik 3 Wheeler	594.85
2499	4938-002	TIST TIAN/APM-424(V)2	15,965.00
2520	7357346BYK4355A	Computer, Notebook	4,100.00
2527	1898S1720VW473±03	Trailer, Antoniva Mast	70,000.00
2546	BY4NJ7247	Computer, Notabook	2,699,00
2548	9Y46V7246	Compuler, Notebook P-133	2,699.00
2561	7HAFA127774	Fax, Plain Paper	319.00
2574	C5G2L	Computer, P293M, DELL	2,000.00
2585	A726BNX20385	Computer, Pil-23317	1.699.00
2805	4	Test Set, Handower	4,000.00
2606	1845	Heat Gun. Electric	3.830.70
2807	GSE419	Millohynmeier, Eigilal	500.00
2608	134E	Test Sci, Funi	*
2609	1005	Teel Sel, Electronic-Pitor Stat	46.85
2619	H2BCEP	Computer, P233M, DELL	8,630.00
2629	SG7BIF32FZ	Fax/Copier Officelet HP300	2,000 00
2690	BG003204	CO External Drive	389.89
2702	9712327596	Control of the contro	955.96
2705	8DBDB019641	Heat Pump, Window	749.00
2706	C177GO	Telephone,Crdls w//us	330.98
2765	FB7414921	Answer Machine (Nigital	39.99
2780		Monker,17	203.00
2836	1FCNF53S910A10381	Vehicle, Mobile Telemetry	125,000.00
	12836	Punch, Kryockout, 8-shaped .750'x .705'	167.79
2837	12837	Punch, Knockout, O-shaped 500" x 469"	156.60
2636	12838	Punch, Knockoul, D-shaped .625" x .594"	175.81
2839	12839	Protractor, Digital	400.00
2845	12845	Apache Main Rotor Tool Ka	12,291.00
2664	LCAUS0419YT304812	Trakes, Telemolry	2,000.00
2871	12871	AMATTS(Apache mag & Alox Tarik Trensfer Sys)	17,376.00
2875	12875	Adepter, Component Hais	5,561.62
2877	12877	Cart, ECS Servicing	17,613,99
2882	12882	ERFS II '8' Kit	595,161.00
4019	DKJST	Computer, Minitower	1,880.00
4027	A807BQM2H962	Computer, Pentium	2,424.00
4059	A813BQM2F895	Computer, Presance Compact	2,424.00

PHNSINN:	PROOFER LEHALD
MODIFIANTS	
	Page 21 of 16

As of 3/17/93			
BAR	SERIAL		
CODE	NUMBER	NOMENCLATURE	COST
4074	USHB626796	Printer, Laser 6L	299.00
4075	AB13BQM2E989	Computer, Towar	
		and the second s	2,424.00
4081	809CA02HD671	Manilor, 17	725.00
4082	809CA02HD670	Maniter, 17°	725,00
4103	002	Test Set, Redio ACA/TS-248	13,000.00
4136	8DAD8003399	Telephone, Cordiess wans	330.98
4138	1154672	Projector Overhead	299.95
4140	4XSPB1617XG009335	Trailer, 7'x16', single axie	3,424.00
4144	A813BQM2H543	Computer, Pff-383M, Desktop	1,899.00
4147	A813BQM2H820	Computer, PII-333M, Deaklep	00.668,1
14162	14162	Computer, Tower	835.00
14198	FB8210651	Monitor, 171	372.00
14204	G39 6 0	Gompuèsir, P-2, DELL	2,940.00
14252	892GJ700559	Computer, Desklep	1,540.00
4253	FB7641451	Montes,17*	303.00
14298	8ICDA030902	Telephone, Cordiese W/Answerer	369.99
14331	8503446BY15090A	Computer, Notebook, Pent II; Dell	2,261.00
4332	85034468Y15167A	Computer, Notebook, Pent II; Dell	2,261.00
4333	8503446BY15166A	Computer, Nebebook, Peni, II; Deli	2,261.00
4334	85034468Y15164A	Computer, Notebook, Pent II; Dell	2,261.00
4335	8503446BY15101A	Computer, Notebook, Pent II, Dell	2,261.00
14384	0107	Oxygen SYS PRBL-6 Person	10,594.73
14385	0103	Oxygen SYS PRBL 6 Person	10,594.73
14428	9603	Tractor, Warelsouse MDL HTAB Olesel(TUG)	22,091.74
14429	9606	Tractor, Warehouse MDL HTAB Diesel(TUG)	22,081 74
14430	9604	Tractor, Warelyouse MDL HTAB Clesser, TUG)	22,081.74
14431	9607	Tractor, Warehouse MDL HTAB Diesel(TUG)	22,081 74
14432	9608	Tractor, Warehouse MDL HTAB Diesel(TUG)	22,081.74
14492	USLE006630	Printer, HP LJ 1100SE	399.95
14495	052526	Deta Transfer AN/CY2-10 V3	534.86
14498	052439	Data Transfer AM/CYZ-10 V3	534.86
14497	2694	KY 100 ACD	4,661.00
14498	2224	KY 100 RCU	4,881.00
14499	2669	KY 100 RCU	4.861.00
14500	1581	KY100 AIRTERM	12,881.00
14501	1578	KY100 AIRTERM	12,851.00
14502	1585	KY100 AIRTERM	
14508	1637A05089	Generaler, Signal HP MOL 8640B	12,981.00 6,592.00
14641	KA104515	Computer, Desidap 150M	6,592.00
14642	KX104684	the same of the sa	1,118.00
14643	KA10455B	Computer, Desktop 150M	1.118.00
14644	KA105061	Computer, Desiron 150M	1,118 00
1.0	The second section of the second sections	Computer, Desktop 150M	1,118.00
14645	KA104530	Computer, Desktop 150M	1,138 08
14648	GC96881283	Monitor, 17" DAEWOO	749.00
14649	GC96881654	Manitor, 17" DAEWOO	749 00
14650	GC96881665	Monitor, 17" DAESYOO	749.00
14851	GC96881666	Monitor, 17" DAEWOO	749 00
14652	GC96881675	Monitor, 17" DAEWOO	749.00

PUNISINN:	DAAH23-03-C-0345
MODIAMO	
	Page 22 nd 46

As of M 17/03		<i>₹</i>	
BAR	SERIAL	The second secon	
CODE	NUMBER	NOMENCLATURE	COST
14679	01036826	Serwing Machine; Kermore	119.00
14892	14692	Computer, Notestack, DELL	2,357.00
4752	1080	Test Sel, Radio T-30M	9,900.00
4754	JN92305183	Delsemblifier	199.00
4755	JN92305201	Dehumidifier	199.00
4762	007C005721D1	Scanner, Flatoed	99.95
4769	J09023718	CO ROM 28 flisc, Todd Enterprises Mdt Titan	
4770	14770	Torque Wrench, 344° SO MA	2,318.16
4791	U19290G0U112665	Surging Machine, Brother Mill 929d	445.31
4792	CN06921418	Scanner, Flathed CLR	259.96
4797	H1085	Radio Set AMPRC-112	299.95
4798	H0323	Raiso Set AN/PRC-112	5,020.00
4799	H1076	Radio Sal ANPRO-112	6,030,90
4800	H0242	Radio Sel AN/PRC-112	5,020,00
4801	H0442	and the second s	5,020,00
4802	H0160	Radio Set ANPRC-112	5,020.00
4803	140208	Radio Set ANYPRO-112	5,020,00
4804	5619A	Redo Set AMPRO 112	5,020.00
4805	N:0319	Radio Set AMPRC-112	5,020,00
4806	H0218	Redo Sel AN/PRC-119	5.020.00
1807	Transfer to the contract of th	Radio Sel ANIFRO-112	5,020.00
1808	H0285	Radio Sel AN/PRC-112	5,020.00
4809	H1068	Radio Set AN/PRC-112	5,039 00
	H0308	Redio Sel AN/PRC-112	5,020.00
4810	H1098	Radio Set AN/PRC-112	5,020,00
4811	H0274	Radio Sat AMPRC-112	5,020.00
4859	OFBQD051548	Telephono, Contiess	199.95
4860	OF8/QD051465	Telephone, Cordess	199.95
1862	OFBQD051561	Telephone, Cordinas	199.96
872	OFBQ0051383	Tokaphone, Cordiess	±99.95
1874	OFBQD051388	Telephone, Cordinas	199.95
1875	OFBQD:051450	Transphone, Cordless	199.95
1934	14934	Replicator, Post	159.00
1952	L07041607	Fácsimila, Amler 1270	139,59
6007	OIBDE094677	Telephone, Cordess	199.95
130	OIBDE095653	Telephone, Condesa	179,96
138	LB272048	Welding Machine, ARC (9431002354728)	3,697.20
140	1153938	Саптега, Zoom	475.00
147	15147	HADS Test Set (Hammand McH, 8901)	895,00
160	61041670	GPS Portable	
332	15332	Bracket, Mounting (Leveling K# Plumb Bob)	775.00
333	15333	Taigat Leveling, Arcraft	1,993,50
344	1KACA112100	Telephone, Cordless	891.45
i 4 39	315982YSP	Recorder, Voice, Digital	179.95
440	315984YSP	Recorder, Voice, Digital	159,99
552	18G1M11	Computer, Desktop	159.99
653	4760326KB\$V1	Monitor, 17" (Iel)	1,200,00
554	47603-26K-BQUK	(Monitor, 17' DELL	220.00
555	55R4M11		200.00
	V-951 178170 1 1	Computer, Desktop	1,453.90

PHNISINN: DAAH23-03-C-0345 MOD/AAED

Fage 13 of 34

As of J/17/03		1	
BAR	SERIAL	Control of the Contro	
CODE	NUMBER	NOMENCLATURE	COST
15556	US17HS2965	Scanner, Desktop	
15557	CZYK105594	Printer, Pixulo Integet	599.00
5639	4W79Q11	Compater, Notebook, DELL	499.00
5640	21790211	Computer, Natebook, 1991.L	1.488.00
15641	7V9Q11	Computer, Mosebook, DELL	1,480.0x
15642	HV9Q11	Computer, Notebook, DELL	1,488.00
5643	C\$9Q11	Computer, Notebook, DELL	. 1,489.00
5644	CT79Q11	Computer, Natebook, DELL	1,488,60
5645	7T79Q11	Gompuler, Natabook, DELL	1,488.00
5646	DW79Q11		1,488,00
6647	7W79Q11	Computer, Notebook, DELL	1,488.00
5648	959Q11	Computer, Notebook, DELL	1,488.00
5649	1V79Q11	Computer, Notebook, DELL	1,488.00
5650	GS79Q11	Computer, Noteback, CELL	1,488.00
5651	8V79Q11	Computer, Notebook, DELL	1,486.00
0003	L7142	Computer, Natabook, DELL	1.498.06
Ú016	A0016	Adapter Assy	11,660.0
0239	A0239	Fool Cabinet Rollinvary	500.00
0372	A0372	Cab Stor 55Hx36Wx50D	653.66
0374	A0374	Cab Stor 551#c36Vnx(\$0)D	653.66
0383	A0383	Cab Skyr 55Hx36Wx50D	663.66
7909	A0909	Cab Stor 55Hx36Wx50t)	∫653.66
0910	A0910	Fan Circ 2 Place Constr	50.00
0912		Fan Circ 2 Piece Constr	50.00
0913	A0912 A0913	Fan Circ 2 Piece Constr	50,00
3914	and the second of the second o	Fart Circ 2 Piece Constr	50.00
2915	A0914	Fan Gro 2 Piece Constr	50.00
9917	A0915	Fan Circ 2 Piece Constr	50.00
1033	A0917	Fan Cirt 2 Place Constr	50.00
1081	A1033	Filing Cab Cap Size (SAFE)	337.00
	15GH-728	Generalor Set, Elect	4,700.60
216	A1216	Ladder,Fibergiass dF	116.00
665	A1665	Cleaner Vac 120V 60HZ	211,00
780 784	A29	MAINT PLY HYD ADJ 10F	1,809.73
	124394	Engravograph	530.00
805	7264	Oxygen Sarvking Unit	1,256.00
044	121	Power Sup PP-4606(p/G	1,989.00
()47	117	Power Sup PP-4606()/G	1,988,00
162	7119	Radio Sel AN/PRC-90	517.31
523	A2523	Scale, Bearn, Phytopia	500.60
853	2005-23	Test Shand, Hydraulic	34,320.00
862	153	TST STAND 79009-100	28,869,00
000	UC01H4	Tractor, White Wise	5.717.00
901	WLOGWY	Fractor, Whid Wrise	6,510.00
110	CM2757	Truck, Van. Instrumentation	16,000,00
192	234704	Oven Leberatory Heat 1244	309.60
929	114797	Oven, Microwave	
022	3350895	Multimater	397.00
029	A8029	Squit Test Set	371.00

PHN/SINN; DAAH23-03-C-0045 MODIAMO

Page 24 of 16

As of 3/17/03			
BAR	SERIAL	The second secon	The state of the s
CODE	NUMBER	NOMENCLATURE	COST
A8316	942-241	Generator Set, Dreset	30,000,00
48317	942-242	Generator Set, Dieses	00.000.00
A8319	A8319	Paracinite, Natl 490	1,155.00
48320	A8320	Parachute, Natt 490	1,155.00
A8392	A8392	Work Bench	300.00
A9408	1105360	Ternanal w/Keyboard	482.00
A9515	S613617	Air Conditioning Unit	4,589.00
A9729	9007-19600	Engine Wesher	2,242.60
A9773	KA769949	Welder, TIG	
19792	3003JG0K2C	Printer, Lasoriet III ^a	4,476.00
19796	UC06YM	Tractor, Wheeled	1,828.00
49866	UDO295	Crane Will Mid	15,471.00
80210	B0210	Milkineter	55,046.00
30397	E005045	er e reconstruction and a second contraction of the	156 00
30501	WC3756TMW	Generator Set 28v (DC,Tdr Mrdd;JET-EX4	10,000.00
30609	EA2928609	Tráler, Utility, Covered	1,000.00
30667	B0857	Reingentor	125.95
30709		Fan Circ 2 Piece Constr	136.95
	K0080	Helmet Unit Inlegrated(IHAADS)	7,708.00
30711	F1069	Heimet Unit knlegrated/(HAADS)	7,706.00
30716	02A9043796	Michael Chala	198.90
30743	80743	Peraclaule, BETA	11,664.00
30744	B0744	Parachule, 8ETA	11,864.00
30745	130745	Paracitule, BETA	11,664.00
30746	B0746	Parachute, 86 TA	11.854.90
30747	B0747	Peraclude, BETA	11,684.00
30748	B0748	Parachute, BETA	11,564.00
30749	B0749	Parachute, BETA	11,664.00
30750	80750	Parachuto,BETA	11,564.00
30751	80751	Perachuke,BETA	11,664.00
30752	B0752	Farachute,BETA	11,564.00
30762	B0762	Parachute Nee 490	1,155.00
30763	80763	Parachule,#a# 490	1,155.00
30819	80819	Parachute,BETA	11,664.00
30820	80820	Parachute, BETA	11,064.00
30821	80821	Parachuta,BEYA	11,684.00
10822	B0822	Parachute, BETA	11,664.00
90860	315JA4359	Printer, Laszofet III	1.599.00
Julkűűűűűű 1	Bulk000001	Case, Black WiFosm	60.68
kilk000001	Bulk000001	Cáse, Black W/Foam	60.65
Bulk000001	Bulk000001	Case, Stack WiFoam	81.00
IUIK000001	Bulk000001	Case, Black WiFgam	\$60,68
Julk000001	Bulk000001	Caso, Black W/Foam	5
Bulk000001	Bulk000001	Case, Black WiFoam	60.68 60.80
lulk960001	Bulk960001	Sling Hopir Ext 10000	80.68
ulk960001	Bulk960001	Sing Heplr Ext 10000	442,00
Julk960001	Bulk960001	Sing Hapir Ext 10000	1442.00
ulk960001	Bulk960001	The state of the s	442.00
	Bulk960004	String Hoptir Ext 10000	422.00

PHINISINN: BAAH23-05-C-0345 MOD/AMD

Page 25 of 36

As of 3/17/03			
BAR	SERIAL	The second secon	
CODE	NUMBER	NOMENCLATURE	COST
3ulk960004	Bulk960004	Jack Hyd Hand 101	720.11
Bulk960004	Bulk960004	Jack Hyd Hand 10T	720 11
Bulk960004	Bulk960004	Jack Hyd Hand 10T	720.11
Bulk970009	Buk870009	Chair, what me, Legacy Low Bk	350.00
Bulk970009	Bu&970009	Chair,wharms,Legacy Low Bk	350.00
Bulk970009	Bulk 970009	Chair, whams, Legacy Low 8k	350.00
Bulk970009	Bulk970009	Char, wilams, Legacy Low Bk	350.00
Bulk970010	Buik970010	Bicycle, Industrial Style C	600.00
Bulk970010	Bulk970010	Bleycki, Industrial Style G	600.00
Bulk970011	Busk970011	Cycle 400 LB Capacity	729.31
Bulk970012	Bulk976012	Chair, Ergo(Legacy YW/Arms)	357.14
Bulk970012	Bulk970012	Chair,Ergo(Legacy W/Arms)	357.14
Bulk970012	Ewik976012	Chair,Engo(Legacy W/Arms)	357.14
Bulk970012	Bulk970012	Chali, Etyo (Legsky W/Arms)	
Bulk970012	Bulk970012	Chair,Ergo(Logacy WArns)	357.14
Bulk970012	Bulk970012	Chair,cago(cagacy www.na) Chair,Enpo(Legacy W/Arms)	357.14 357.14
Bulk970012	Bulk970012	Chair,Ergo(cegacy YWArms)	Contraction of the State of the
Bulk970014	Bulk970014	Cycle 100 LB Capacky	357.14
Bulk980004	Bulk980004	Life Raft inflatable	729.31
D0119	D0119	Tire Changing Tool	1,075.68
00724	ITZVF	the state of the s	432.00
D0728	1TZVH	Computer, Dat 486	2,338.00
D0742	D0742	Computer, Del 486	2,338.00
DO748	K0140	Extension Boom Fork Mill AKB	850.00
00749	E1365	Heimet Unit Imagreted(IHAADS)	7,706.00
D0750	A0743	Heimet Unit Integrabet(IHAADS)	7,708 00
D0755	A1862	Helmot Unit Imagrated (IHAADS)	7,708.00
D0756	A0892	Heimet Unit integrated(IHAADS)	11,960.00
00770	1106996	Hemet Unit Integrated (HAADS)	15,270.00
		Typéwiler,WP	279.00
00815	K920491450	Gongrador Sci	11,558.00
00816	K920492717	Genevator Set	11.900.00
NO BC NO BC	744011	VZ Ar Stapler	120.00
NO BC	N/A N/A	1/4" SQ.OR. Mini Preu Rechet Wrench	91.00
		3/61 SQ.DR. Pneumalis Ratcher Wrench	\$2.39
NO BC	N/A	4' Wood Tabie	100.00
NO BC	014*A	Adapter RF Mdl 1609-04 (Comp of 05817)	
NO BC	0151	Adapter RF Mol 1609-D4 (Comp of 09817)	
NO BC	13852-750	Ausapter, Hutt-blade	3,370 00
NO BC	103074-101	Adapter, Trans, MMS	0,258.04
WO BC	3175AA	Amplifier, Radio Frequency(NON_POST)	10.020.50
WO BC	3194/\/\	Amplifier, Radio Frequency(NON_POST)	10,020,50
NO BC	9707 118 4774	Arswering Machine	52,00
NO BC	17506B	Aviators Night-Vision	14,869,00
NO BC	18359B	Aviations Naght-Vision	14,869.00
₩O BC	17043B	Aviatore Night-Vision	14,899,180
NO BC	17400B	Aviators Night-Vision	14,069.00
NO BC	17499B	Aviators Night-Vision	14,869.00
NO BC	17500B	Aviaiore Might-Vision	14,869.00

PHN/SINN:	DAAH23-03-C-0345
MODIAMD	
	Page 26 of 36

As of 3/17/03			
BAR	SERIAL	· · · · · · · · · · · · · · · · · · ·	
CODE	NUMBER	NOMENCLATURE	COST
NO BC	17501B	Aviatom Night-Vision	54 DCD BO
NO BC		mana ang manasang sa	14,859,00
	175028	Aviatora Night-Vision	14,889.00
NO BC	17503B	Aviatora Night-Vision	14,869.00
NO BC	175048	Aviabore Nigitil-Vision	14,869.00
NO BC	17505B	Aviators Night-Vision	14,869.00
NO BC	8945A	Aviators Night-Vision	14,859.00
NO BC	N/A	Bag, Camera (voMR# 69 179)	50.00
NO BC	GSE252	Bench Power Supply, PM#L30-5	100.00
NO 8C	AC01724	Spard Drawing, Calcomy Digitizer	400 00
NO BC	N/A	Board, Charl	100.00
NO BC	N/A	Bookcase Stands	100.00
NO BC	N/A	Gockcase Stands	100.00
NO BC	N/A	Bookcase Tops	100,00
NO BC	N/A	Bookcase Tops	100.00
NO BC	WA	Bookcase Wistand & top-Metal	47.85
NO BC	NA	Bookcasa Wistand & top-Matal	47.85
NO BC	NA	Bookcase W/sland & top-Metal	47.85
NO BC	N/A	Bookcases, gray,metal	50.00
NO BC	N/A	Bockcases, gray, metal	50.00
NO BC	0139	Boresight Kil Captive	318,270.00
NO BC	9320\$1712	BUILDING Portable, 20x20 w/2 heat pumps	8,000.00
NO BC	N/A	Bulletin Acard witaghts & Lettering	755.00
NO BC	N/A	Carbinet, Filing Ltv SZ	100.00
NO BC	N/A	Cabinot, Open	100.60
NO BC	N/A	Csbiret Open	···
NO BC	NIA	The state of the s	100.80
NO BC	N/A	Cabinet, Safety 4-gal	253,90
WO BC	9849	Cabinet, File 2-drawer	100.00
		Cable Assembly (comp of 074 t8)	
NO BC	9851	Cable Assembly (comp of 07418)	
NO BC	EKH82801584	Camera,Digital Zeom	857.00
NKO BC	NIA	Cargo Net, Tie Down, PM# SP-7074-1	100.00
NO BC	N/A	Cargo Net, Tie Down, PN# SP-7074-1	100.00
N/OBC	N/A	Cargo Net, Tin Cown, PN# SP-7074-1	100.00
AO BC	N/A	Cargo NeLTie down,PN# 98752-57E45475-1	100.00
NO BC	N/A	Cargo Not, Tie down, PN# 96762-67E46475-1	100.00
NO BC	N/A	Cargo Nel,Tie down,PN# 98752-57E46475-1	100.00
NO BC	MR69517	Cart, Mobile Power	29,765,00
NO BC	MR69927	Cart, Mobile Power	29,765.00
NO BC	MDL 145E5941-1	CH-47, Fligging Kit	2.211.83
NO BC	T101284-107	CH-47,Bling Assy Holat	2,451.50
NO BC	N/A	Chair Adjustable Dark Blue w/Arms	175.00
NO BC	N/A	Cheir Adjustable Dark Blue wiArms	175.00
NO BC	N/A	Chair Rotary w/arms beigs	126.60
NO BC	NVA	Chair Rotary wharms beinge	126.60
NO BC	N/A	Chair Rotary włamia beige	128.60
NO BC	N/A	Chair Rotary Warms beige	125.60
NO BC	N/A	Chair Rotary Warms beige	126.60
NO BC	N/A	Cheir Rotary wianns beige	126.60

PUNSINN:	DAAH23-03-01-0345
чорамь	
	Bons 17 of 16

As of \$(17/03			
BAR	SERIAL	· · · · · · · · · · · · · · · · · · ·	
CODE	NUMBER	NOMENCLATURE	COST
40 BC	N/A	Chair Rolary wlarms beign	128.60
40 BC	N/A	Chair Robery Warms beige	126.50
NO BC	N/A	Chair Rollary whaters beige	126.80
NO BC	NIA	Chair Rolary wearns beige	125.60
VO BC	N/A	Chair Rolary wdarms beige	128.80
IO BC	N/A	Chair Rolary wierns beige	125 60
NO BC	N/A	Chair Rotary wizens beign	126.60
NO BC	N/A	Chair Rosary wiscons beage	126.60
10 BC	N/A	Chair Rotary whams besps	126.60
10 BC	N/A	Chair Rotary warms beige	126.50
10 BC	N/A	Chair Rotary witamis beinge	128.60
₩ BC	N/A	Chair Rolary warms helge	126.(3)
KO BC	N/A	Chair Rotary w/ARMs LIN: D85075	50.00
O BC	N/A	Chair Rotary We Arms beige	Committee of the contract of the second state of the second secon
IO BC	NA	Chair Rotary Wko Arms beige	111.42
IO BC	N/A	Chair Ratary Wa Arms beige	111.42
10 BC	N/A	Chair Rollery W/o Arms beige	111 42
IO BC	N/A	Cher Rolary Wo Arms beige	111.42
IO BC	N/A	Cheir Rotary Wo Arms beige	119 42
IO 8C	N/A	Chair Rolary Wio Arms heige	111,42
10 BC	N/A	7 To the consequence of the cons	1111.42
10 BC	N/A	Chair Rotary Wio Ames beige	111.42
IO BC	N/A	Cheir Rotary Wio Arms In: C96887	66.00
IO BC	N/A	Chair Rotary Wo Arms In: C85887	56.00
IO BC	N/A	Chair Straight Warms, Ladderback	3145
O BC	N/A	Chair Straight warms, Lacklerback	31.45
IO BC	N/A	Chair Straight whams, Lackforback	31.45
O 8C	NA	Chair Straight wisms. Ladderback	31.15
0 8C	N/A	Chair Straight warms, Ladderback	31.45
O BC	NVA	Chair W/O Arms-Blus	100.00
O BC	N/A	Chair WVO Arins-Blue	100.00
OBC	N/A	Chair, Arm	150.00
O BC	N/A	Cheir, Arm	150.00
0 BC	N/A	Chair, Retary	70.83
TO THE RESERVE ASSESSMENT OF	A SECURE AND A SECURE AND ADDRESS OF THE ADDRESS OF	Chair, Biraight W/Arms	100.00
O BC	N/A	Chair. Straight Wio Arms	100.00
O BC	N/A	Chair, Straight W/o Arme	100.00
O BC	N/A	Chair, Straight Wio Arms	100.00
O BC	N/A	Charr, Swrog	150.00
O BC	N/A	Char, Swivel W/O Arms	100.00
0 BC	NA	Chair, Swivel VVO Arms	100.00
260	N/A	Cher, W/ Anns	100.00
0 BC	N/A	Cháir, W/ Arms	100.00
O BC	N/A	Chair, Servel W/Armie	100,00
0.00	N/A	Chair, WIO Arms	100.00
O BC	N/A	Coal Rack	100,00
O BC	NA	Coal Radi.	100.00
D BC	N/A	Cost Rack	100.00
O BC	9A*	Compressor (ALQ, 136(V))	57,174.00

PHYSINA:	DAAH23-03-C-0349
MORVAMO	
MILITARY AND STATES	forme the set

As of 3/17/03			
BAR	SERIAL.		
CODE	NUMBER	NOMENCLATURE	COST
NO BC	N/A	Computer Table Brown 48*	239.94
₩O B¢	N/A	Computer l'able Brown 40°	239.94
∜O BC	5001253048	Computer, 486DX2-66	2,074.00
40 BC	6424HKD32041	Computer, Compaq	2,015.00
40 BC	\$057027729D	Computer, Equium 5160DE	2,500.00
AO BC	S057328249D	Computer, Equium 516004E	\$2,500,00
40 BC	S057028210D	Computer, Equium 5160DE	2,500.00
NO BC	4433007987	Compulsy, Mril VESA 486DX-33	1,429.00
NO BC	HK1U843764	Container, Shipping 40'	2,000.00
VO BC	N/A; PN28445	Containment System 2-drum, hardlup	616.85
NO BC	Y6917	Convirot Unit-Mid 3274-C-61	4,180.00
VO BC	2961AA	Control, Radio Set (NON-POST)	4,862.76
40 BC	2962AA	Control, Radio Set (NON-POST)	4,862.76
NO BC	N/A	Criscionaria	\$6.10
NO BC	NIA	Creditruza Melai Ofc	111.00
NO BC	028700	CTRM S ANIALQ-136(V)1	1,093.00
VO BC	N/A	Cylinder Compressed Gas	260.00
NO BC	NA	Cylinder Compressed Gas	200.00)
40 BC	N/A	Oesk	250.00
IO BC	N/A	Ossk aich Lumi	124.98
IQ BC	N/A	Desk sich L-unif	124.93
NO BC	N/A	Dosk alch Luait	124.96
VO BC	N/A	Cest DIP	100.00
40 BC	N/A	Desk D/P	100.00
40 BC	N/A	Desk Dis	100.00
40 BC	N/A	Desk DVP	100,00
4O EC	N/A	Desk DVP	100.00
NO BC	NYA	Desk DVP	(100.00
40 BC	N/A	Deak Orb	100.00
40 BC	NA	Desk Double Ped	100.00
40 8C	N/A	Desk Stest Gray	
IO BC	NVA	Desk, Computer Type Nood Construction	69,00
NO BC	NA	Dask, Double	400.00
VÓ BC	N/A	Deak, Oak Leminalis; 6(kr/30x/29	350.00
10 BC	3115	Detector, Radio Frequency	350.00
VO BC	C077GD1	Digital Ans Maching	323.28
10 BC	C077GD2	Digital Aris Machine	61.00
NO BC	1611096002432000	Olgan Headsot Talaphone	60.00
10 BC	1611096005214000	A STATE OF THE PARTY OF THE PAR	310.00
10 BC	27007	Oigkal Headeel Telephone Oisplay Station Type 3276-005	310.00
IO BC	48M71	Oisplay Station Type 3278-005	2,967.88
IO BC	48M76	Display Station Type 3278-005	2,967.88
IO BC	J2868	the second contract of	2,967.88
10 BC	J2871	Olapiay Station Type 1278-Mdd 002	2,960.00
IO BC	S1382	Oisplay Station wrkeyboard-mid 3278-002	2,960.00
	Part Comments of the Comments	Olaplay Station wikeyboard-mid 3278-002	2,960.00
IO BC	51383	Display Station wrkeytoard and 3278-002	2,960.00
IO BC	C7536	Dieplay Station wikeytopard-mid 3279-03X	2,574.00
IO BC	270U8	Display Station wikeyboard-mdl 3287-005	2,987.00

PUN/SINN: BAAH23-83-C-0345 MORAMO

Page 29 of 36

As of \$017/03			
BAR	SERIAL.	- Consideration of the Constant of the Constan	obere de santa Badra ana a
CODE	NUMBER	NOMENCLATURE	COST
NO BC	48/477	Display Station wikeybosed-redi 3287-605	73 ACT RC
VO BC	NVA	Drag Brace Tool, PM: 11743	2,967.00 380.00
NO BC	N/A	Drif Guide, General	4
10 BC	SHEA	Drill, 45 degree Angre	48.25 382.14
10 BC	SKBA	Dril, 90 degres Angle	
NO BC	N/A	Orill, Prieumatic	382.14
NO BC	MA	Drum Truck (Doly)	270.16
√0 8C	WA	Drycell Minigas Kir	380.00
NO BC	N/A	Electronic Caliper	1,475.00
40 BC	NIA	Electronic Caliper	100.00
NO BC	N/A	Electronic Catpar	172.92
(O BC	N/A	Extract Screw	172.92
IO BC	N/A	Filing Calsines	316,00
IO BC	N/A	Filing Cahlnet	150,02
10 BC	N/A	Fling Cabinet,4 DRW	160.02
IO BC	N/A	Filing Cabnel,5 DRW	100.00
10 BC	N/A	Gas Booster, PN: S486JN36	100.00
#0 BC	N/A	Ges Booster PN, S468JM36	2,000.00
KO BC	N/A	Generic Cadd Upgrade	150 00
IO BC	700352	The same of the sa	108.00
IO BC	700353	GUIDED MSL TRING MOS	14,350,00
IO BC	J0167	GUIDED MSL TRING M36	14,350.00
IO BC	Z004	Helmet Unit Integrated (MAADS)	7,708.00
IO BC	C0697	Helmet Like International HAADS)	11,900.00
IO BC	E1326	Helmet Unit Integrated(IHAADS)	15,270.00
Ю ВС	JXX282	Helmet Unit Integrated(IHAA)(9)	
O BC	J0321	Hebrot Urit Integrated(IHAADS)	7,708.00
OBC	K0079	Haknet Unit Integrated (IHAAIXS)	7.708.00
O BC	U2272	Harnet Unit Integrated (IHAADS)	7,708.00
O BC	N/A	Heanet Unit Integrated (IHAADS)	11,900,00
O BC	INA	Helmel, Flyers	178.06
OBC	INA	Helmet, Fivers	176.06
OBC	0054	Helmes, Flyors	176.06
OBC	3265A82840	Holding Fixture, TUR	707.00
OBC	301	HP Standel IIC, Scanner	1.145.00
O BC	1292	IR JAM ANALO-164(V):	12,129.00
OBC	1405	Jack Hyd Tripod 3 Ton	938,31
O BC	N/A	Jack Hyd Tripod 3 Ton	938.31
0 BC	N/A	Keyboard FC 4623 (comp of Display Station)	
OBC	N/A	Keyboant FC 4623 (comp of Display Station)	
OBC	N/A	Keytoard FC 4624	100 00
0 BC	N/A	Keyboard FC 4024 (comp of Claplay Station)	
O BC	12140690	Keyboard FC 4652 (comp of Display Stellon)	
0 BC	A0730178	Keyboard Midl RT88751	194,00
O BC	42242643	Keyboard Mdl RT6875T	129.00
OBC	the second secon	Keyboard, Compaq	100.00
O BC	A2730367	Keyboard, 815255T	100.00
	1000B1502G10150B	Kit. Sonic 1000S Basic W/2 components	6.730.51
) BC	2172	KY 100 RCU	4,861.00

PRINGSINN:	DAAH23-03-C-0345
MODYAMO MANGORA	
	Form 10 nd to

As at 3/17/03			
BAR	SERIAL.	The second secon	
CODE	NUMBER	NOMENCLATURE	COST
NO BC	770099	Launch GD MS LB XM299	58,565,00
NO BC	770020	Lauren GD MS LB XM299	58,566,00
10 BC	NA	Lata Preserver, Underson	187 42
NO BC	N/A	Lite Preserver, Underarm	187.42
10 BC	N/A	Liss Preserver, Underson	187 42
40 BC	N/A	Life Preserver, Undersom	187.42
VO BC	NA	Les Preserver, Underarm	187.42
IO BC	N/A	Life Preserver, Underarm	197.42
NO BC	N/A	Life Proservex, Uncknam	187.42
VO BC	N/A	Life Preserver, Uniterarm	187.42
NO BC	NA	Life Preserver, Undersim	187.42
NO BC	NA	Life Preserver, Underarm	187.42
NO BC	N/A	Life Preserver, Undersim	\$67.42
NO BC	N/A	Life Preserver, Undersom	187.42
40 BC	N/A	Life Preserver, Underarm	187.42
NO BC	N/A	Life Preserver, Underarm	187.42
NO BC	N/A	Life Preserver, Underson	187.42
NO BC	N/A	The second secon	A THE RESERVE THE PARTY OF THE
10 BC	N/A	Lile Presenver, Undersom	187.42
NO BC	N/A	Life Preserver, Undersom	187.42
NO BC	N/A	Life Preserver, Underarm	187.42
10 BC	N/A	Life Preserver, Underami	187,42
NO BC	N/A	Life Preserver, Underarm	187.42
10 BC	N/A	Life Preserver, Undererm	187.42
10 BC	N/A	Life Preserver, Underarm	187.42
VO BC	N/A	Life Preserver, Undererm	187.42
NO BC	N/A	Life Preserver, Linderann	187.42
	and the second second second in the second s	Life Preserver, Underson	187.42
WO BC	N/A	Life Preserver, Linderarm	187.42
VO BC	N/A	Life Preserver, Underarm	187.42
40 BC	N/A	Life Preserver, Underann	187.42
NO BC	N/A	Life Preserver, Undersom	187.42
₩O BC	N/A	Life Preserver, Briderarm	187.42
VO BC	212593	LNCHR OM AIRCRAFT	67,471.60
40 BC	N/A	Locker Storage System(60 Units)	4,123.20
O BC	N/A	Magnetic Project Control Kit 4'x 5'	389.00
KO BC	23T-2098	Marking Mach Elec Wire	8,500,00
NO BC	11539	Marking Mach, MCM-860	8,500.00
NO BC	11840501	Meter, Fire Hydrani	F895 0X
KO BC	11546838	Meter, Fire Hydrani	695.00
NO BC	N/A	Microsoft Adv Server 3.5-24disks	100 D0
KO BC	NIA	Microsoft Project for Windows	424.95
KO BC	N/A	Microsoft Project for Windows	424.95
(OBC	N/A	Microsofi Windows 3.5-23diska	424.95
NO BC	N/A	Моюжен	100.00
NO BC	S05721001	Monitor, 17° Equium 26	500.0 0
#OBC	S05720995	Monitor, 17 Equium 26	600.00
AO BC	\$05721030	Maniler, 17" Equium 26	500.00
VO BC	ATC9302000565	Montler, Color 14" RGB	300.00

PHNISANN: DAAH23-03-C-0345 MOD/AMD

Page 31 of 36

As of 3/17/03			
BAR	SERIAL.		
CODE	NUMBER	NOMENCLATURE	COST
NO BC	MC-30211917	Monitor, Color 14" SVGA	378 00
10 BC	MC-30801040	Munitor, SVGA MdI 1510	374.00
NO BC	107011325	Monitor, Missubishi	\$00 00
VO BC	2180	MTU KY-100 Airtenn	12,861.00
NO BC	HS901272B	Oven, Microwave: GE	119.00
NO BC	2768	Parachuta,BETA	11,684,00
NO BC	N4517	Parachute Chair Mdl PRof Reg williamess	1,425.00
VO BC	N/A	Partition	100.00
VO (BC	NA	Partiko	100.00
IO BC	N/A	Partition	100.00
NO BC	N/A	Pedestal Fens	190.00
10 BC	MA	Pedestal Module 3 Drawer	384 (%)
NO BC	25661	Part-a-Cool Fart, PN: PAC2K361S	1,995.00
VO BC	121001-001063	Power Supphy, Ballery	
NO BC	N/A	PROCOMPLUS 3.0 Sneware Control #00540	5,904.69 99.95
NO BC	N/A	PROCOMPLUS 3.0 Software Control #00541	99.95
VÓ BC	N/A	PROCOMPLUS 3.0 Software Control #00542	
NO BC	NVA	PROCOMPLUS 3.0 Software Control #10543	99.95
NO BC	NVA	PROCOMPLUS 3.0 Software Control #00544	99.95
VO BC	NA	PROCOMPLUS 3.0 Software Control #00545	99.95
NO BC	N/A	The first of the first own own of the first own	99.85
NO BC	N/A	PROCOMPLUS 3.0 Seftware Control #90546	99.95
√O BC	N/A	PROCOMPLUS 3.0 Software Control #00547 PROCOMPLUS 3.0 Software Control #00548	99,95
NO BC	N/A	with the control of t	99.95
NO BC	N/A	PROCOMPLUS 3.0 Software Control #00549	99,95
NO BC	N/A	PROCOMPLUS 3.0 Software Control #00550	99.65
VO BC	N/A	PROCOMPLUS 3.0 Software Control #00551	99.95
VO 8C	NA.	PROCOMPLUS 3.0 Software Control #00552	99.85
NO BC	N/A	PROCOMPLUS 3.0 Software Control #00553	99.95
*****	resident and a contract of the contract of	PROCOMPLUS 3.0 Software Control #80554	99.95
40 BC	LBG-2A	Public Address System	400.00
***************************************	H0319	Rado Sel ANIPRC-112	5,020.00
40 BC	H0242	Fado Set AN/FRC-112	5.020.00
40 BC	H1076	Rado Sal ANIPRC-112	5,020.00
	H9285	Radio Set ANIPRC-112	5,020.00
40 BC	H0442	Redio Sel AMPRC-112	5,020.00
40 BC	H0160	Radio Sel AN/PRC 112	5,020.00
40 BC	H0323	Radio Sel AMPRO-112	5,020.00
40 BC	H1058	Radio Set AW/PRC-112	5,020.00
40 BC	H1099	Rado Sel ANPRC-112	5,020,00
IO BC	H1065	Radio Sel AN/PRC-112	5,020.00
KO BC	H0208	Radio Sal AN/PRC-112	8,020.00
10 BC	H0274	Radio Set AN/PRC-112	5,020.00
40 BC	H0308	Radio Set AN/PRC 112	5,020.00
KO BC	1:10218	Radio Sel AN/PRC-112	5.020.00
40 BC	475FBQ0175	Radio, Mandheld, Portable	481.00
VO BC	475FBQ0189	Radio, Handheid, Portable	481.00
10 BC	475FAC4520	Radio, 2 channel wichsarger	481.00
AO BC	475FAC4345	Radio,2 channel w/charger	481.00

PHN/SINN:	DAAH29-03-C	-0345
MODIAMD		
	Page 32	of 36

As of 3/17/93			
BAR	SERIAL.	The second secon	
CODE	NUMBER	NOMENCLATURE	COST
NO BC	475FAC4577	Radio 2 charmel wicharger	481.00
NO BC	475FAC4576	Redio.2 channel wicharger	461 (0)
VO 8/C	475FAC4368	Radio,2 channel wicharger	481.00
NO BC	475FAC4566	रिस् टा दमहानहीं अ दिनवातुका	441 00
NO BC	475FAAD377	Radio,2 channel w/charger	481.00
NO BC	475FXW1417	Radki, Portable: Motorola	451.00
40 BC	475FXW1458	Radio, Portable; Molinrota	451.00
4O BC	3143AA	Receiver-Transmitter, Radio (NCN-POST)	
10 BC	3144AA	Receiver-Transmitter, Radio (NON-POST)	13,846,42
K) BC	\$32190021	Reingerator, Whitipool (0FVB1ET12DCXL)	t3,846.42
10 BC	80802	Respirator, Welding	250.00
IO BC	2/1/2876	Rivertor, Blind, Preumallo	250.00
IO BC	N/A	Riverter, Blind, Presumatic, 2/6" in Olameter	788.90
l0 8C	RBN2074	Sandar Beltijase 2/3 HP	(6,148.13
IO BC	NA	Saw, Jig	119.00
IO 8C	DM-092714	Sarw, Spirat Roso Np Mol SC SO t	365.00
IO BC	1638830	Sheet Feeder	79.99
IO BC	L-89017	The Address - Ad	200.00
IO BC	1692	Shelter, Rigid Wall 9 x 23	18,000,00
OBC	1793	SICATT Assembley HDM	2.535.00
OBC	1919	SIGHT Assembley HDM	2.535 00
O BC	3367	SIGHT Assembley HDM	2,535.00
,0 BC 0 BC	3954	SIGHT Assembley H(XV)	2,535.00
IO BC	4993	SIGHT Asservatey HDM	2.535.00
OBC	2009A	SIGHT Assembley H(3M)	2,636.00
OBC	2721A	Signal Generalor, Mdl SG-1288/G	6,301.00
OBC	are the second s	Signal Generator, Mill SG-1289/G	1,301.00
OBC	(0020	Sing Asservity	2,230.00
OBC	N/A	SMA Tool Kit	433.36
	B236GO-1	SPRINT Tele Anag System	49,99
O BC	13800	Stacker, Battery operated, Presio Met 8678-2000	1,780.00
ÓBC	N/A	Stand Printer wifecelver & Shelf	189.00
OBC	N/A	Survival Kir CLD CLIMATE	236.00
OBC	N/A	Survival Kir CLO CLIMATE	Z\$6.00
0 BC	N/A	Sizvival X≹ CLD CLMATE	236.00
OBC	N/A	Survival Kit CLD CLEMATE	236.00
OBC	N/A	Survival Kit CLD CLIMATE	236.00
O BC	N/A	Survival Kil CLD CLIMATE	236.00
OBC	N/A	Survival Kill CLD CLIMATE	236 00
O BC	WA	Survival Kit HOT CLIMATE	180.00
O BC	N/A	Survival Kil HOT CLIMATE	180 00
0.80	N/A	SUMIVALKILHOT CLIMATE	180.00
OBC	N/A	Survival Kit HOT CLIMATE	180.00
OBÇ	N/A	SURVIVAL KILHOT CLIMATE	180.00
OBC	N/A	Survival Kit HOT CLIMATE	160.00
OBC	N/A	Survival Kill HOT CLIMATE	180.00
O BC	NIA	Survival Kit HOT CLIMATE	
OBC	N/A	SURVING KR HOT CLIMATE	180.00
O BC	N/A	Survival Kit HOT CLIMATE	180.00

PIENZSINN:	DAAH33-03-C-0348
MODAMO	
	Page 33 of 36

As of 3/17/03			
BAR	SERIAL.	The second secon	
CODE	NUMBER	NOMENCLATURE	cost
NO BC	NVA	Survival KT Overwater	858.00
NO BC	NVA	Survival KT Overwater	850.00
NO BC	N/A	Survival Sheiter	183.68
WO BC	N/A	Survival Sheliter	163.69
NO BC	N/A	Survival Shelter	163.68
MO BC	N/A	Survival Statitus	163,68
NO BC	NJA	Survival Shetter	163.69
NO BC	N/A	Survival Shelter	163 68
NO BC	N/A	Survival Shelter	163.68
NO BC	N/A	Survival Shelter	163.68
NO BC	N/A	Survival Sheller	163.68
NO BC	NIA	Survival Sheller	163.68
NO BC	N/A	Survival Sheller	163.58
NO BC	N/A	Surweal Sheller	163.68
NO BC	N/A	Survival Shotter	163.68
NO BC	N/A	Survivol Sheller	163.08
NO BC	N/A	Survival Shellor	t63.68
NO BC	N/A	Survival Sheller	163.68
NO BC	N/A	Survival Sheller	163.68
NO BC	N/A	Survivat Sheller	163.68
NO BC	NA	Symanton Norton Ulikes OOS 3.5 disks -2	100.00
NO BC	NAZAL	Table 45'	100.00
NO BC	N/A	Table computer, Putty (ii)*	171.28
NO BC	NVA	Table computer, Pully 60*	171.20
NO BC	N/A	Table Terminal Workstation 60"x30"x27"	
NO BC	NVA.	Teble, 3x4	149.41
NO BC	N/A	Tuble, Adjustable	
NO BC	N/A	Table, Administrative	125.00
NO BC	N/A	Table, Administrative	100.00
NO BC	N/A	Table, Computer	100.00
NO BC	N/A	Table, Computer	100.00
NO BC	N/A	The second secon	100.00
NO BC	NIA	Table, Metal	137.00
NO BC	N/A	Table, Mistal	100.00
NO BC	N/A	The state of the s	100.00
NO BC	N/A	Table, Mod. Blonde	1000.00
NO BC	JBXC03126F	Table, Wood	100.60
NO BC	KX-TG25838	Telephone, Cordiess	199.95
NO BC	N/A	Telephone, Cordless	\$79.99
NO BC	N/A	Terminal Workstation Brown Non-Adjusting	149.40
NO BC	102	Testminal Workstation Brown Non-Argusting	149.40
NO BC	N/A	Test Set Vertical Display	12,384.00
NO BC	N/A	Tire Inflation Kit PNW 1075	500 (0)
NO BC	N/A	The Indiabon Kil FW# 1075	500.00
NO BC	The state of the comment of the state of the	Tire inflation Kill PWW 1875	500.00
ere gran	131184	Tool, Cutoff, Front Exhaust (3" Diamaler)	349.00
40 BC	1J3185	Yool, Cutoff, Front Edward (3° Diameter)	349.00
40 BC	NOSN	Tool Set, Drive Shaft	501.50
KO BC	2298	Topper Stand, PNN TMSPECC	

PHIN/SINN:	DAA1120-03-C-0345
MORKAMO	
	Page 34 of 36

As of 3/17/03			
BAR	SERIAL.	And the second s	
CODE	NUMBER	NOMENCLATURE	COST
NO BC	N/A	Tower Antenna COMMU	1,500.00
NO BC	N/A	Tower Radio, Antenna (Culaida)	583.00
NO BC	N/A	Towar, Artienna RBX-60 (kip of 30164)	742.50
VO BC	676639	TRAINER CAPTIVE FL.)	
40 BC	810030	TRAINER CAPTIVE FLT	32,110.00
40 BC	Component f	Transducar, Spectrum C17L(Sonic 1080S Kil)	3,510.00
VO BC	Component 2	Fransitucer, Spectrum E&L(Sonic 1000S Kit)	0.00
VO BC	3F0W6588YMA19048	Truck, 4x2, Crew Ceb Diesel (REG, CT2457)	0.00
VO BC	USANG17PM	Truck, Cargo 5/4 Ton M1028	47,211.50
VO BC	G&A	TS-3651(ALQ-135(V))*	14,141.00
VO BC	N/A	17 E. S. of 1964 Communications and a process of the communication of th	67,174.00
VO BC	KNAT	Typing Deek D/P UH-80 Hub Kii(PN# SPCK-107A1-1/N2K)	100.00
10 BC	37643929		1,075.00
VO BC	0400000598317	Vaccum Cleaner, Dusi Motor	430.00
10 BC	4433007172	Vaccum, 14" Lipright; Hoover Mdi v7089080	551.00
10 8C	N/A	VESA B Computer Md. 4860X-33	1,429.00
40 BC	The second section of the second section is a second section of the second section sec	Visual Obasa Professional Ver 5.5	160.00
40 BC	N/A	Wood Table	100.00
10 BC	WS8-WS276	Work Pietform, PN# (14.40431000	317.00
	WS4-WS275	Work Pleikern, PNW 04-40431000	317.00
IO BC	N/A	Workbench	100.00
IO BC	N/A	Workstation/Computer/Watnut/E4-BDY WL	108.00
IO BC	N/A	Workslation/Cemputer/Watral/E4-BDY-WL	109.00
IO BC	N/A	Wronch ST HYB OPN END	150.00
10 8C	N/A	Wrench ST HYD OPN END	150.00
lo ec	NA (SN:1)	Wronch, forque	46.26
IO BC	NA (SN:2)	Wrench Torque	48.25
IO BC	HU828S7048	Writer, CD Flus	374.99
0001	T0001	Cab Stor SSHx36Wx50D	653.66
0113	T0113	Puter Kit, Universel	784.00
0273	9201207	Dala/sx Machine	2,995.00
0444	T0444	Parachulo, Natl 490	1,155,60
0453	KA324TM338	Computer, DEC 433DXLP	1,893,00
0513	3877023NA	Monitor, NEC, 3FGE	887.00
0522	T0522	Perachute, Nall 490	1.155.00
0531	JPBF068678	Printer, Laserget 4	
0576	LOT 93	Carl, Fuel Servicing	1,880,00
0581	T0581	Porachube, Hatt 425	5,000.00
) 5 82	T0582	Parachuto New 425	1,100.00
0654	1329689310	Jack, 5 Ton	1,100 00
)775	2088775	Typewinter, Electronic Smith Corona 250DLE	1,703.00
)B44	T0844	Parechale, XTC 500 Seal	99.95
X8 52	T0852	Cabinet, Lista MYC9066	2,104.00
¥854	T0854	The state of the s	672 52
N956	T0856	Caldnet Lists MTC9005	572 52
1858	тов58	Cablest Lists 1350	[926.00
860	T0860	Cabinet, Lista MTC9005	1577.52
1861	T0861	Cabinet, Lista MTC9008	672.52
1862	or ∲ re exercises	Cabinel, Lista MTC9005	672.52
NUCE	T0562	Cabinel, Lista MTC9005	672.52

PHNSINK:	DAAH23-69-C-0045
MODIAMO	
	Page 35 of 36

As of 3/17/00			
BAR	SERIAL		· · · · · · · · · · · · · · · · · · ·
CODE	NUMBER	NOMENCLATURE	COST
T0083	T0863	Cabinot, Lista MTC3005	672,52
T0864	T0864	Cabinet Lista MTC9005	672.52
F0902	T0902	Cathent, Lista MTC9005	*** **** *** * * * * * * * * * * * * * *
T0972	4X29417ME	Monitor, NEC, 3FGE	2,785.00
T1129	0578	Toest Sex YS-248	697.00
T1203	T1203	Parachute,XTC 500 Seat	4,231.55
T1222	T1222	Parachuta, HETA	2,104.03
T1240	SYS 001	Auto Tool Inv Catri & Track Sys	11,684.00
T1247	T1247	Test Sel: Avn Vib Ana	3,500.00
T1248	T1248	Test Set AVN VIB ANA	14,112.00
T1270	WLOESZ	Truck of Digsgl 15000 B	14,112.09
11273	841122	Shredder, Paper, C-1000	45,641.00
T1275	EFE0502203.	Refrigerator, 2 Door	220.00
T1277	F1277	and the same of th	302.99
T1304	T1304	Adapter, Bet, Tell Flot	1,058.32
Γ1306	F1306	Fan, Floer	357.00
¥1311	5719623LR	Fan, Floer	357.00
F1312	T1312	Monikar, NEC, XE17	1.105.00
1315 1315	•	Cebinet, Lista MTC9005	672,52
[1318	T1315	Cabinet, Lista MTC9005	672.52
11319	11318	Cebinet,Storage	786 00
г 1318 Г1320	T1319	Cabinel, Lista	872.52
11320 11322	T1320	Cabinel, Lists MTC9005	672.52
11322 [1323	T1322	Cătănei, Lisla	672.52
the services in particular to the contract of the	T1323	Cobred/Storage	786.00
[1328 [1355	T1326	Cabinel, Lists MTC9005	672.52
[1355	T1355	Cabinet,Storage,Lista SD1350	744.37
1380	T1380	Cabinet,Slorage,Lista SD1350	744 37
1396	T1396	Storage Rack	759.14
1397	T1397	Storage Rack	759 14
1432	1010-341	Maint Pli Hyd Acţ 10F	1,409.73
T1433	35	Maintenance Platform: Hyd Adj to 10"	1,800.73
1435	T1435	Scale, Bonch, Okylisi	640.00
1464	918629551005K	Montker, 17", DELI	739.00
C001	94091300619	Barcode Reader, Portsible	1,095.00
C002	94102500121	Barcode Printer, Mul 3000	1,347 00
C003	TC003	Wedge Reader	300.00
C004	3392231	Modern Marks Mulli-Fech	780.00
R1120	015	Caligher, Died	141.84
R1127	088	Fowordyne, "CBU" Applicator	17,529.00
R1183	TIR1183	UH60 Sing Engine Lifting	1,139,00
R1186	483272	Ul 160 Universal Sting	730.00
R1237	0214	ACFT Electronic Repair Kill	8,422 11
R870	TR870	3/8" Tarque Wrench	60.41
R873	TR873	1/2" Torque Wranch	64.8£)
R876	TR876	1/2" Torque Wrench	64.59
R878	TR878	1/2" Torque Wrench	64.69
R879	TR879	1/2" Torque Wrench	64.59
R880	TR880	3/8" Torque Wrencis	60.41

PHN/SINN:	DAAH23-03-C-0345
MONAMD	
	Francisk of ti

As of 3/17/03			
BAR	SERIAL		
CODE	NUMBER	NOMENCLATURE	COST
TR894	C0126RZ	Caliper,Dial, Outside	123.50
TR928	TR928	Tensiomaler 10-200LBS	418.28
TR937	TR937	Check & Filetinii, UH60	8,590 00
TR949	4247	Powerdyne; Multiplier	2,711.14
	# cxf Unms, 1584	Česl	47233,639.53